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ABSTRACT 
Zachary C. Berwick 
 
ROLE OF VOLTAGE-DEPENDENT K+ AND Ca2+ CHANNELS IN CORONARY 
ELECTROMECHANICAL COUPLING:  
EFFECTS OF METABOLIC SYNDROME 
 
Regulation of coronary blood flow is a highly dynamic process that maintains the 
delicate balance between oxygen delivery and metabolism in order to preserve cardiac 
function. Evidence to date support the finding that KV and CaV1.2 channels are critical 
end-effectors in modulating vasomotor tone and blood flow. Yet the role for these 
channels in the coronary circulation in addition to their interdependent relationship 
remains largely unknown. Importantly, there is a growing body of evidence that suggests 
obesity and its pathologic components, i.e. metabolic syndrome (MetS), may alter 
coronary ion channel function. Accordingly, the overall goal of this investigation was to 
examine the contribution coronary KV and CaV1.2 channels to the control of coronary 
blood flow in response to various physiologic conditions. Findings from this study also 
evaluated the potential for interaction between these channels, i.e. electromechanical 
coupling, and the impact obesity/MetS has on this mechanism. Using a highly integrative 
experimental approach, results from this investigation indicate KV and CaV1.2 channels 
significantly contribute to the control of coronary blood flow in response to alterations in 
coronary perfusion pressure, cardiac ischemia, and during increases in myocardial 
metabolism. In addition, we have identified that impaired functional expression and 
electromechanical coupling of KV and CaV1.2 channels represents a critical mechanism 
underlying coronary dysfunction in the metabolic syndrome. Thus, findings from this 
investigation provide novel mechanistic insight into the patho-physiologic regulation of 
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KV and CaV1.2 channels and significantly improve our understanding of obesity-related 
cardiovascular disease.  
 
 
 
 Johnathan D. Tune, Ph.D., Chair 
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Figure 1-1 The coronary 
circulation by Leonardo da Vinci. 
First anatomical recording of the 
origin of the coronary arteries “in a 
bullock’s heart” (~1513, Quaderni 
d’ Anatomia). 
Chapter 1: Introduction 
Historical Perspective 
  Often viewed as the first experimental physiologist, Galen (200 A.D.) initially 
identified that arteries contain blood and not air (235). His views that blood traverses 
from the left to right side of the heart and filled with “vital spirit” by the lungs were not 
dispelled until later works by Vesalius and Servetus in the early 1500s. At the same time 
the first accurate description of arteries on the heart was recorded pictorially by 
Leonardo da Vinci (Fig. 1-1, (169)). Anatomists termed these arteries coronary from the 
Latin word coronarius meaning “of a crown” for the way the arteries encircled the heart. 
However, the greatest hallmark arises from William Harvey who originally described 
modern fundamentals of the heart and circulation in 1628, thus establishing the basis for 
investigations into blood flow regulation (4). Studies performed at the beginning of the 
20th century by Bayliss and Starling identified unique biophysical properties intrinsic to 
the vasculature and myocardium and gave a brief glimpse into the complexity of 
cardiovascular physiology (21; 274). Advances in cell biochemistry and biophysics in the 
1950s helped to identify the delicate balance between cardiac function, metabolism, and 
coronary blood flow as the heart is the only organ to 
control its own perfusion and resistance to perform 
work. Thus, regulation of coronary blood flow 
occurring in elegant coordination with the mechanics 
of the heart, as demonstrated by the Wiggers diagram 
(309), represents one of the most dynamic processes 
in human physiology. Yet despite the best efforts of 
modern science, we are far from a complete 
understanding of how coronary blood flow is 
regulated.  
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Regulation of Coronary Blood Flow  
 The heart is unique in that it requires more energy in relation to its size than any 
other organ in the body. Operating primarily under oxidative metabolism, the heart can 
reach ~40% efficiency during ejection with respect to external work performed per 
oxygen consumed, compared to ~30% for most man-made machines (166; 282). The 
heart also extracts ~70% of the available oxygen delivered at rest (vs. 30% in skeletal 
muscle), thus a constant supply of oxygen is required to meet the metabolic 
requirements of the myocardium. Accordingly, any increase in myocardial metabolism 
that arises from elevations in heart rate, contractility, or systolic wall tension must be 
compensated by acute increases in oxygen delivery (86; 294; 296).   
 
 
 
  
 
 
 
 
 
 The degree of oxygen delivery to the myocardium is determined by the amount of 
coronary blood flow and the oxygen-carrying capacity of the blood (13). Although 
oxygen-carrying capacity is important under clinical conditions of anemia and 
hypoxemia, in all other circumstances the magnitude of coronary blood flow is the 
predominant determinant of oxygen delivery. Therefore, regulation of coronary blood 
flow is an essential process required to match oxygen delivery with myocardial 
metabolism in order to maintain adequate cardiac performance. The mechanisms that 
Figure 1-2 Myocardial O2 supply/demand balance. Schematic representation of the factors which 
maintain the balance between oxygen delivery and myocardial metabolism. Adapted from Ardehali and 
Ports (13). 
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regulate coronary blood flow do so via alterations in coronary microvascular resistance. 
Putative factors that function in parallel to control vascular resistance include endothelial 
and metabolic, aortic pressure/autoregulation, myocardial extravascular compression, as 
well as neural and humoral mechanisms (Fig. 1-2 (82; 99)).  
 Balance between coronary blood flow and myocardial metabolism. Although 
many factors contribute to the regulation of coronary blood flow, the primary determinant 
is myocardial metabolism. Thus, local metabolic control of coronary blood flow is the 
most important mechanism for matching increases in coronary blood flow with 
myocardial oxygen consumption (MVO2), i.e. metabolic demand of the heart (235). 
Figure 1-3A depicts this linear relationship and strict coupling between MVO2 and 
coronary blood flow. As outlined above, high resting O2 extraction significantly limits the 
degree to which increases in O2 extraction can be utilized to meet increases in MVO2. 
This point is best evidenced by the close proximity of the normal operating relationship 
(black line) relative to the condition of maximal (100%) O2 extraction (red line, Fig. 1-
3B). To this extent, evaluating coronary venous PO2 (CvPO2), an index of myocardial 
tissue PO2, relative to MVO2 provides a more sensitive method for detecting changes in 
the balance between coronary blood flow and metabolism (294; 331). The consistency of 
CvPO2 with increases in MVO2 further demonstrates the tight balance between 
metabolism and coronary blood flow (Fig. 1-3C). Importantly, any reduction in the 
relationship between CvPO2 and MVO2 indicates that the magnitude of coronary blood 
flow is insufficient, i.e. the heart is forced to utilize the limited O2 extraction reserve to 
meet the oxidative requirements of the myocardium. If increases in coronary blood flow 
are completely abolished (red line, Fig. 1-3D), elevations in MVO2 are strictly limited to 
increases in myocardial O2 extraction (i.e. ~15-20% increase from rest). Thus, assessing 
the relationship between CvPO2 and MVO2 is a sensitive method to evaluate the overall 
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Figure 1-3 Relationship between myocardial oxygen delivery and consumption. (A) Coronary blood flow is 
associated with myocardial metabolism as indicated by the linear relationship between coronary blood 
flow and MVO2. (B) The relationship between coronary blood flow and MVO2 operates at near maximal 
oxygen extraction (red line). (C) CvPO2 as an index of myocardial tissue PO2 remains constant at a given 
MVO2 due to changes in coronary blood flow with metabolism. (D) Supply-demand imbalance is 
evidenced by alterations in the relationship between CvPO2 vs. MVO2 where increases in MVO2 can be 
limited by available oxygen extraction reserve (red line).  
balance between coronary blood flow and myocardial metabolism under physiologic and 
pathophysiologic conditions.  
 
 Extravascular compression and coronary perfusion pressure. In all circulations, 
perfusion pressure is dependent on the arterial-venous pressure gradient. The heart 
however is unique in that it generates the pressure for its own perfusion with aortic 
pressure serving as the driving force for coronary blood flow. Unlike peripheral vascular 
beds, the heart is also a constantly contracting muscle. During systole, tissue pressure 
exceeds venous pressure due to extravascular compression and therefore determines 
the magnitude of coronary blood flow in this phase. Consequently, release of 
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compressive forces during diastole re-establishes the arterial-venous gradient resulting 
in high diastolic coronary blood flows; a process termed “vascular waterfall” (Fig. 1-4A, 
(82; 99)). Therefore, alterations in the chronotropic, inotropic or lusitropic state of the 
heart can have significant effects on phasic coronary blood flow and is particularly 
important with regard to subendocardial perfusion (99). These influences not only affect 
tissue pressure, but can also alter MVO2. 
 Another important distinction of the coronary circulation is that it perfuses the 
organ which provides pressure to the entire circulation (99). Physiologic interventions 
that change peripheral vascular resistance also influence aortic pressure and contribute 
to coronary perfusion. As a result, it is often necessary to calculate the conductance of 
the coronary circulation (flow/pressure) to determine changes in coronary blood flow. 
Moreover, alterations in peripheral resistance that are met with parallel adjustments in 
the contractile state of the heart, as described by Anrep (302), significantly affect 
myocardial perfusion directly and secondary to changes in metabolism (99). Importantly, 
adequate coronary blood flow permits the generation of pressure sufficient to overcome 
afterload of the left ventricle and represents the interdependent relationship of coronary 
perfusion with aortic pressure and the peripheral circulation. 
 Coronary pressure-flow autoregulation. Coronary perfusion pressure and 
myocardial metabolism are highly integrated into the control of coronary blood flow. This 
can be evidenced by examining mechanisms of coronary autoregulation. By definition, 
coronary pressure-flow autoregulation refers to the intrinsic ability of the coronary 
circulation to maintain coronary blood flow constant in the presence of changes in 
perfusion pressure. The autoregulatory phenomenon is classically found within 
pressures ranges of 60-120 mmHg, beyond which coronary blood flow becomes largely 
pressure dependent (Fig. 1-4B, (99; 100; 160)). Coronary autoregulation is 
hypothesized to consist of myogenic and metabolic components. The metabolic 
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Figure 1-4 Effects of coronary perfusion pressure on coronary blood flow. (A) Dotted line demonstrates the 
effect of increases in pulse pressure (bottom panel) as may occur during exercise on phasic tracings and 
elevations in coronary blood flow. (B) Coronary pressure-flow autoregulation maintains blood flow constant 
within a specific range of perfusion pressures, beyond which the magnitude of coronary blood flow 
becomes pressure dependent (235). 
component of autoregulation poses that decreases in nutrient delivery during reductions 
in coronary perfusion pressure activate a local metabolic feedback mechanism to 
decrease vascular resistance in order to maintain coronary blood flow constant (157). 
The myogenic postulate of autoregulation rests on findings from Bayliss in that 
alterations in the degree of pressure or stretch of vascular smooth muscle evoke 
compensatory adjustments in vascular tone (21). However, a definitive role for either of 
the proposed components of coronary pressure-flow autoregulation has not been 
resolved. Determining potential mechanisms remains critical given the ability for 
perfusion pressure-mediated alterations in MVO2 to occur both in the presence and 
absence of steady-state flow conditions (99; 124). Termed the “Gregg effect”, studies 
identified that MVO2 increases with elevations in coronary perfusion pressure; an effect 
observed at higher perfusion pressures and in poorly autoregulating beds (99; 100). 
Theories explaining the observation that perfusion pressure can alter MVO2 include 
coronary pressure-induced increases in contraction and vascular-volume mediated 
distention of the myocardium (17). Regardless, pressure-flow autoregulation represents 
a critical mechanism by which coronary blood flow is regulated and how alterations in 
perfusion pressure can affect the metabolic demands of the myocardium. 
 
 
 
 
 
 
 
 
 7 
 Neural control of coronary blood flow. Although autoregulation maintains 
coronary blood flow constant over a wide range of pressures, many physiologic 
conditions require activation of mechanisms that increase blood flow to sustain cardiac 
function. Neural modulation of coronary vascular resistance is one such mechanism as 
coronary smooth muscle is innervated by both the parasympathetic and sympathetic 
divisions of the autonomic nervous system (99). Dually innervated coronary vessels 
undergo vagal-cholinergic vasodilation as well as both constriction and dilation via 
sympathetic activation of α and β adrenoceptors, respectively (Fig. 1-5, (99)). 
Distinguishing the direct neural contribution to blood flow regulation is difficult given 
confounding effects on metabolism. For example, in order to observe parasympathetic 
coronary vasodilation, vagal bradycardia must be prevented (99). A similar trend holds 
true for sympathetic stimulation. Overall sympathetic stimulation increases coronary 
blood flow due to positive inotropic-induced increases in myocardial metabolism via 
activation of cardiac β adrenoceptors (102). More recent studies demonstrate that direct 
sympathetic activation of coronary β receptors causes marked increases in coronary 
blood flow (82; 84; 99; 102; 116). In addition, a greater microvascular distribution of β 
receptors relative to α-adrenoceptors suggests that β-mediated coronary vasodilation 
plays a prominent role in the cardiovascular response to sympathetic activation. 
Accordingly, β-mediated coronary vasodilation is particularly important during exercise 
and has been proposed to contribute ~30% to adrenergic-induced increases in coronary 
blood flow (82; 88; 122; 123). Interestingly, α-mediated constriction limits local metabolic 
coronary vasodilation ~30% and decreases CvPO2 (99). Moreover, variable transmural 
distribution of α-adrenoceptors enables enhanced vasoconstriction via α2 activation in 
arterioles (particularly during hypoperfusion and ischemia) as compared to α1 in larger 
arteries (56; 57; 141; 180). Therefore, elevations in α-adrenergic control of coronary 
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vascular tone can significantly impair O2 delivery and is in direct competition with local 
metabolic/β-mediated coronary vasodilation. 
 Humoral control of coronary blood flow. Regulation of coronary blood flow also 
occurs by many neural independent mechanisms. Both circulating and local release of 
vasoactive humoral factors play a role in determining coronary microvascular resistance. 
Particular peptide hormones implicated include antidiuretic (106; 238; 243), natriuretic 
(79; 92; 163; 187; 192), vasoactive intestinal (104; 137), substance P (64; 283) calcitonin 
gene-related (162; 164; 229) and neuropeptide Y (128; 285). With the exception of 
antidiuretic hormone and neuropeptide Y, exogenous administration of these hormones 
significantly dilates coronary vessels. However, the extent to which these factors 
influence coronary vascular resistance at physiologic concentrations has not been fully 
characterized. Other more investigated candidates include components of the renin-
angiotensin-aldosterone system (RAAS). Notwithstanding the systemic and renal 
influences of these hormones, angiotensin II (AngII) and aldosterone causes 
vasoconstriction in coronary arterioles via activation of AT1,2 and mineralcorticoid 
receptors (Fig. 1-5, (155; 186)). Although endogenous AngII has modest effects on the 
coronary circulation under normal physiologic conditions, exogenous administration 
dose-dependently reduces coronary blood flow (329) by enhancing Ca2+ influx, 
stimulating the release of endothelin, and inhibiting bradykinin dilation (81; 261; 322). 
Aldosterone also produces dose-dependent vasoconstriction in vivo in open-chest dogs 
(114), in vitro in isolated perfused rat hearts (220), and in isolated coronary arterioles 
(186). Binding of intracoronary aldosterone via mineralcorticoid receptors has also been 
shown to decrease coronary blood flow in ischemic and non-ischemic hearts in addition 
to modulating cardiovascular function through regulating renal Na+ and K+ homeostasis 
(114). More recent evidence suggests that aldosterone may be capable of potentiating 
AngII constriction by increasing AT1 receptor expression and/or impairing K
+ channel 
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function (10; 318). Thus, changes in circulating hormone levels or functional expression 
of aldosterone and/or AngII receptors in disease states may significantly influence the 
regulation of coronary blood flow.  
 
 
 
 
 
 
 
 
 
 
 
 
 Adenosine in feedback control of coronary blood flow. Investigations to date 
indicate that alterations in coronary vascular tone occur predominantly via local feedback 
mechanisms. Under this premise, alterations in tissue PO2 release metabolites 
producing an error signal in proportion to the deviation in myocardial metabolic 
homeostasis. The metabolite produced or other downstream error signal effectors 
respond by adjusting coronary blood flow to regain the normal metabolic balance. 
Therefore, most changes in coronary blood flow occur secondary to a change in the 
metabolic rate (99). Only two exceptions to this statement have been documented and 
include feedforward (no error signal) adrenergic and H2O2-mediated coronary 
vasodilation (122; 217; 264). However, feedback control mechanisms and/or metabolites 
implicated vary with physiological conditions, i.e. exercise vs. ischemia. 
Figure 1-5 Various factors that determine coronary vasomotor tone. Mechanisms discussed in the control 
of coronary arterial diameter include: PO2, oxygen tension; ACh, acetylcholine; Ang II, angiotensin II; AT1, 
angiotensin II receptor subtype 1; A2, adenosine receptor subtype 2; β2, β 2-adrenergic receptor; α1 and α2, 
α-adrenergic receptors; KCa, calcium-sensitive K
+
 channel; KATP, ATP-sensitive K K
+
 channel; KV, voltage-
sensitive K
+
 channel. Receptors, enzymes, and channels are indicated by an oval or rectangle, respectively 
(82). See text for further explanation. 
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 One classic metabolite widely investigated in both of these conditions is 
adenosine, whereby increases in cardiac metabolism or reduced oxygen delivery lead to 
increases in cardiac interstitial adenosine from catabolic breakdown of ATP (98). 
Originally suggested as the primary metabolite for local metabolic control of coronary 
blood flow under normal conditions by Berne in 1963, the adenosine hypothesis has 
since received extensive scrutiny. The postulate of a prominent role for adenosine was 
in part attributed to the large molar ratio of ATP to adenosine (~1000:1). Thus, small 
reductions in ATP were predicted to significantly increase production of this potent 
dilator and consequently coronary blood flow. However, more recent investigations fail to 
find a significant contribution of adenosine to exercise and ischemic-induced hyperemia; 
albeit many of these conclusions were derived from the use of the non-selective 
adenosine receptor antagonist 8-Phenyltheophylline (73; 82; 87; 297). As a result, only 
more recently has the role for individual adenosine receptors subtypes in the coronary 
circulation been investigated. Of the four adenosine receptors expressed in vascular 
smooth muscle, data indicate that the A2A and A2B receptor subtypes mediate 
vasodilation in response to adenosine (Fig. 1-5, (25; 136; 170; 172; 221; 284; 293)). 
However, the extent to which these receptors contribute to coronary vasodilation in vivo 
has not been characterized and remains as an important question given the ability for 
exogenous adenosine administration to cause marked coronary vasodilation in addition 
to its various clinical applications. 
Studies from the Feigl laboratory affirm that levels of myocardial adenosine 
production during exercise are not sufficient to be vasoactive (297). Yet coronary venous 
adenosine concentration progressively increases above 166 nM when coronary 
perfusion pressure is < 70 mmHg (277). Such levels reported are well within the 
vasoactive range for endogenous adenosine (ED50 = 77 nM, (279)) and suggests that 
adenosine may still play a vasodilatory role in the transition to ischemia (277). Although 
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previous reactive hyperemia experiments would argue against this statement (73), 
pharmacologic limitations of non-selective antagonists may underscore the importance 
of adenosine in ischemic coronary vasodilation, particularly with regard to adenosine 
receptor subtypes. Thus, the functional contribution of individual adenosine receptors to 
adenosine-mediated ischemic coronary vasodilation requires further investigation.  
 
Coronary Ion Channels in Vasomotor Control 
  Adenosine along with many aforementioned mechanisms involved in regulating 
coronary blood flow achieve their effect via subsequent modulation of end-effector ion 
channels. Various ion channels regulate the cellular membrane potential (EM) of 
coronary artery smooth muscle (CASM) consequently determining the level of 
vasomotor tone and blood flow. The resting membrane potential (EM) of CASM is closer 
to the Nernst potential for K+ (~83 mV) than it is to the equilibrium potential of most other 
ions (54). Thus, K+ channels are largely responsible for determining the EM. However, in 
CASM the EM ranges from -60 to -40 mV due to cation permeability through other 
channels with more positive reversal potentials (74). Several ion channels maintain 
activation thresholds close to the EM for CASM cells and often operate in a narrow 
electrical range of one another. Therefore, small changes in EM can have dramatic 
effects on the type and magnitude of ion channel conductance; a process that is central 
to the control of coronary vascular resistance. For example, small reductions in EM will 
promote extracellular Ca2+ influx and CASM contraction (Fig. 1-6A). Evidence indicates 
that the predominant ion channels involved in this response are voltage-gated Ca2+ 
channels, i.e. CaV1.2. Although activation of CaV1.2 channels contributes to 
vasoconstriction, many channels modulate CaV1.2 activity through hyperpolarization and 
increases in smooth muscle EM. Since the resting EM is determined by intracellular K
+ 
efflux, channels that conduct K+ hyperpolarize the membrane, prevent activation of 
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Figure 1-6 Electromechanical coupling of voltage-dependent Ca
2+
 and K
+
 channels. (A) Contribution of 
interactions between potassium and calcium channels to the control of coronary diameter (154). (B) 
Interdependent modulation of coronary EM by voltage-sensitive Ca
2+
 and K
+
 channels (74). 
CaV1.2 channels and attenuate vasoconstriction (Fig. 1-6B, (74)). The degree to which 
K+ channels are activated directly contributes to decreases in vascular resistance and 
allows for significant increases in coronary blood flow. Moreover, because vasomotor 
tone varies greatly with small changes in smooth muscle EM, voltage-sensitive K
+ 
channels maintain a large contribution to the overall control of blood flow. This dynamic 
relationship between voltage-sensitive coronary K+ and Ca2+ channels is termed 
“electromechanical coupling” and represents a proposed critical mechanism for 
regulating coronary vascular resistance. 
 
 
 
 
 
 
 
 
 
Voltage-gated K+ Channels 
 Of the many K+ channels expressed in the coronary circulation, i.e. Ca2+-
activated (KCa), ATP-sensitive (KATP), and inwardly rectifying (Kir) K
+ channels, voltage-
gated KV channels (KV) contribute the most to outward K
+ current at physiologic 
membrane potentials (73; 74). KV channels maintain a tetrameric structure of pore-
forming α subunits with more than 40 different subunits that provide a broad range of KV 
channel activity (74). Members of the same KV family co-assemble in a homo or 
heteroterameric manner to form functional channels (292). Auxililary β subunits further 
contribute to the diversity of KV channels as they co-assemble with α subunits and 
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Figure 1-7 Structural characteristics of 
smooth muscle KV channels. Schematic 
representation of voltage-sensing S4 
linker, K+ selective P-loop, and 
biophysical modulating β-subunit which 
comprise functional KV channels (270). 
regulate both biophysical properties and channel 
trafficking to the membrane (Fig. 1-7, (292)). The 
number of KV channels per cell varies with 
different β-dependent trafficking within vascular 
beds and accross species. Estimating the 
number of channels with N = I/iPo (where I is 
whole-cell current, i is single channel current, and 
Po is the open-state probability) indicates there 
are ~5,000 channels in porcine coronary vs. 750 
in rabbit cerebral arteries (226). Although only KV1 and KV3 families have been identified 
in CASM, there are likely others that display similar properties of delayed rectification 
with little time-dependent inactivation (74). Voltage-sensitivity of KV channels is provided 
by positively charged amino acids (lysine or arginine) in S4 transmembrane region and a 
tripeptide sequence motif located in P-loop of the S5-S6 linker represents the K+ 
selectivity filter for the pore (270). The combination of these two structural characteristics 
allows for an activation threshold for K+ conductance within the range of basal 
membrane potentials reported for CASM. Since KV channels in the coronary circulation 
are delayed rectifiers and have noninactivating properties, coronary KV channels provide 
a tonic hyperpolarization of the smooth muscle Em (226; 255).  
 The two primary components for delayed rectifier KV channel classification are 
that they are both 4-aminopyridine (4AP) sensitive and tetraethylammonium insensitive 
(292). KV channels can also be classified according to their unitary conductance and fall 
broadly into two groups. In the porcine coronary circulation, a small conductance of 7.3 
pS for KV channels has been reported using 4-6 mM extracellular K
+ concentrations 
([K+]o) in cell-attached patch-clamp configurations (300). In contrast, larger single 
channel conductance of 70 pS has also been demonstrated in rabbit coronary artery at 
 14 
140 mM [K+]o (150; 152). These findings are attributable to the voltage-dependence of KV 
channels where although tonic activation occurs at normal physiologic ion 
concentrations, single channel current increases with depolarization of CASM over the 
physiological range of membrane potentials (226). Single KV channel voltage-
dependence is hypothetically illustrated below based on experimental data of 0.07, 0.17, 
and 0.50 pA at -60, -40 and 0 mV, respectively (Fig. 1-8A, (255; 299; 300)). In addition, 
the open probability (NPo) of KV channels also increases with depolarization (Fig. 1-8B). 
Increases in NPo also represents the voltage-dependent activation/inactivation kinetics of 
the channel as NPo increases steeply with membrane depolarization until a steady-state 
NPo is reached and inactivation kinetics becomes significant. If this were not the case, 
such as that which is observed in KATP channel experiments, then whole cell KV current 
recordings (Fig. 1-8C) would be graphically similar to single channel current voltage 
relationships and be directly dependent on the number of channels present and basal 
NPo (225; 226). Thus, small changes in CASM EM has marked affects on NPo and the 
overall magnitude of whole cell KV channel current. This sensitivity of KV channels to 
changes in EM is central to their physiologic role in controlling arterial diameter and 
consequently coronary blood flow. 
 
 
 
Figure 1-8 Determination of whole cell K
+
 currents by KV channel biophysical properties. (A) 
Experimentally based theoretical representation of increases in single channel KV current with 
membrane depolarization. (B) Open probability of KV channels increases with reductions in CASM 
membrane potantial. (C) Potential-dependent modulation of KV channels contributes to whole cell K
+
 
currents (226). 
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Figure 1-9 Contribution of KV channels to coronary 
blood regulation. (A) Inhibition of coronary KV 
channels dose-dependently reduces coronary blood 
flow. (B) Reductions in coronary blood flow in 
response to 4AP are sufficient to cause 
subendocardial ischemia as supported by significant 
ST segment depression (73).   
 KV channels are highly implicated 
in local feedback control of coronary 
blood flow as several important 
metabolites have been shown to activate 
coronary KV channels. Patch clamp 
studies indicate that nitric oxide, 
prostacyclin, and H2O2 increase outward 
KV current (3; 74; 196; 256). The 
intracellular mechanisms by which this 
occurs has not been determined, but evidence suggests that a cAMP/GMP-dependent 
protein kinase pathway is likely involved (74). Because previous investigations show that 
adenosine activates both cAMP and KV channels, it is quite possible that cAMP is a 
common pathway for KV activation (134; 135; 172). In contrast, few electrophysiological 
studies have identified factors that directly inhibit coronary KV channels, although data 
from other vascular beds demonstrate that endothelin, Ang II, and thromboxane A2 
attenuate KV channel current via subsequent activation of protein kinase C (74). 
Although these findings at the cellular level are important, the functional contribution of 
coronary KV channels is clearly evident in vivo. Inhibition of coronary KV channels by 
4AP dose-dependently reduces coronary blood flow (Fig. 1-9A, (73)). These reductions 
in coronary blood flow are sufficient to cause subendocardial ischemia as demonstrated 
by significant ST segment depression (Fig. 1-9B). In addition, blockade of KV channels 
markedly attenuates coronary reactive hyperemia by ~30%, thus implicating these 
channels in ischemic coronary vasodilation (73). Moreover, the vasodilatory response to 
pacing and norepinephrine induced increase in MVO2 are significantly attenuated by 
4AP (264). Therefore, KV channels play an important role in the regulation of coronary 
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blood flow. However, the contribution of coronary KV channels to physiologic-induced 
increases in coronary blood flow has not been determined. Moreover, whether KV 
channels regulate coronary blood flow solely through changes in CASM EM or via 
subsequent modulation of coronary CaV1.2, i.e. electromechanical coupling (Fig. 1-6), 
channels requires further investigation.  
 
Voltage-gated Ca2+ Channels 
CaV1 belongs to a group of at least ten members that comprise the gene 
superfamily class of voltage-dependent Ca2+ channels (161; 292). CaV1.2 channels 
represent the high-voltage activated dihydropyidine-sensitive subclass and consist of 
four 6-transmembrane pore-forming α subunits. Similar to KV channels, CaV1.2 contains 
a voltage-sensitive S4 segment (118). The S5 and S6 segments line the pore along with 
pore loop that connects them (Fig. 1-10). Ca2+ selectivity is conferred by a pair of 
glutamate residues within the pore loop (161). These channels are different in topology 
compared to KV channels in that only 1 pore-forming subunit is required to form a CaV1.2 
channel pore whereas KV channels require the entire tetramer. Like many ion channels, 
the biophysical properties of CaV1.2 are also altered by auxillilary subunits. These 
include α2δ1 and β units; each arise from 4 different genes and are implicated in the 
modulation of channel kinetics and membrane targeting of the α pore (118). In smooth 
muscle, 3 different β subunits have been identified which are disulfide linked to multiple 
α2δ1 splice variants. When coexpressed, these two subunits enhance the level of 
expression and enable normal gating properties of the channel (55). In addition, these 
channels are slow inactivating, i.e. “Long” lasting (L-type) with activation thresholds that 
fall in the same range of resting CASM EM.  
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In the presence of physiologically large transmembrane Ca2+ gradients, opening 
of only a few CaV1.2 channels during depolarization can cause large (~10-fold) 
increases in [Ca2+]i (161). Thus, modest alterations in CASM EM can have large affects 
on CaV1.2-mediated Ca
2+ conductance and vascular tone as it has been reported that a 
change of even 3 mV can yield a 2-fold increase/decrease in [Ca2+]i (225; 227). The 
magnitude of Ca2+ influx through CaV1.2 channels depends on the number of channels, 
rate of Ca2+ entry, and NPo of the channel. In smooth muscle, Ca
2+ channels are 
abundantly expressed with ~5000 channels at a density of 4 µm2 (118). These channels 
have a unitary conductance of 3.5-5.5 pS and 5.5-11.0 pS using using 2.0 mM Ca2+ and 
Ba2+ as charge carriers, respectively (117; 119; 259). Single channel currents for CaV1.2 
channels in physiologic solutions have been reported at ~0.17 pA and increase with 
membrane deplarization as normal amplitudes of 0.23, 0.42 and 0.79 pA are observed at 
-40, -30 and -20 mV, respectively (Fig. 1-11A, (118)). Under EM conditions (-50 mV), this 
suggests a remarkable 1.04 million ions/s can permeate through a single Ca2+ channel 
(118; 225). Therefore, opening of only one CaV1.2 channel can raise the [Ca
2+]i 2.3 µM/s 
assuming there is no buffering or extrusion (36; 117; 118). This means that even with a 
low NPo and only ~1-10 channels open at more negative potentials of -60 mV, CaV1.2 
Figure 1-10 Structure of CaV1.2 Ca
2+
 channels. Six hexameric subunits with voltage-sensing and Ca
2+
 
selective regions form the functional channel. Auxillary α2δ1 and β subunits modify biophysical properties 
and membrane targeting of the α1c channel pore (55).  
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channels are constituitively active and likely contribute to basal vascular tone (118). 
Interestingly, single channel experiments demonstrate long inactivation periods that 
would serve to limit increases in NPo. Moreover, single channel recordings do not 
support steep increases in Po with depolarization (Fig. 1-11B) or the final steady-state 
values for NPo with 2 mM Ca
2+. Therefore, it has been proposed that an additional slow 
inactivating component over physiologic ranges of membrane potentials shifts the 
voltage-dependence of NPo to more possitive potentials by a constant factor of ~6 . This 
supports not only the steep voltage dependence of NPo, but also and most importantly 
the marked increases in current and [Ca2+]i with membrane depolarization (Fig. 1-11C, 
(36; 55; 117; 118; 161; 225; 292)).  
 
 
 
  
 
 
 
 Alterations in the regulation of steady-state Ca2+ entry by CaV1.2 channels have 
marked effects on coronary vasomotor tone. Modulation of CaV1.2 channels can occur in 
response to multiple mechanical, metabolic, and signaling mechanisms. It has been 
demonstrated that increases in intraluminal pressure of resistance arteries cause graded 
depolarization and Ca2+ influx (68; 191). Studies also indicate that CaV1.2 channels can 
also be activated by stretch (67; 69). However, more recent findings by Davis et al 
indicate that this response is secondary to stretch activation of nonselective cation 
channels (292). Regardless, activation of CaV1.2 channels in response to such 
mechanical stimuli is a critical component underlying coronary myogenic tone. Moreover, 
Figure 1-11 Contribution of CaV1.2 channel properties to whole cell Ca
2+
 current. Single CaV1.2 channel 
current (A) and open probability (B) increases with membrane depolarization. (C) Elevations in single 
channel activity with reductions in membrane potential alters the I-V relationship to significantly increase 
intracellular calcium levels (118). 
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recent investigations also indicate that protein kinase C (PKC) also contributes to the 
coronary myogenic response through alterations in CaV1.2 (214). In addition to PKC, 
protein kinase A and protein kinase G are also prominent activators of smooth muscle 
CaV1.2 channels and represent important pathways by which receptor-dependent 
activation of kinases can alter CaV1.2 channel activity (168). Thus, CaV1.2 channels 
serve as critical end-effectors to a wide array of factors. 
 Given the significant contribution of coronary CaV1.2 channels to regulating Ca
2+ 
influx in response to various mechanical and intracellular activation pathways, resulting 
alterations in CaV1.2 channel activity has marked effects on the regulation of coronary 
blood flow. This statement is evidenced by significant increases in coronary 
microvascular vasoconstriction in response to the CaV1.2 agonist Bay K 8644 (Fig. 1-
12A). More importantly, inhibition of coronary CaV1.2 channels relaxes coronary arteries 
and arterioles producing marked dose-dependent increases in coronary blood flow (Fig. 
1-12B). Because the degree of CaV1.2 channel activity has such dramatic effects on the 
magnitude of coronary blood flow, any change in the channel themselves or alterations 
in upstream modulators under pathological conditions may significantly impair coronary  
blood flow regulation.  
 
 
 
Figure 1-12 Contribution of CaV1.2 channels to coronary blood flow regulation. (A) Activation of CaV1.2 
channels with Bay K 8644 produces significant coronary vasoconstriction of isolated, pressurized 
arterioles. (B) Inhibition of CaV1.2 channels with nifedipine dose-dependently increases coronary blood 
flow. Adapted from Knudson et al (175).  
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 In summary, there is a significant and well documented role for coronary KV and 
CaV1.2 channels in regulating smooth muscle EM, vascular tone and coronary blood flow. 
However, the functional contribution of these channels to normal physiologic responses 
such as exercise-induced coronary vasodilation and pressure-flow autoregulation has 
not been determined. Such findings are critical to our understanding of coronary 
physiology as diminished control of coronary blood flow is associated with the 
development of cardiovascular disease and an increased incidence of mortality in many 
patient populations. Importantly and as outlined below, many disease states also impair 
ion channel function. Specifically, vascular K+ and Ca2+ channel dysfunction has been 
identified in hypertension, hyperglycemia, and dyslipidemia; conditions which are often 
associated with obesity (38; 41; 45; 132; 133; 175; 195; 199; 200; 310). Thus it is not 
surprising given the growing rate of obesity and it’s associated co-morbitities that the 
incidence of cardiovascular disease and mortality is also rising. Accordingly, determining 
the role for KV and CaV1.2 channels in the regulation of coronary blood flow under 
physiologic and pathophysiologic conditions may provide novel mechanistic insight into 
coronary dysfunction and obesity-related cardiovascular disease.  
 
Epidemic of Obesity and Metabolic Syndrome 
With an estimated 100 million Americans being obese or overweight, obesity in 
Western Society has now reached epidemic proportions (127). In addition, global 
estimates indicate that there are ~1 billion persons worldwide who are overweight (body 
mass index 25-30 kg/m2) (311). Moreover, many of these individuals display other 
clinical disorders such as dyslipidemia, insulin resistance/impaired glucose tolerance, 
and/or hypertension which is often accompanied by pro-inflammatory and thrombotic 
states (126). The combination of these factors with general obesity is classified into the 
disorder termed metabolic syndrome (MetS). The incidence of this disorder has reached 
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pandemic levels, as ~20-30% of adults in most developed countries can be classified as 
having MetS (126; 230). In addition, individual components of this prediabetic syndrome 
are independent risk factors for cardiovascular disease (126). The increased prevalence 
of MetS is associated with a 2-fold increased risk for cardiovascular disease, 5-fold 
increased risk for type 2 diabetes mellitus, and 1.5-fold increase in all-cause mortality 
(115; 222; 228). As a result MetS patients have significantly elevated morbidity and 
mortality to many cardiovascular-related diseases including: stroke, coronary artery 
disease, cardiomyopathies, myocardial infarction, congestive heart failure, and sudden 
cardiac death (127; 138; 189). Given that heart disease remains a leading cause of 
death around the world (126), elucidating mechanisms by which MetS increases 
cardiovascular risk is essential for developing future treatments and preventing this 
global epidemic. 
Alterations in the control of coronary blood flow could underlie increased 
cardiovascular morbidity and mortality in the MetS. As previously indicated, regulation of 
myocardial oxygen delivery is critical to overall cardiac function as the heart has limited 
anaerobic capacity and maintains a very high rate of oxygen extraction at rest (70-80%) 
(20; 82; 99; 294). Thus, the myocardium is highly dependent on a continuous supply of 
oxygen to maintain normal cardiac output and blood pressure. MetS impairs the ability of 
the coronary circulation to regulate vascular resistance and balance myocardial oxygen 
supply and demand (39; 269; 329). Coronary microvascular dysfunction in MetS is 
evidenced by reduced coronary venous PO2 (39; 269; 329), diminished vasodilation to 
endothelial-dependent and independent agonists (i.e. flow reserve) (23; 179; 246; 265; 
289; 290), and altered functional and reactive hyperemia (22; 37; 39; 269; 329). 
Importantly, these changes occur prior to overt atherosclerotic disease and have been 
associated with left ventricular systolic and diastolic contractile dysfunction in humans 
(95; 120; 245; 301; 313) and animal models of MetS (7; 39; 75; 248). 
 22 
Coronary blood flow in Metabolic Syndrome 
 Resting flow and vasodilator responses. There is little change in baseline 
coronary blood flow in either animals (25; 37; 38; 76; 176; 201; 269; 329) or humans 
(179; 244; 246; 265; 289) with MetS. While myocardial perfusion is equivalent, 
myocardial oxygen consumption (MVO2) is elevated in proportion to increases in stroke 
volume, cardiac output, and blood pressure; i.e. characteristic “hyperdynamic circulation” 
(39; 59; 75; 244; 248). Basal coronary venous PO2 is reduced in MetS, indicating an 
imbalance between coronary blood flow and myocardial metabolism (39; 269; 329). 
These findings suggest that the MetS forces the heart to utilize its limited oxygen 
extraction reserve by affecting one or more primary determinants of coronary flow, 
including: 1) myocardial metabolism; 2) arterial pressure; 3) neuro-humoral, paracrine 
and endocrine influences; and 4) myocardial extravascular compression (82; 99). 
Additionally, MetS increases sympathetic output (190; 204; 280; 288) and activates the 
RAAS (12; 60; 307; 308; 329), increasing blood pressure, myocardial oxygen demand, 
and coronary vascular resistance. The determinants of coronary flow in MetS are also 
influenced by diminished nitric oxide (NO) bioavailability (35; 49; 129; 211; 275) and 
augmented endothelial-dependent vasoconstriction (146; 176; 206-208; 316). However, 
despite these changes it is not surprising that basal coronary flow is largely unaffected 
by MetS, as it is well established that inhibition of NO synthesis (9; 29; 51; 83; 295) or 
endothelin-1 receptors (121; 207; 212; 213) does not alter myocardial perfusion in 
normal, lean subjects. To date, no studies have specifically examined the effects of 
MetS on myocardial compressive forces. 
MetS attenuates coronary flow responses to pharmacologic vasodilator 
compounds such as acetylcholine, adenosine, papaverine, and dipyridamole (179; 201; 
218; 246; 265; 289; 290). Decreases in coronary flow reserve directly correlate with 
waist-to-hip ratio (171), body mass index (265), blood pressure (290), degree of insulin 
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resistance (179; 290), and the clinical diagnosis of MetS (246). Interestingly, our data 
indicate that specific receptor subtypes and downstream K+ channels involved in 
coronary microvascular dilation are altered in Ossabaw swine with early-stage MetS, 
prior to any absolute change in coronary flow reserve (25). In contrast, decreased 
coronary flow reserve is evident in swine with later-stage MetS (38; 44; 218) and 
worsens with the onset of type 2 diabetes (179; 265). Exact mechanisms underlying 
impaired pharmacologic coronary vasodilation in MetS have not been clearly defined, 
but are likely related to altered functional expression of receptors and ion channels (25; 
38; 74; 201; 218; 219), endothelial and vascular smooth muscle function (35; 50; 74; 
275), paracrine and neuro-endocrine influences (174; 175; 190; 240; 280; 288; 308), 
structural remodeling of coronary arterioles (110; 276; 278), and/or microvascular 
rarefaction (111; 112; 273).  
 Coronary response to increases in cardiac metabolism. Energy production of the 
heart is almost entirely dependent on oxidative phosphorylation for contraction in relation 
to ventricular wall tension, myocyte shortening, heart rate, and contractility (82). Since 
the heart maintains a very high rate of O2 extraction at rest, increases in myocardial 
energy production must be met by parallel increases in myocardial O2 delivery (82; 99; 
294; 296). Exercise is the most important physiologic stimulus for increases in coronary 
blood flow, as many of the primary determinants of myocardial O2 demand are elevated 
by -adrenoceptor signaling (82; 296). Data from our laboratory indicate that MetS 
impairs the ability of the coronary circulation to adequately balance myocardial O2 
delivery with myocardial metabolism at rest and during exercise-induced increases in 
MVO2. In particular, coronary vasodilation in response to exercise is attenuated in 
Ossabaw swine with MetS. This effect is evidenced by reduction of the slope between 
coronary blood flow and aortic pressure, which supports that exercise-mediated 
increases in vascular conductance are attenuated in MetS (Fig. 1-13A). Diminished local 
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metabolic control of the coronary circulation is also evidenced by decreased coronary 
blood flow at a given coronary venous PO2 (Fig. 1-13B), an index of myocardial tissue 
PO2 which is hypothesized to be a primary stimulus for metabolic coronary vasodilation 
(82; 99; 294). Importantly, coronary venous PO2 is also depressed by MetS relative to 
alterations in MVO2 (the primary determinant of myocardial perfusion) both at rest and 
during exercise (Fig. 1-13C). Together, these findings demonstrate coronary 
microvascular dysfunction in MetS leads to an imbalance between coronary blood flow 
and myocardial metabolism that could contribute to the increased incidence of cardiac 
contractile dysfunction and myocardial ischemia in obese patients (115; 126; 147; 189). 
This point is supported by an ~25% reduction in baseline cardiac index (cardiac output 
normalized to body weight) and a marked increase in myocardial lactate production 
(onset of anaerobic glycolysis) in swine with the MetS (39).    
 
 
 
 Coronary response to myocardial ischemia. Coronary vasodilation in response to 
myocardial ischemia is a critical mechanism increasing O2 delivery to the heart to 
mitigate ischemic injury and infarction (232; 260). To address the effects of MetS on 
ischemic vasodilation, we examined coronary flow responses to a 15 sec occlusion in 
anesthetized, open-chest lean and MetS Ossabaw swine (37). Representative tracings 
Figure 1-13 Effects of metabolic syndrome on coronary blood flow at rest and during exercise. (A) 
Reduction of the slope between coronary blood flow and aortic pressure indicates that exercise-mediated 
increases in vascular conductance are significantly attenuated by the MetS. (B) Diminished local metabolic 
control is also evidenced by decreased coronary blood flow at a given coronary venous PO2. (C) 
Imbalance between myocardial oxygen supply and demand in MetS is evidenced by the reduction of 
coronary venous PO2 relative to alterations in MVO2 (the primary determinant of myocardial perfusion) 
both at rest and during exercise. 
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illustrating reactive hyperemia in lean vs. MetS swine are shown in Figure 1-14A. 
Because coronary reactive hyperemia varies directly with baseline blood flow, estimating 
overall repayment of incurred oxygen debt is critical for analyzing ischemic dilator 
responses (232; 260). Our finding that vasodilation in response to cardiac ischemia is 
impaired by MetS, relative to the deficit in coronary blood flow (i.e. repayment/debt ratio; 
Fig. 1-14B), is consistent with decreased reactive hyperemia of peripheral vascular beds 
in obese humans (70; 149). We propose that impaired ischemic dilation in MetS could 
exacerbate myocardial injury in patients with flow-limiting atherosclerotic lesions or acute 
coronary thrombosis.  
In summary, microvascular dysfunction in MetS upsets the balance between 
coronary blood flow and myocardial metabolism as well as impairs blood flow responses 
to pharmacologic vasodilator compounds (coronary flow reserve), exercise-induced 
increases in MVO2 (physiologic stimuli), and cardiac ischemia (pathophysiologic stimuli). 
Potential ion channels implicated in the impaired control of coronary blood flow are 
explored below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-14 Effect of the metabolic syndrome on coronary vasodilation in response to cardiac ischemia. 
(A) Representative tracings illustrating reactive hyperemic responses in lean and MetS swine. (B) 
Coronary vasodilation in response to cardiac ischemia is impaired by metabolic syndrome as evidenced 
by the significant reduction in percent repayment of incurred coronary flow debt (i.e. repayment/debt ratio). 
* P < 0.05 vs. lean-control. 
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Metabolic Syndrome and Coronary Ion Channels 
As previously indicated, coronary smooth muscle cells express a variety of ion 
channels which regulate EM and vascular tone (74). Major types include voltage-
dependent K+ (KV) and Ca
2+ (CaV1.2) channels. However, several other important K
+ 
channels are functionally expressed in the coronary circulation including large 
conductance, Ca2+-activated (BKCa), ATP-sensitive (KATP), and inwardly rectifying (Kir) K
+ 
channels. With the exception of BKCa, the affect of metabolic syndrome on the function 
of these prominent channels has not been characterized.  
 BKCa channels activate at a more depolarized EM (38), but also respond to local 
Ca2+ signaling (218). Recently, we found that the MetS significantly attenuates coronary 
BKCa channel function, as evidenced by a reduction in vasodilation to the BKCa channel 
agonist NS1619 (Fig. 1-15B, (38)). This decrease in vasodilation corresponded with 
reductions in coronary vascular smooth muscle BKCa current (Fig. 1-15A) and a 
paradoxical increase in BKCa channel α and 1 subunit expression (38). Decreases in 
total K+ current and spontaneous transient outward currents, which are elicited by Ca2+ 
sparks and indicative of BKCa channel activation, have also been reported in coronary 
microvessels of diabetic dyslipidemic swine (218; 324). Studies in obese, insulin 
resistant rat models also support these findings and suggest that the reductions in BKCa 
current are related to alterations in the regulatory β1 subunit (203; 324). Although 
diminished BKCa channel function in obesity/MetS is well established, data fail to support 
a significant role for BKCa channels in the control of coronary blood flow at rest, during 
increases in MVO2 or during cardiac ischemia in lean or MetS animal models (37). 
However, BKCa channels have been shown to modulate coronary endothelial-dependent 
vasodilation in normal-lean subjects (215; 216). Thus, we propose that decreases in 
BKCa channel function likely contribute to coronary endothelial dysfunction observed in 
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the setting of the MetS (24), but play little role in the overall impairment of coronary 
vascular function. 
 Coronary KV channels in metabolic syndrome. In contast to BKCa, KV channels 
are activated in the physiological range of EM and thus have been implicated in the 
control of coronary blood flow (74). In particular, our laboratory previously demonstrated 
that KV channels regulate coronary blood flow at rest, during ischemia, and with 
increasing MVO2 in normal-lean animals (30; 73; 256; 257; 264). More recent data 
indicates that metabolic coronary vasodilatation is also reduced in KV1.5 knockout mice 
(231). Importantly, individual components of MetS have been associated with KV channel 
dysfunction. Although the specific mechanisms underlying the impairment of coronary KV 
channels are unclear, there is evidence that dyslipidemia, hyperglycemia, hypertension, 
and/or oxidative stress may contribute (43; 45; 132; 133; 195; 198; 199). Activation of 
the sympathetic nervous system, RAAS, and PLC-PKC signaling pathways could also 
be involved (26; 63; 74). However, no study to date has determined the extent to which 
MetS alters coronary KV channel function and the potential affects this may have on 
coronary blood flow regulation.  
 Coronary CaV1.2 channels in metabolic syndrome. CaV1.2 Ca
2+ channels are the 
predominant voltage-dependent Ca2+ channel expressed in coronary smooth muscle 
(168). Ca2+ regulates contraction and gene expression; therefore, alterations in CaV1.2 
channel function by MetS could have many consequences (118; 272; 303). In particular, 
increased activation of vasoconstrictor pathways (e.g. α1 adrenoceptors, AT1 receptors) 
along with decreased function of smooth muscle K+ channels (e.g. BKCa channels, KV 
channels) would serve to augment CaV1.2 channel activity and vasoconstriction (74). 
Data from our laboratory support this hypothesis as we previously demonstrated that the 
MetS increases intracellular Ca2+ concentration (38), CaV1.2 channel current (Fig. 15C) 
and arteriolar vasoconstriction to the CaV1.2 channel agonist Bay K 8644 (175) (Fig. 
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Figure 1-15 Effect of metabolic syndrome on coronary vasoconstriction and ion channel function. (A) 
Reductions in coronary vascular smooth muscle BKCa current in response to the BKCa channel agonist 
NS1619 directly correspond with (B) diminished coronary vasodilation to NS1619 in MetS swine. Data from 
reference (175). (C) Increases in coronary vascular smooth muscle L-type Ca
2+
 channel current activation 
in response to Bay K 8644 are associated with (D) augmented coronary arteriolar vasoconstriction to Bay K 
8644 in obese dogs.  
15D). We also found that coronary vasodilation in response to the CaV1.2 channel 
antagonist nicardipine is markedly elevated in obese dogs with the MetS (175). These 
findings are in contrast with earlier studies which documented reductions in CaV1.2 Ca
2+ 
channel current in hypercholesterolemic and/or diabetic dyslipidemic swine (41; 310). 
Taken together, these data indicate that the entire MetS milieu is critical in determining 
the overall functional expression of CaV1.2 channels in the coronary circulation. Whether 
increases in CaV1.2 channel activation contribute to the impaired control of coronary 
blood flow at rest or during increases in MVO2 in the MetS merits further investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, coronary dysfunction is a central contributor to increased mortality in 
MetS patients. However, the mechanisms underlying impaired regulation of coronary 
blood flow remain poorly understood. Investigations to date demonstrate that the MetS 
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Figure 1-16 Schematic diagram illustrating mechanisms by which the metabolic syndrome impairs 
control of coronary blood flow. Factors, receptors and ion channels that are downregulated in metabolic 
syndrome are depicted in green. Factors, receptors and pathways that are upregulated in metabolic 
syndrome are depicted in blue and/or with + symbol. ET-1 (endothelin-1); Ang II (angiotensin II); AT1 
(angiotensin II type 1 receptor); α1 (α1 adrenoceptor); NE (norepinephrine); MVO2 (myocardial oxygen 
consumption); TRP (transient receptor potential channel); BKCa (large conductance, Ca
2+
 activated K
+
 
channel); ETA (endothelin type A receptor). eNOS (endothelial nitric oxide synthase); ECE (endothelin 
converting enzyme).  
 
significantly attenuates the balance between coronary blood flow and myocardial 
metabolism. Data obtained from our laboratory and others attribute this imbalance to 
elevated constrictor/diminished dilator pathways observed in MetS (see schematic 
diagram in Fig. 1-16). Yet our ability to target these pathways has been only modestly 
effective in attenuating adverse cardiovascular complications associated with the MetS. 
Importantly, many of the targeted pathways in MetS modulate coronary vasomotor tone 
via activation of downstream ion channels. However, little is known of the influence MetS 
has on particular key ion channels, namely K+ and Ca2+ channels. Thus, investigating 
the contribution of KV and CaV1.2 channels to coronary microvascular dysfunction in 
MetS will greatly improve our understanding of the patho-physiologic regulation of 
coronary blood flow and poor cardiovascular outcomes in patients with the MetS.  
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Hypothesis and Investigative Aims 
Evidence to date support the finding that KV and CaV1.2 channels are critical end-
effectors in modulating coronary vasomotor tone and blood flow. Yet the role for these 
channels under physiologic conditions remains largely unexplored. In addition, the 
pathways/mechanisms that regulate channel activity are not fully understood and may 
involve a strong interdependent relationship, i.e. electromechanical coupling, due to the 
biophysical properties of KV and CaV1.2 channels. Importantly, there is a growing body of 
evidence that suggests the MetS and its pathologic components may alter coronary ion 
channel function. Therefore, we propose that determining the contribution of these 
channels to the physiologic regulation of coronary blood flow and the degree to which KV 
and CaV1.2 channels are altered by MetS may elucidate underlying mechanisms of 
coronary dysfunction in patients with MetS. Accordingly, the overall goal of this 
investigation was to: 1) delineate the functional role for coronary KV and CaV1.2 channels 
in the coronary response to ischemia, exercise, and pressure-flow autoregulation; 2) 
determine potential electromechanical coupling between these channels; and 3) 
examine the contribution of KV and CaV1.2 channels to coronary microvascular 
dysfunction in MetS. Findings from this investigation stand to offer novel mechanistic 
insight into the patho-physiologic regulation of KV and CaV1.2 channels and significantly 
improve our understanding of obesity-related coronary vascular disease.  
 
 Aim 1 was designed to elucidate the contribution of adenosine A2A and A2B 
receptors to coronary reactive hyperemia and downstream K+ channels involved. 
The rationale for this study derives from investigations that determined coronary 
vasodilation in response to adenosine occurs primarily through the activation of A2A and 
A2B receptor subtypes (25; 136; 170; 172; 221; 284; 293). However, the relative 
contribution of these subtypes to ischemic coronary vasodilation has not been clearly 
 31 
defined. Earlier studies demonstrate that both A2A and A2B receptor subtypes converge 
on downstream KATP to induce coronary vasodilation (58; 65; 66; 134-136; 148; 172; 
298). More recent data from our laboratory also indicate that KV channels play a 
significant role in the coronary vascular response to adenosine (73). Importantly, both 
KATP and KV channels have been shown to modulate coronary vasodilation in response 
to cardiac ischemia (58; 73; 165; 328). However, the extent to which A2A and/or A2B 
receptor activation contributes to this effect of K+ channels has not been investigated.  
 
 Aim 2 was designed to examine the contribution of KV and CaV1.2 channels 
to coronary pressure-flow autoregulation in vivo. The rationale for this aim is 
obtained from previous studies implicating KV channels in coronary vasodilation during 
reductions in coronary perfusion pressure (73) and CaV1.2 channels in the myogenic 
response to elevations in pressure; both proposed components of coronary pressure-
flow autoregulation. In contrast to other ion channels investigated in coronary 
autoregulation (i.e. KATP (277)), KV channels may play a more prominent role given their 
contribution to the control of coronary blood flow under a variety of physiologic 
conditions (30; 32; 73; 256; 257; 264). In addition, a myogenic component of coronary 
autoregulation is likely critical for mitigating pressure-induced increases in coronary 
blood flow (184; 210). Increases in intraluminal pressure and stretching of vascular 
smooth muscle cells results in graded decreases in smooth muscle membrane potential 
and increases in intracellular [Ca2+] that has been attributed to extracellular influx via 
voltage-gated (CaV1.2) Ca
2+ channels (68; 69; 76; 142). Importantly, the extent to which 
KV and CaV1.2 channels contribute to changes in coronary vasomotor tone in response 
to alterations in coronary perfusion pressure in vivo has not been determined. 
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 Aim 3 was designed to determine the role for KV channels in metabolic 
control of coronary blood flow and to test the hypothesis that decreases in KV 
channel function and/or expression significantly attenuate myocardial oxygen 
supply-demand balance in the MetS. The rationale for this aim stems from previous 
investigations demonstrating that KV channels represent a critical end-effector 
mechanism that modulates coronary blood flow at rest (73; 264), during cardiac pacing 
or catecholamine-induced increases in myocardial oxygen consumption (MVO2) (264), 
following brief periods of cardiac ischemia (73), and endothelial-dependent and 
independent vasodilation (25; 32; 73). However, the functional contribution of KV 
channels to metabolic control of coronary blood flow during physiologic increases in 
MVO2, as occur during exercise, has not been examined. In addition, decreases in KV 
channel activity have been associated with key components of the MetS, including 
hypercholesterolemia (132; 133), hypertension (45), and hyperglycemia (195; 199; 200). 
We hypothesize that such reductions in the functional expression of KV channels 
contribute to the impaired control of coronary blood flow in the setting of the MetS. 
 
  Aim 4 was designed to delineate the relationship between coronary KV and 
CaV1.2 channels and to evaluate the contribution of CaV1.2 channels to coronary 
microvascular dysfunction in MetS. The overall rationale for performing experiments 
in this study is based on previous investigations implicating CaV1.2 channels as a 
predominant regulator of extracellular Ca2+ influx and coronary vascular resistance. In 
addition, depolarizations resulting from KV channel inhibition increase cytosolic [Ca
2+] 
and are abolished by removal of extracellular Ca2+ (205). However, the extent to which 
CaV1.2 channels regulate coronary blood flow as a consequence of alterations KV 
channel function and the functional importance of this potential interaction is unknown. 
Importantly, data from our laboratory demonstrate that the MetS increases intracellular 
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Ca2+ concentration (38), CaV1.2 Ca
2+ channel current and arteriolar vasoconstriction to 
the CaV1.2 channel agonist Bay K 8644 (175). We also found that coronary vasodilation 
in response to the CaV1.2 channel antagonist nicardipine is markedly elevated in obese 
dogs with the MetS (175). Whether increases in CaV1.2 channel activation contribute to 
the impaired control of coronary blood flow at rest or during increases in MVO2 in the 
MetS has not been determined. 
 The significance of the proposed research is that coronary dysfunction is an 
important contributor to cardiovascular morbidity and mortality in patients with the MetS. 
The experimental design of these studies utilizes an integrative approach of in vitro (e.g. 
patch-clamp electrophysiology, western blot, flow cytometry, immunohistochemistry) and 
in vivo (acute and chronically instrumented swine) experimental techniques to examine 
the aims of this investigation. Experiments were conducted in lean canines and swine 
(Aim 1, 2) in addition to our Ossabaw swine model of the MetS (Aims 3, 4) fed either a 
normal maintenance or a high calorie atherogenic diet for 16 weeks. This excess 
atherogenic diet consistently produces clinical phenotypes of MetS including obesity, 
insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, 
hyperleptinemia, and coronary atherosclerotic disease (38; 44; 281). Taken together, 
results from this investigation improve our knowledge of obesity-related coronary 
vascular disease and may afford novel therapeutic strategies to treat a developing 
national epidemic. 
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Abstract 
 This study was designed to elucidate the contribution of adenosine A2A and A2B 
receptors to coronary reactive hyperemia and downstream K+ channels involved. 
Coronary blood flow was measured in open-chest anesthetized dogs. Adenosine dose-
dependently increased coronary flow from 0.72 ± 0.1 to 2.6 ± 0.5 ml/min/g under control 
conditions. Inhibition of A2A receptors with SCH58261 (1 μM) attenuated adenosine-
induced dilation by ~50%, while combined administration with the A2B receptor 
antagonist alloxazine (3 μM) produced no additional effect. SCH58261 significantly 
reduced reactive hyperemia in response to a transient 15 sec occlusion; debt/repayment 
ratio decreased from 343 ± 63 to 232 ± 44%. Alloxazine alone attenuated adenosine-
induced increases in coronary blood flow ~30% but failed to alter reactive hyperemia. 
A2A receptor agonist CGS21680 (10 μg bolus) increased coronary blood flow by 3.08 ± 
0.31 ml/min/g. This dilator response was attenuated to 0.76 ± 0.14 ml/min/g by inhibition 
of Kv channels with 4-aminopyridine (0.3 mM) and to 0.11 ± 0.31 ml/min/g by inhibition of 
KATP channels with glibenclamide (3 mg/kg). Combined administration abolished 
vasodilation to CGS21680. These data indicate that A2A receptors contribute to coronary 
vasodilation in response to cardiac ischemia via activation of KV and KATP channels. 
 
 
 
 
KEYWORDS: Reactive hyperemia, coronary vasodilation, adenosine receptor, 
potassium channel, canine. 
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Introduction 
 Since adenosine was first proposed as a constituent of coronary vasomotor 
regulation by Berne in 1963 (28), the role of this local purinergic metabolite has evolved 
considerably.  Although studies have demonstrated that adenosine is not required for the 
regulation of coronary blood flow at rest or during increases in myocardial metabolism 
(15; 87; 297), adenosine has been shown to contribute to coronary vasodilation when 
myocardial oxygen requirements are not sufficiently met during episodes of ischemia 
(85; 101; 193). In particular, coronary vasodilation in response to exercise is diminished 
by combined enzymatic degradation and non-selective inhibition of adenosine receptors 
in dogs with a coronary stenosis (coronary perfusion pressure = 40 mmHg) (193). This 
finding is in agreement with data from Stepp and Feigl who demonstrated that cardiac 
adenosine production is markedly elevated by reductions in coronary perfusion pressure 
below 60 mmHg (277). Other studies indicate that adenosine contributes to coronary 
vasodilation in response to brief episodes of cardiac ischemia, i.e. coronary reactive 
hyperemia (15; 263), however, this is not a consistent finding (33; 73).  
 The cardiovascular effects of adenosine are mediated via four extracellular 
receptor subtypes; A1, A2A, A2B and A3 (223). Although coronary microvascular 
vasodilation in response to adenosine occurs primarily through the activation of A2A and 
A2B receptor subtypes (25; 136; 170; 172; 221; 284; 293), the relative contribution of 
these subtypes to ischemic coronary vasodilation has not been clearly defined. Recently, 
Zatta and Headrick (328) found that selective inhibition of adenosine A2A receptors 
reduced coronary reactive hyperemia in isolated, buffer-perfused mouse hearts by ~20-
30%. The contribution of A2A receptors to microvascular regulation was also 
demonstrated by Frobert et al. who found that the selective A2A antagonist ZM241385 
attenuated hypoxic dilation of isolated porcine coronary arteries by ~30% (113). A2B 
receptors have also been shown to contribute to coronary vasodilation in response to 
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adenosine (170; 221; 224), although, not in response to hypoxia (113).  At present, it is 
unclear whether A2A and/or A2B receptors regulate coronary blood flow during cardiac 
ischemia in vivo. 
 Earlier studies demonstrate that both A2A and A2B receptor subtypes converge on 
downstream ATP-dependent K+ channels (KATP) to induce coronary vasodilation (58; 65; 
66; 134-136; 148; 172; 298).  More recent data from our laboratory also indicate that 
voltage-dependent K+ channels (Kv) play a significant role in the coronary vascular 
response to adenosine (73). Importantly, both KATP and Kv channels have been shown to 
modulate coronary vasodilation in response to cardiac ischemia (58; 73; 165; 328). 
However, the extent to which A2A and/or A2B receptor activation contributes to this effect 
of K+ channels has not been investigated. Accordingly, the purpose of this investigation 
was to examine the hypothesis that adenosine A2A and/or A2B receptors mediate 
coronary vasodilation in response to cardiac ischemia via activation of downstream Kv 
and/or KATP channels. Our findings provide important new data on the functional 
contribution of adenosine receptor subtypes to increases in coronary blood flow in 
response to endogenously produced ischemic metabolites in vivo. 
 
Methods 
 All protocols were approved by the Institutional Animal Care and Use Committee 
in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 
85-23, Revised 1996).  Male mongrel dogs (n = 16) weighing between 20-30 kilograms 
were administered morphine (3 mg/kg, s.c.) as a sedative, pre-anesthetic before 
inducing anesthesia with α-chloralose (100 mg/kg, iv).  Following completion of 
experimental protocols, hearts were fibrillated and excised as recommended by the 
American Veterinary Medical Association Guide on Euthanasia (June 2007).   
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 Surgical preparation. Following induction of anesthesia, dogs were intubated and 
ventilated with room air supplemented with O2. A catheter was placed into the thoracic 
aorta via the right femoral artery to measure aortic blood pressure and heart rate. The 
left femoral artery was catheterized to supply blood to an extracorporeal perfusion 
system used to perfuse the left anterior descending coronary artery (LAD). A catheter 
was also inserted into the right femoral vein for injection of supplemental anesthetic, 
heparin and sodium bicarbonate. Arterial blood gases were analyzed periodically 
throughout the experimental protocol and adjustments made as needed to maintain 
blood gas parameters within normal physiological limits. Following a left lateral 
thoracotomy, a proximal portion of the LAD was isolated distal to its first major diagonal 
branch. Following heparin administration (500 U/kg), the LAD was cannulated with a 
stainless steel cannula connected to an extracorporeal perfusion system. Coronary 
perfusion pressure was maintained at 100 mmHg throughout the experimental protocol 
by a servo-controlled roller pump. Hemodynamic parameters were allowed to stabilize 
for ~30 min before initiation of the experimental protocol.  
 Experimental Protocol. Adenosine (3 - 30 μg/min) was infused at a constant rate 
into the LAD perfusion circuit before and during administration of the selective A2A 
receptor antagonist SCH58261 (1 μM, i.c.), followed by the subsequent inhibition of A2B 
receptors with alloxazine (3 μM, i.c.). Coronary reactive hyperemia was assessed by a 
15 sec occlusion of the LAD before and during administration of SCH58261 (1 μM, i.c.) 
followed by alloxazine (3 μM, i.c.). Adenosine dose-response and reactive hyperemia 
studies were also performed in the absence and presence of the A2B antagonist 
alloxazine alone (i.e. without SCH58261 administration).  Additional studies were also 
conducted with the selective A2A agonist CGS 21680 (10 µg bolus, i.c.), before and after 
administration of the KV channel antagonist 4-aminopyridine (4-AP, 0.3 mM, i.c.) and/or 
inhibition of KATP channels with glibenclamide (3 mg/kg, i.v.). CGS 21680 infusions were 
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separated by at least 45 min as time control studies revealed similar coronary 
vasodilation in response to CGS 21680 following a 45 min washout period. Coronary 
reactive hyperemia studies were also conducted in the presence of 4-AP, gliblenclamide, 
and 4-AP + glibenclamide. All drugs, with the exception of glibenclamide (dissolved in 
equal parts of ethanol, propylene glycol, 1N NaOH) and 4-AP (in saline) were dissolved 
in DMSO, diluted 1:10 with saline and infused i.c. at a constant rate (~300 µl/min) for ~5 
min prior to measurements in order to achieve the desired coronary plasma 
concentration. LAD perfusion territory was estimated as previously described by Feigl et 
al. (103). 
  Statistical analyses. Data are presented as mean ± SE from n dogs.  Reactive 
hyperemic volumes were calculated as area under the curve using Prism software 
(GraphPad, San Diego, CA). Duration parameters were evaluated at 35 seconds post 
occlusion and the point at which hyperemic flow had returned to within 5% of baseline. 
Statistical comparisons were made by t-test, one-way or two-way repeated measures 
analysis of variance (ANOVA) as appropriate. If statistical differences (P < 0.05) in these 
analyses were noted, a Student-Newman-Keuls multiple comparison test was 
performed. 
 
Results 
   Contribution of A2A and A2B receptors to adenosine-mediated coronary 
vasodilation. Effects of A2A and A2B receptor blockade on baseline hemodynamic 
variables are listed in Table 2-1. Treatment with vehicle, SCH58261 and/or alloxazine 
did not significantly affect arterial blood pressure or coronary blood flow under baseline-
resting conditions. Heart rate was modestly elevated during combined blockade of A2A 
and A2B receptors. Under control conditions, exogenous adenosine administration dose-
dependently increased coronary blood flow from 0.81 ± 0.07 at rest to 2.53 ± 0.51 
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Figure 2-1 Effect of A2A and A2B 
receptor inhibition on 
adenosine-induced coronary 
vasodilation. Inhibition of A2A 
receptors with SCH58261 (1 
μM, ic) significantly attenuated 
coronary vasodilation in 
response to exogenously 
infused adenosine. Combined 
administration of SCH58261 
with the A2B receptor antagonist 
alloxazine (3 μM, ic) produced 
no additional effect. * P < 0.05 
control. 
 
ml/min/g at the highest dose of adenosine (30 µg/min, i.c.). Administration of the A2A 
receptor antagonist SCH58261 significantly reduced coronary vasodilation in response 
to adenosine ~70% (Fig. 2-1, n = 4). Subsequent administration of the A2B receptor 
antagonist alloxazine had no additional effect on adenosine dilation. In separate studies, 
alloxazine alone attenuated adenosine-induced increases in coronary blood flow ~30% 
(Fig. 2-3A, n = 3).  
Table 2-1 Effect of A2A and A2B receptor blockade on baseline hemodynamics. 
                               
Condition
Systolic 
Pressure, 
mmHg
Diastolic 
Pressure, 
mmHg
Mean 
Arterial 
Pressure, 
mmHg
Heart Rate, 
bpm
Coronary  
Pressure, 
mmHg
Coronary 
Flow, 
ml/min/g
Control 125 ± 11 79 ± 7 98 ± 8 75 ± 12 100 ± 1 0.81 ± 0.07
Vehicle 123 ± 11 79 ± 6 97 ± 7 77 ± 12 100 ± 1 0.91 ± 0.07
SCH 58261 123 ± 7 87 ± 7 102 ± 7 97 ± 13 99 ± 1 0.96 ± 0.09
SCH + Alloxazine 115 ± 7 82 ± 3 96 ± 4 105 ± 13* 100 ± 1 1.00 ± 0.09
     Values are means ± SE for n=7 dogs. * P  < 0.05 vs. respective vehicle control.  
 
  
  
 
 
 
 
  
  
 Contribution of A2A and A2B receptors to coronary reactive hyperemia.  Table 2-2 
shows the effects of vehicle, A2A and subsequent A2B receptor blockade on key coronary 
reactive hyperemia variables. Importantly, drug-vehicle had no significant effect on the 
coronary reactive hyperemic response. Inhibition of A2A receptors with SCH58261 
significantly reduced coronary vasodilation in response to brief, 15 sec coronary artery 
occlusion (Fig. 2-2A, n = 7). In particular, SCH58261 diminished the duration of the 
 41 
hyperemic response and the overall volume of repayment (Table 2-2). This reduced the 
repayment of coronary flow debt from 343 ± 63% in vehicle treated hearts to 232 ± 44% 
following SCH58261 administration (Fig. 2-2C). Successive blockade of A2B receptors 
with alloxazine had no additional effect on the coronary reactive hyperemic response 
(Fig. 2-2B, Table 2-2). Sole administration of alloxazine also failed to significantly alter 
the hyperemic response (Fig. 2-3B; n = 3).  
Table 2-2 Effect of A2A and A2B receptor blockade on coronary reactive hyperemia. 
                   
Condition
Peak Flow,                                            
ml/min/g
Debt Area,
ml/g
Repayment      
Area,         
ml/g
Δflow at 35 
seconds, 
ml/min/g             
 Duration, 
seconds
Control 3.15 ± 0.2 0.20 ± 0.02 0.71 ± 0.07 0.92 ± 0.14 83.14 ± 6.24
Vehicle 3.26 ± 0.2 0.23 ± 0.02 0.74 ± 0.11 0.92 ± 0.12 83.57 ± 5.75
SCH 58261 3.05 ± 0.1 0.24 ± 0.02 0.51 ± 0.06* 0.57 ± 0.10* 65.00 ± 4.43*
SCH + Alloxazine 3.29 ± 0.1 0.25 ± 0.02 0.57 ± 0.09* 0.69 ± 0.17* 73.29 ± 8.07
     Values are means ± SE for n = 7 dogs. * P  < 0.05 vs. respective vehicle control. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 Role of adenosine A2A and A2B receptors in ischemic coronary vasodilation. (A) Inhibition of 
A2A receptors with SCH58261 (1 µM, ic) significantly reduced coronary vasodilation in response to a 15 
sec transient coronary artery occlusion. (B) The coronary reactive hyperemic response was unaffected by 
additional blockade of A2B receptors with alloxazine (3 µM). (C) Effects of A2A and A2B receptor blockade 
on the repayment of coronary flow debt. A2A receptor blockade significantly reduced the debt-repayment 
ratio relative to vehicle-control. Addition of the A2B receptor antagonist alloxazine produced no additional 
effect. Figures show grouped average traces for n = 7 dogs. * P < 0.05 vs. vehicle. 
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 A2A receptor activation of coronary K
+ channels.  Experiments were conducted to 
assess the contribution of KV and KATP channels to coronary vasodilation mediated by 
A2A receptor activation. Coronary blood flow increased from 0.75 ± 0.09 to 3.32 ± 0.17 
ml/min/g following intracoronary administration of the selective A2A agonist CGS 21680 
(10 µg, n = 4). A2A -mediated vasodilation was significantly attenuated by inhibition of 
either KV (~70%, n = 3) or KATP channels (~96%, n = 3) alone (Fig. 2-4). Combined 
administration of 4-AP and glibenclamide essentially abolished the response to CGS 
21680 (Fig. 2-4, n = 4).  
 
 
 
 
 
 
 
 
Figure 2-4 Effect of selective K
+
 
channel blockade on A2A 
receptor-mediated dilation. 
Coronary vasodilation in 
response to A2A receptor 
activation with CGS 21680 (10 
μg bolus, ic) was markedly 
attenuated by inhibition of KV 
channels with 4-AP (0.3 mM, i.c.) 
and KATP channels with 
glibenclamide (3.0 mg/kg, i.v.). 
Combined administration of 4-AP 
and glibenclamide essentially 
abolished A2A receptor-induced    
coronary vasodilation. * P < 0.01 
vs. control. 
Figure 2-3 Contribution of A2B receptors to exogenous adenosine and ischemia induced vasodilation. (A) 
Alloxazine (3 μM, i.c.) significantly reduced coronary blood flow during cumulative adenosine infusions. 
(B) No effect of A2B receptor blockade on reactive hyperemia.    * P < 0.05 vs. control. 
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 As recently demonstrated by our laboratory (37; 73), inhibition of KV (n = 5) 
and/or KATP (n = 3) channels markedly reduced the coronary reactive hyperemic 
response (Fig. 2-5). In particular, the decrease of both peak flow and the duration of the 
hyperemic response following combined K+ channel blockade significantly reduced the 
repayment of coronary flow debt from 422 ± 51% to 162 ± 40%. 
 
 
 
 
DISCUSSION 
 This study examined the hypothesis that adenosine A2A and/or A2B receptors 
significantly contribute to coronary vasodilation in response to cardiac ischemia via 
activation of downstream Kv and KATP channels. To test this hypothesis, we measured 
changes in coronary blood flow in open-chest anesthetized canines in response to 
selective adenosine A2A and A2B receptor blockade during both exogenous adenosine 
infusion and following a brief coronary artery occlusion. In addition, the coupling of A2A 
receptors to KV and KATP channels was also assessed. The major findings of this study 
are: 1) A2A receptors contribute to coronary vasodilation in response to exogenous 
adenosine administration and cardiac ischemia; 2) A2A receptor-induced coronary 
vasodilation is mediated via signaling pathways that converge on KV and KATP channels; 
3) A2A and A2B receptors do not contribute to the regulation of coronary blood flow under 
Figure 2-5 Effect of K
+
 channel blockade on ischemic coronary vasodilation. Averaged group tracings 
showing impaired coronary ischemic vasodilation in response to A: KV channel blockade with 4-AP (n = 
5). B: KATP channel blockade with glibenclamide (n = 3). C: Combined inhibition of both KV and KATP 
channels (n = 3). 
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baseline-resting conditions; and 4) A2B receptors contribute to coronary vasodilation in 
response to exogenous adenosine, but are not required for dilation in response to 
cardiac ischemia. These data indicate that A2A receptors contribute to coronary 
vasodilation in response to cardiac ischemia via activation of KV and KATP channels. 
 Contribution of A2A and A2B receptors to the control of coronary blood flow. 
Findings from this investigation indicate that A2A and A2B receptors contribute to coronary 
vasodilation in response to exogenous adenosine in vivo, with the A2A receptor pathway 
playing the predominant role. In particular, inhibition of A2A receptors significantly 
reduced the increase in coronary blood flow to the highest dose of adenosine (30 
µg/min) ~40% beyond that of A2B receptor blockade alone (Figs. 2-1 and 2-3). Earlier in 
vitro studies using selective antagonists and/or genetic knockout of A2 receptor subtypes 
in isolated coronary arteries (25; 113; 170) and buffer-perfused mouse hearts (221; 284; 
328) support this finding. In addition, recent in vivo studies have also documented 
marked coronary vasodilation in response to selective A2A receptor agonists (144; 293). 
Although A2 receptors are expressed and capable of mediating vasodilation in the canine 
coronary circulation, it is important to recognize that inhibition of A2A and/or A2B receptors 
failed to significantly diminish resting coronary flow (Table 2-1). Therefore, our data do 
not support a role for either A2A or A2B receptors in the regulation of baseline coronary 
vasomotor tone in vivo. This conclusion is supported by numerous previous studies 
utilizing enzymatic and/or non-selective adenosine receptor antagonists (15; 87; 297; 
320).  
 A2A and A2B receptors in coronary reactive hyperemia. A primary goal of this 
investigation was to assess the functional contribution of A2A and A2B receptors to 
coronary vasodilation in response to endogenous metabolites produced during cardiac 
ischemia. We show, for the first time in vivo, that A2A receptors contribute to coronary 
reactive hyperemia, as inhibition of A2A receptors with SCH58261 reduced repayment of 
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coronary flow debt ~32% (Fig. 2-2). Although earlier studies indicate that the 
mechanisms of coronary reactive hyperemia are dependent on species, experimental 
preparation and the duration of coronary occlusion (109; 131; 328), our finding is 
consistent with data from Zatta and Headrick who reported that SCH58261 (100 nM) 
resulted in an ~20-30% reduction in the coronary reactive hyperemic response in 
isolated mouse hearts (328). In addition, data from Frobert et al. demonstrate that the 
selective A2A blockade attenuates hypoxic dilation of isolated porcine coronary arteries 
by ~30% (113). The effect of A2A receptor inhibition on coronary reactive hyperemia is in 
contrast with our recent study which found little/no effect of the non-selective adenosine 
receptor antagonist 8-phenyltheophylline on ischemic vasodilation in the canine coronary 
circulation (73). We hypothesize these discrepant findings are related to the opposing 
effects A1 vs. A2 receptors on coronary microvascular resistance (65; 221; 284; 287).  
 Although A2B receptor blockade reduced coronary vasodilation in response to 
exogenous adenosine (Fig. 2-3A; see Limitations of the study), alloxazine did not 
significantly affect the coronary reactive hyperemic response (Fig. 2-3B). Similarly, 
hypoxic coronary vasodilation of isolated coronary artery rings was unaffected by 
selective A2B receptor inhibition with MRS1754 (113). This lack of effect of A2B receptor 
blockade is consistent with the lower affinity of A2B vs. A2A receptors for adenosine (Ka 
ranges 1-20 nM for A2A vs. 5-20 μM for A2B) (105; 234) as well as the differential 
expression of A2A receptors in the coronary microcirculation vs. A2B receptor expression 
in larger coronary arteries (136). Taken together, these findings argue against a 
prominent role for A2B receptors in the modulation of coronary blood flow in response to 
endogenously produced adenosine. 
 A2A activation of coronary K
+ channels. Based on our initial findings, the next goal 
of this investigation was to determine the relative contribution of K+ channels to A2A 
receptor mediated coronary vasodilation in vivo. This question is important because 
 46 
although numerous earlier studies have demonstrated that adenosine and A2 receptor 
signaling converge on KATP channels (14; 58; 65; 134-136; 148; 172; 182; 319), more 
recent data from our laboratory indicate that KV channels also play a significant role (25; 
73). In addition, both KATP and Kv channels have been shown to modulate coronary 
vasodilation in response to cardiac ischemia (58; 73; 165; 328). Accordingly, we 
conducted experiments to examine the effects of KV and KATP channel inhibition on the 
coronary vasodilatory response to the selective A2A agonist CGS 21680 (136; 172; 317). 
We found that coronary vasodilation in response to A2A receptor activation is mediated 
via signaling pathways that converge on both KATP and KV channels as inhibition of either 
KV channels or KATP channels markedly attenuated vasodilation in response to CGS 
21680 (Fig. 2-4). Importantly, the decrease in the coronary reactive hyperemia following 
inhibition of KV and KATP channels (~60% reduction; Fig. 2-5) was much greater than the 
relatively modest effect A2A receptor blockade alone (~30% reduction; Fig. 2-2A). These 
data support previous studies implicating a prominent role for K+ channels in ischemic 
coronary vasodilation (37; 73; 89) and indicate that while A2A receptor signaling is a 
component of KV and KATP channel activation in response to cardiac ischemia, numerous 
other pathways must also converge on these channels to mediate the marked increase 
in coronary blood flow following a brief episode of cardiac ischemia. 
  Limitations of the study. We fully acknowledge that conclusions derived from this 
study regarding the relative contribution of A2A vs. A2B receptors to the regulation of 
coronary blood flow are dependent on the selectivity of the antagonists used. SCH58261 
is an A2A receptor antagonist that effectively inhibits A2A mediated coronary vasodilation 
at 1 µM (253), the concentration used in the present study. Alloxazine is a non-xanthine 
A2 antagonist with a KB value of 2.3 µM for A2B receptors (284); a coronary plasma 
concentration of 3 µM was used for these experiments. Our studies with these 
antagonists revealed somewhat paradoxical results in that SCH58261 reduced coronary 
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vasodilation in response to adenosine (~70%), with no additional effect of alloxazine. 
However, alloxazine alone (when administered without SCH58261) also reduced 
adenosine-induced increases in coronary blood flow by ~30%. Since SCH58261 is 
~1000-fold more selective for A2A over A2B receptors (233; 234; 323), while alloxazine 
has much more limited selectivity (~10-fold greater selectivity for A2B vs. A2A; (109)), we 
propose the most likely explanation for our paradoxical results is that alloxazine also 
impaired A2A signaling as opposed to an SCH58261-induced impairment of A2B 
signaling. However, the extent to which SCH58261 and alloxazine selectively inhibit A2A 
and A2B induced coronary vasodilation in vivo requires further investigation.  
 Equally important in this study is the selectivity of the K+ channel antagonists 
used. We recently demonstrated that 0.3 mM 4-AP, the same concentration used in the 
present study, significantly attenuates coronary vasodilation in response adenosine, but 
does not affect increases in coronary blood flow to the KATP channel agonist pinacidil 
(73). However, glibenclamide has been shown to attenuate voltage-gated K current in 
rabbit kidney (325). This could explain the similar effect of glibenclamide alone vs. 
glibenclamide + 4-AP on CGS 21860 dilation (Fig. 2-4) and the coronary reactive 
hyperemic response (Fig. 2-5). Regardless, the reduction of the coronary reactive 
hyperemic response following K+ channel inhibition was much greater than the relatively 
modest effect of A2A receptor blockade alone. 
 In conclusion, findings from this investigation indicate that adenosine A2A 
receptors contribute to coronary vasodilation in response to exogenous adenosine 
infusion and cardiac ischemia. Importantly, these findings are consistent with earlier 
studies in A2A and A2B receptor knockout mice (247; 253; 254; 258).  We have also 
identified that A2A-induced coronary vasodilation in vivo is mediated via activation of KV 
and KATP channels. Although A2B receptors are functionally expressed, our data do not 
support an active role for A2B receptors in the endogenous regulation of coronary blood 
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flow in healthy control subjects. However, it is important to note that Bender et al. 
recently found that the obese-metabolic syndrome augments the contribution of A2B 
receptors to adenosine-induced dilation in vitro (25). Interestingly, this increase was 
accompanied by a decrease in coronary A2B receptor protein expression as well as a 
loss of downstream KATP channel activation. Other studies in human atrial appendage 
microvessels (170) support that disease states may significantly alter the functional 
contribution of A2 receptor subtypes to the control of coronary microvascular tone. The 
significance of these changes along with the role of alternative adenosine receptor 
subtypes (A1 and A3) remains to be elucidated. 
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Abstract 
 The mechanisms responsible for coronary pressure-flow autoregulation, a critical 
physiologic phenomenon that maintains coronary blood flow relatively constant in the 
presence of changes in perfusion pressure, remain poorly understood. This investigation 
tested the hypothesis that voltage-sensitive K+ (KV) and Ca
2+ (CaV1.2) channels play a 
critical role in coronary pressure-flow autoregulation in vivo. Experiments were 
performed in open-chest, anaesthetized Ossabaw swine during step changes in 
coronary perfusion pressure (CPP) from 40-140 mmHg before and during inhibition of KV 
channels with 4-aminopyridine (4AP, 0.3 mM, ic) or CaV1.2 channels with diltiazem (10 
µg/min, ic). 4AP significantly decreased vasodilatory responses to H2O2 (0.3 - 10 µM, ic) 
and coronary flow at CPPs = 60-140 mmHg. This decrease in coronary flow was 
associated with diminished ventricular contractile function (dP/dT) and myocardial 
oxygen consumption. However, the overall sensitivity to changes in CPP from 60 to 100 
mmHg (i.e. autoregulatory gain; Gc) was unaltered by 4-AP administration (Gc = 0.46 ± 
0.11 control vs. 0.46 ± 0.06 4-AP). In contrast, inhibition of CaV1.2 channels 
progressively increased coronary blood flow at CPPs > 80 mmHg and substantially 
diminished coronary Gc to -0.20 ± 0.11 (P < 0.01), with no effect on contractile function 
or oxygen consumption. Taken together, these findings demonstrate that: 1) KV channels 
tonically contribute to the control of microvascular resistance over a wide range of CPPs, 
but do not contribute to coronary responses to changes in pressure; 2) progressive 
activation of CaV1.2 channels with increases in CPP represents a critical mechanism of 
coronary pressure-flow autoregulation. 
 
 
KEYWORDS: autoregulation, coronary blood flow, potassium channel, calcium channel, 
swine. 
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Introduction 
 Coronary pressure-flow autoregulation is an essential mechanism by which the 
coronary circulation maintains constant blood flow in the presence of alterations in 
perfusion pressure. The autoregulatory capacity of the coronary vascular bed is 
particularly important during flow-limiting stenosis where if absent, hypoperfusion can 
rapidly diminish cardiac function (100; 304). Alternatively, lack of vascular responses to 
elevations in perfusion pressure can lead to increases in coronary vascular volume, 
myocardial stiffness and oxygen consumption (MVO2), i.e. Gregg Phenomenon (17; 
124). However, despite the importance of coronary pressure-flow autoregulation, the 
mechanisms underlying this phenomenon remain poorly understood.  
 Previous investigations of coronary autoregulation have focused primarily on the 
contribution of myocardial tissue pressure, local metabolic and myogenic mechanisms 
(71; 77; 99; 100; 157). Although support for tissue pressure can be found in 
encapsulated organs such as the kidney (143; 158), evidence in the heart is limited as 
similar increases in intramyocardial pressure occur in the presence and absence of 
pressure-flow autoregulation (80; 99). In contrast, more prominent implications for local 
metabolic control have been identified as studies by the Feigl laboratory support that 
~23% of the changes in coronary conductance that occur with alterations in perfusion 
pressure are mediated by the synergistic effects of CO2 and O2 (46). Other studies 
suggest that additional metabolites such as nitric oxide (NO), hydrogen peroxide (H2O2) 
and adenosine could also be involved, albeit at lower perfusion pressures (52; 267; 271; 
321). However, inhibition or catalytic degradation of these metabolites has failed to 
significantly alter coronary responses to changes in perfusion pressure (i.e. 
autoregulatory closed-loop gain). Subsequent data show that blockade of end effector 
KATP channels, which contribute to vasodilation in response to adenosine, also does not 
influence coronary autoregulatory capacity (277). We propose that voltage-sensitive K+ 
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(KV) channels may play a more prominent role as these channels contribute to the 
control of coronary blood flow at rest, in response to brief episodes of cardiac ischemia 
and during increases in MVO2 (30; 32; 73; 256; 257; 264). However, the contribution of 
KV channels to coronary pressure-flow autoregulation has not been investigated.  
 In addition to metabolic mechanisms, myogenic vasoconstriction is likely critical 
for mitigating pressure-induced increases in coronary blood flow (184; 210). Data from 
isolated vessel preparations indicate that coronary responses to increases in intraluminal 
pressure activate an endothelium-independent (183), mechanosensitive mechanism that 
results in graded decreases in smooth muscle membrane potential (68; 142). Stretching 
vascular smooth muscle cells also induces an ~50% increase in intracellular [Ca2+] that 
has been attributed to extracellular influx via voltage-gated (CaV1.2) Ca
2+ channels (69). 
Importantly, the extent to which CaV1.2 channels contribute to changes in coronary 
vasomotor tone in response to alterations in coronary perfusion pressure in vivo has not 
been determined.  
 Accordingly, the purpose of this investigation was to test the following 
hypotheses: 1) vasoactive metabolites produced in response to changes in perfusion 
pressure modulate coronary vascular resistance and autoregulatory capacity via a KV 
channel-dependent mechanism; 2) progressive activation of CaV1.2 channels in 
response to elevations in perfusion pressure is critical for pressure-flow autoregulation in 
the coronary circulation.  
 
Methods 
 This investigation was approved by the Institutional Animal Care and Use 
Committee in accordance with the Guide for the Care and Use of Laboratory Animals 
(NIH Pub. No. 85-23, Revised 2011).  Animals utilized for this study were Ossabaw 
swine (n = 12) weighing 30-60 kg.  Following completion of experimental protocols, 
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hearts were fibrillated and excised as recommended by the American Veterinary Medical 
Association Guide on Euthanasia (June 2007).   
 Surgical preparation. Swine were initially sedated with telazol (5 mg/kg, sc), 
zylazine (2.2 mg/kg, sc) and ketamine (3.0 mg/kg, sc). Following endotracheal intubation 
and venous access, anesthesia was maintained with morphine (3.0 mg/kg, sc) and α-
chloralose (100 mg/kg, iv). The animals were mechanically ventilated (Harvard 
respirator) with room air supplemented with oxygen. Catheters were placed into the right 
femoral artery and vein for systemic hemodynamic measurements and administration of 
supplemental anesthetic, heparin, and sodium bicarbonate, respectively. The left femoral 
artery was catheterized to supply blood to an extracorporeal perfusion system used to 
perfuse the left anterior descending (LAD) coronary artery at controlled pressures. 
Arterial blood gases were analyzed periodically throughout the experimental protocol 
and adjustments made as needed to maintain blood gas parameters within normal 
physiological limits. A left lateral thoracotomy was performed to expose the heart, and 
the LAD was isolated and cannulated distal to its first major diagonal branch following 
heparin administration (500 U/kg, iv). Coronary perfusion pressure (CPP) was regulated 
by a servo-controlled roller pump and coronary blood flow was continuously measured 
by an in-line Transonic Systems flow transducer (Ithaca, New York, USA).  A catheter 
was also inserted into the interventricular coronary vein for venous sampling of blood 
draining the LAD perfusion territory. Left ventricular contractile function was measured 
with a Millar Mikro-Tip manometer (Millar Instruments, Inc. Houston, TX). Data were 
continuously recorded on IOX data acquisition software from Emka Technologies (Falls 
Church, VA).  
 Experimental protocol. Following a stabilization period (~20 min post 
cannulation), H2O2 (0.3 - 10 μM) was infused into the LAD perfusion circuit before and 
during administration of the KV channel antagonist 4-aminopyridine (4AP; 0.3 mM, i.c.) 
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with CPP held constant at 100 mmHg (n = 5). Pressure-flow autoregulation was 
assessed by 10 mmHg increment changes in CPP from 140 mmHg to 40 mmHg before 
or during intracoronary infusion of 4AP (0.3mM, n = 7) or the CaV1.2 channel antagonist 
diltiazem (10 µg/min, n = 5). Arterial and coronary venous blood samples were collected 
simultaneously once hemodynamic variables were stable at each CPP. Blood samples 
were analyzed with an Instrumentation Laboratories automatic blood gas analyzer (GEM 
Premier 3000) and CO-oximeter (682) system. MVO2 (µl O2/min/g) was calculated by 
multiplying coronary blood flow by the arterial coronary venous difference in oxygen 
content. As previously reported (17), closed-loop autoregulatory gain (Gc) was 
calculated from the following formula: Gc = 1 − [(∆F/F)/(∆P/P)]. Changes in flow and 
pressure were assessed relative to control responses at CPP = 100 mmHg. All drugs 
were dissolved in saline, adjusted to physiologic pH, and infused at a constant, 
continuous rate. 
 Statistical analyses. Data are presented as mean ± SE for n swine. Statistical 
comparisons were made using a one-way or two-way (Factor A: drug treatment; Factor 
B: pressure) repeated measures analysis of variance (ANOVA) as appropriate (Sigma 
Stat 11.0 Software). If statistical differences (P < 0.05) in these analyses were noted, a 
Student-Newman-Keuls multiple comparison test was performed.  
 
Results 
 Contribution of KV channels to H2O2-mediated coronary vasodilation. Consistent 
with previous studies (257), intracoronary administration of H2O2 (0.3-10 µM) dose-
dependently increased coronary blood flow from 0.52 ± 0.03 ml/min/g, under control 
conditions, to 1.40 ± 0.04 ml/min/g at the highest dose of H2O2 (P < 0.001, n = 5). 
Inhibition of coronary KV channels with 4AP (0.3 mM) at CPP = 100 mmHg decreased 
coronary blood flow, indices of cardiac contractile function (dP/dtmax and dP/dtmin), and 
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MVO2. Mean aortic pressure and heart rate were unaffected by 4AP (Table 3-1). 
Coronary vasodilation in response to exogenous H2O2 was markedly depressed by the 
administration of 4AP (Fig. 3-1, P < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 Coronary vascular response to changes in perfusion pressure. Effects of 
alterations in CPP on systemic hemodynamics are listed in Table 3-1. Modest changes 
in coronary blood flow (0.11 ± 0.02 ml/min/g) were noted over a CPP range of 60-100 
mmHg, without significant effects on cardiac contractile function or MVO2 (n = 7). 
Determination of Gc indicated an autoregulatory capacity of 0.46 ± 0.11 in untreated 
hearts over a CPP range of 60-100 mmHg (Gc = 1 being perfect). However, Gc was 
significantly reduced to -0.43 ± 0.29 at CPPs ranging from 100-140 mmHg and -0.52 ± 
0.42 at CPPs ranging from 40-60 mmHg (Fig. 3-2D). Reductions in coronary blood flow 
below CPP 60 mmHg (Fig. 3-2A) were associated with diminished dP/dtmax, dP/dtmin, 
MVO2 and mean aortic pressure (Table 3-1).  
 
Figure 3-1 Role of KV channels in H2O2-mediated coronary vasodilation. Intracoronary administration of 
H2O2 dose-dependently increased coronary blood flow. Coronary vasodilation in response to exogenous 
H2O2 was markedly depressed by the administration of 4AP. Figure shows grouped average traces for n 
= 5 swine; *P < 0.05 vs. control, same concentration of H2O2. 
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 KV channels in coronary pressure-flow autoregulation. Relative to untreated 
control conditions, inhibition of coronary KV channels with 4AP significantly attenuated 
coronary blood flow ~20% at CPPs ranging from 60-140 mmHg (Fig. 3-2A, P < 0.05). 
ntracoronary 4AP administration had no effect on mean aortic pressure at CPPs > 50 
mmHg (Table 3-1, n = 7). The reductions in coronary blood flow were associated with 
diminished cardiac contractile function as evidenced by the ~10-20% decrease in 
dP/dtmax and dP/dtmin over a wide range of CPPs (Table 3-1, P < 0.05). These changes 
in contractile function were also accompanied by decreases in MVO2 at CPPs ranging 
from 50-140 mmHg (Table 3-1, P < 0.05). However, 4AP administration did not alter the 
relationship between coronary blood flow and MVO2 (Fig. 3-2C). Importantly, inhibition of 
KV channels did not affect the overall change in coronary blood flow at CPPs < 120 
mmHg (Fig. 3-2B) as flow only varied 0.08 ± 0.01 ml/min/g over CPPs of 60-100 mmHg 
(P = 0.53 vs. untreated control). Calculation of Gc over this range of CPPs also revealed 
Table 3-1 Hemodynamic, cardiac and blood gas parameters during variable coronary perfusion pressure  
with and without 4AP or Diltiazem. Values are mean  SE for Control, 4AP (n = 7), and diltiazem (n = 5).  
* P < 0.05 vs. control same CPP; † P < 0.05 vs. 4AP. 
 
 58 
essentially identical Gc’s for both control (0.46 ± 0.11) and 4AP (0.46 ± 0.06) treated 
conditions (Fig. 3-2D, P = 0.99). Administration of 4AP also failed to significantly 
influence Gc over CPPs ranging from 40-60 mmHg (P = 0.78) or 100-140 mmHg (P = 
0.46). Alternatively, pressure-induced increases in coronary blood flow were attenuated 
by 4AP at CPPs of 130-140 mmHg (Fig. 3-2B), while coronary zero flow pressure (Pzf) 
was unaffected (average = 23 ± 2 mmHg).  
 
 
 CaV1.2 channels in coronary pressure-flow autoregulation. Inhibition of coronary 
CaV1.2 channels with diltiazem (10 µg/min) progressively increased coronary blood flow 
(Fig. 3-3A, P < 0.05) and significantly increased the change in blood flow to 0.42 ± 0.06 
ml/min/g over CPPs ranging from 60-100 mmHg (Fig. 3-3B; P < 0.01 vs. untreated 
Figure 3-2 Role of KV channels in coronary pressure-flow autoregulation. (A) Inhibition of coronary KV 
channels with 4AP significantly attenuated coronary blood flow at CPPs from 60-140 mmHg. 4AP 
administration did not affect the change in coronary blood flow at CPPs < 120 mmHg (B), the balance 
between coronary blood flow and MVO2 (C) or autoregulatory gain (D). Figures show grouped average 
traces for n = 7 swine. *P < 0.05 vs. control, same CPP. 
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control). Diltiazem administration reduced mean aortic pressure and increased heart rate 
at all CPPs (Table 3-1, P < 0.05). However, this vasodilatory effect was not associated 
with alterations in indices of cardiac contractile function or MVO2 (Table 3-1). Thus, 
diltiazem-mediated increases in coronary blood flow were independent of changes in 
MVO2 (Fig. 3-3C). Importantly, inhibition of coronary CaV1.2 channels markedly reduced 
Gc to -0.20 ± 0.11 over a CPP range of 60-100 mmHg, i.e. essentially abolished 
pressure-flow autoregulation (Fig. 3-3D, P < 0.01). Diltiazem did not affect Gc at CPPs 
ranging from 40-60 mmHg (P = 0.79), 100-140 mmHg (P = 0.47) or significantly alter Pzf 
relative to untreated controls (average = 20 ± 1 mmHg). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3 Role of CaV1.2 channels in coronary pressure-flow autoregulation. Inhibition of coronary 
CaV1.2 channels with diltiazem (10 µg/min) significantly increased coronary blood flow at CPPs > 
80 mmHg (A) and the change in blood flow to over a wide range of CPPs (B). Coronary 
vasodilation in response to diltiazem was independent of MVO2 (C) and abolished pressure-flow 
autoregulation within CPPs ranging from 60-100 mmHg (D). Figures show grouped average traces 
for n = 5 swine. *P < 0.05 vs. control. 
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Discussion 
 First identified in the coronary circulation by Eckel in 1949 (77), coronary 
autoregulation refers to the intrinsic ability of the heart to maintain constant blood flow 
despite changes in arterial perfusion pressure (158). Although numerous studies have 
focused on delineating the interdependent relationship between coronary blood flow and 
CPP (103; 236; 305), the underlying mechanisms responsible for coronary pressure-flow 
autoregulation have not been clearly defined. Given the important role for voltage-
dependent KV and CaV1.2 channels in the control of smooth muscle membrane potential 
and coronary vascular resistance (225; 292; 312), we hypothesized that these specific 
channels may also serve as critical end-effectors in modulating the vascular responses 
to alterations in CPP. Findings from this investigation demonstrate that KV channels 
tonically contribute to the control of microvascular resistance over a wide range of CPPs, 
but do not contribute to coronary responses to changes in perfusion pressure within the 
autoregulatory range. In contrast, progressive activation of CaV1.2 channels with 
increases in CPP represents a critical mechanism of coronary pressure-flow 
autoregulation.  
 Role of H2O2 and KV channels in coronary pressure-flow autoregulation. 
Experiments performed in this study were designed to test the hypothesis that 
vasoactive metabolites produced in response to changes in perfusion pressure modulate 
coronary vascular resistance and autoregulatory capacity via a KV channel-dependent 
mechanism. The rationale for this hypothesis is based on earlier studies by our group 
which demonstrated that activation of KV channels is critical to the regulation of coronary 
blood flow (30; 37; 73) and that several key vasoactive metabolites (e.g. adenosine, NO, 
H2O2) mediate coronary vasodilation predominantly via KV channels (32; 73; 256; 257). 
Consistent with prior studies in dogs (257), the present findings indicate that H2O2 
induces marked coronary vasodilation via activation of KV channels in swine (Fig. 3-1). 
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We propose this dilator effect is due to direct activation of smooth muscle KV channels 
as Rogers et al. found that H2O2 dose-dependently activates 4AP sensitive K
+ current in 
coronary smooth muscle cells (256) and that denudation has no effect on H2O2-induced 
dilation of isolated coronary arterioles (257). These data are in contrast with alternative 
studies that documented H2O2 is a key endothelium-derived hyperpolarizing factor that 
mediates coronary vasodilation via a BKCa channel-dependent mechanism (197; 330).   
 To examine the role of KV channels in coronary pressure-flow autoregulation, we 
performed experiments in anesthetized, open-chest swine in which CPP was varied from 
40 mmHg to 140 mmHg via a servo-controlled, extracorporeal perfusion circuit. In these 
studies, we demonstrated that the inhibition of KV channels significantly reduced 
coronary blood flow over a wide range of CPPs (Fig. 3-2A). However, 4AP 
administration did not affect the change in coronary blood flow with alterations in 
perfusion pressure at CPPs < 120 mmHg (Fig. 3-2B) or influence the overall 
autoregulatory capacity (Gc) of the coronary circulation (Fig. 3-2D). Thus, given that 
4AP abolished H2O2-mediated coronary vasodilation, our findings do not support a 
prominent role for KV channel-dependent pathways, such as H2O2, in modulating 
coronary vascular responses to changes in perfusion pressure within the autoregulatory 
range. This conclusion differs from that of Yada et al. who suggested that H2O2, in 
cooperation with NO and adenosine, plays an important role in coronary pressure-flow 
autoregulation in vivo in dogs (321). However, other investigations fail to support a 
prominent role for NO or adenosine in coronary autoregulation (178; 180; 271; 277). 
Closer examination of the data presented by Yada et al. also indicates that the 
significant reductions in coronary blood flow at lower CPPs in the presence of L-NAME 
and/or catalase did not significantly alter the coronary pressure-flow relationship; i.e. 
closed-loop autoregulatory gain. Interestingly, our findings with KV channel inhibition are 
similar with those of Stepp et al. who determined that blockade of KATP channels with 
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glibenclamide produced a tonic decrease in coronary blood flow, but did not significantly 
influence the autoregulatory capability of the coronary circulation (277). Taken together, 
these data indicate that neither KV channels, KATP channels, nor the upstream 
vasodilatory factors known to converge on these channels, are necessary to support a 
metabolic component of coronary pressure-flow autoregulation (188). In contrast, the 
limitation of pressure-induced increases in coronary flow by 4AP supports earlier studies 
implicating KV channels as an important negative-feedback mechanism that limits 
myogenic constriction, especially at high perfusion pressures (CPP > 120 mmHg) (2; 78; 
315).    
 Role of CaV1.2 channels in coronary pressure-flow autoregulation. Functioning 
as a predominant mediator of extracellular Ca2+ influx, CaV1.2 channels constitutively 
contribute to the control of coronary microvascular resistance. This is evidenced in vivo 
by the marked, dose-dependent increases in coronary blood flow observed in response 
to CaV1.2 channel blockade (175). Findings from the present study are the first to 
demonstrate that inhibition of coronary CaV1.2 channels results in a progressive 
increase in coronary blood flow as CPP is elevated (Fig. 3-3A). Thus, administration of 
diltiazem significantly augmented pressure-induced changes in coronary blood flow (Fig. 
3-3B), resulting in responses that would be predicted in a maximally dilated bed; i.e. 
passive vasculature. Importantly, the dose of diltiazem used (10 g/min) did not produce 
maximal dilation (coronary flow = 0.86 ± 0.06 ml/min/g at CPP = 100 mmHg) but did 
markedly diminish coronary autoregulatory capacity as Gc was reduced to -0.20 ± 0.11 
within the autoregulatory range of 60-100 mmHg (Fig. 3D), i.e. inhibition of CaV1.2 
channels essentially abolished pressure-flow autoregulation (see Limitations of the 
study). This observed decrement of pressure-flow autoregulation supports that 
increasing activation of CaV1.2 channels with elevations in CPP is a central mechanism 
underlying the intrinsic ability of the coronary circulation to maintain blood flow constant 
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with changes in perfusion pressure. Our findings are consistent with earlier in vitro 
myogenic studies demonstrating pressure-induced increases in membrane potential and 
arteriolar wall [Ca2+] are dependent on CaV1.2 channels (68; 69). Experiments in 
isolated, pressurized arterioles indicate a functional myogenic component also exists in 
the human and porcine coronary microcirculation (159; 185; 214). However, evidence for 
the involvement of other mechanosensitive, nonselective cation channels in myogenic 
vasoconstriction has also been reported (68; 142). Consequently, it is important to point 
out that the present data cannot distinguish between a strictly myogenic vs. metabolic-
induced activation of CaV1.2 channels. Regardless, the present data demonstrate that 
CaV1.2 channel-dependent pathways represent a critical mechanism of coronary 
pressure-flow autoregulation in vivo.  
 Relationship between coronary blood flow, CPP, and MVO2. Coronary blood flow 
is dependent on CPP and MVO2 (269), and coronary pressure can arguably influence 
metabolism via the “Gregg Phenomenon” (124; 268). Although the Gregg effect is more 
pronounced in poorly autoregulating hearts (~55% increase in MVO2 over CPP range of 
60-120 mmHg (17)), modest changes in MVO2 are detected in hearts with effective 
pressure-flow autoregulation (~20% increase in MVO2 over CPP range 60-120 mmHg 
(17; 78)). Thus, changes in arterial pressure and/or myocardial metabolism can influence 
the overall level of myocardial perfusion. In this study, administration of both 4AP and 
diltiazem altered these determinants of coronary blood flow. In particular, 4AP-mediated 
reductions in coronary flow were accompanied by reductions in cardiac function and 
MVO2, while diltiazem decreased arterial pressure and reflexively increased heart rate 
(Table 3-1). Changes in arterial pressure did not directly influence CPP as these 
experiments were conducted in a cannulated, extracorporeal perfused preparation. 
However, to account for these drug-induced alterations, we plotted coronary blood flow 
relative to its respective MVO2 at CPPs ranging from 40-140 mmHg. These plots indicate 
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that 4AP did not significantly affect the balance between coronary blood flow and MVO2 
as CPP was changed over this range of perfusion pressures (Fig. 3-2C). Alternatively, 
blockade of coronary CaV1.2 channels resulted in a progressive increase in coronary 
blood flow at a given level of MVO2 (Fig. 3-3C). Thus, the increases in coronary blood 
flow induced by diltiazem were not mediated by significant increases in MVO2; i.e. reflect 
pressure-mediated increases in coronary flow, not metabolic vasodilation. Regardless of 
the experimental condition, our findings support a strong interdependent relationship 
between CPP, MVO2, and coronary blood flow. To evaluate the individual contribution of 
each of these factors, additional examination of the interrelationship between coronary 
blood flow, MVO2 and CPP was assessed by 3-dimensional analysis. These data further 
support that inhibition of KV channels did not significantly affect the relationship between 
coronary blood flow, MVO2 and CPP (Fig. 3-4A). In contrast, increases in coronary 
blood flow observed with elevations in CPP and MVO2 were significantly augmented 
following diltiazem administration (Fig. 3-4B), further supporting a prominent role of 
CaV1.2 channels in coronary pressure-flow autoregulation.    
 
 
Figure 3-4 Effects of KV and CaV1.2 channel inhibition on 3-dimensional analysis of coronary pressure-
flow autoregulation. Inhibition of KV channels reduced coronary blood flow and MVO2 but did not affect 
pressure-induced changes in coronary flow (A). Blockade of coronary CaV1.2 channels significantly 
increased coronary blood flow as CPP and MVO2 were elevated (B). Figures show individual data for n 
= 7 (control, 4AP) or n = 5 (diltiazem) swine. 
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 Limitations of the study. Conclusions regarding the role of KV and CaV1.2 
channels in coronary pressure-flow autoregulation are confounded by specific effects of 
both 4AP and diltiazem on cardiac function and MVO2. In the case of 4AP, we found that 
inhibition of KV channels significantly decreased coronary blood flow, and that these 
reductions in flow were accompanied by decreases in left ventricular dP/dt and MVO2 
(Table 3-1). Such data pose a circular argument as to whether 4AP-mediated decreases 
in coronary flow resulted in diminished contractile performance and subsequent 
decreases in MVO2, or alternatively if 4AP initially decreased contractile function which 
then led to reductions in MVO2 and coronary blood flow. Importantly, when 4AP 
administration is initiated, we typically find that coronary blood flow falls within a matter 
of seconds, which contrasts with reductions in left ventricular dP/dt that typically occur 
within ~ 2 min of 4AP administration. Accordingly, we conclude that 4AP resulted in rapid 
(tonic) coronary vasoconstriction that was followed by commensurate reductions in 
contractile function and MVO2; an effect consistent with characteristics of myocardial 
hibernation (53). The present findings are in contrast with earlier studies (264) regarding 
the effect of 4AP on the balance between coronary blood flow and myocardial 
metabolism as 4AP failed to significantly decrease coronary venous PO2 at CPPs <140 
mmHg. We propose this discrepancy is related to the higher levels of MVO2’s reported in 
these studies at rest (70-100 µl O2/min/g) and during increases in metabolism (up to 
~400 µl O2/min/g), relative to the much lower levels of MVO2 reported in our current 
preparation (~50 µl O2/min/g at rest). This point is supported by the significant reduction 
in coronary venous PO2 in the presence of 4AP when MVO2 was elevated to ~60 µl 
O2/min/g at CPP = 140 mmHg (Table 3-1).  
Earlier studies have demonstrated that administration of coronary vasodilator 
agents significantly impair coronary pressure-flow autoregulation (77; 140). In the 
present study, inhibition of CaV1.2 channels resulted in an ~70% increase in baseline 
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coronary flow at CPP = 100 mmHg. This effect of diltiazem significantly complicates 
interpretation as to whether decreased coronary autoregulatory capacity following 
diltiazem administration was due to the inhibition of CaV1.2 channels alone or simply to 
its vasodilator influence. This matter is further complicated by the fact that compounds 
induce vasodilation via activation of coronary K+ channels (167), which hyperpolarizes 
smooth muscle and inhibits CaV1.2 channels (42; 91; 139; 151; 286). Thus, studies 
which demonstrate reductions in coronary autoregulation in the presence of vasodilators 
actually support our present conclusion regarding the role of CaV1.2 channels in 
pressure-flow autoregulation. Importantly, the dose of diltiazem used in the present 
study is selective for CaV1.2 channels and increased coronary blood flow from 0.50 to 
0.86 ml/min/g; i.e. an average flow that is within the “normal range” of baseline coronary 
blood flow (82). Despite these confounding effects, inhibition of CaV1.2 channels has 
been shown to produce marked, dose-dependent increases in baseline coronary blood 
flow (175), which supports a prominent role for these channels in the regulation of 
coronary vasomotor tone. 
Summary and Implications. We have identified a tonically active role for KV 
channels in the control of coronary microvascular resistance over wide range of CPPs 
(60-140 mmHg). However, our data indicate that these channels, and the vasodilatory 
pathways known to converge on them (adenosine, NO, H2O2), are not required for 
coronary responses to changes in perfusion pressure within the autoregulatory range. 
Although KV channels are not necessary for coronary pressure-flow autoregulation, it is 
possible that alternative pathways/channels are activated to compensate for KV channel 
inhibition. Alternatively, our findings do support that KV channels serve as a negative-
feedback mechanism that limits myogenic constriction, especially at high perfusion 
pressures (CPP > 120 mmHg). These findings are important in light of recent studies 
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implicating impaired KV channel activity in a variety of disease states including 
hypercholesterolemia, hypertension, and hyperglycemia (45; 132; 133; 195; 199; 200). 
Data from this study are the first to demonstrate that inhibition of CaV1.2 
channels with diltiazem essentially abolishes the ability of the coronary circulation to 
maintain blood flow constant with alterations in perfusion pressure. Although our findings 
support a critical role for CaV1.2 channels in pressure-flow autoregulation, the 
mechanism by which CaV1.2 channels are activated (myogenic vs. metabolic) requires 
further investigation. Delineating mechanisms of coronary CaV1.2 channel activation is 
important given findings supporting elevated CaV1.2 channel function and associated 
activators (e.g. PKC) during hypertension and metabolic syndrome (175; 214; 242; 249). 
We propose that administration of CaV1.2 channel blockers to such patients would likely 
prove beneficial, despite effects on autoregulatory capacity, as these agents would act to 
increase coronary blood flow, reduce left ventricular afterload, and improve the balance 
between myocardial oxygen delivery and metabolism. 
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Abstract 
 The purpose of this investigation was to test the hypothesis that KV channels 
contribute to metabolic control of coronary blood flow and that decreases in KV channel 
function and/or expression significantly attenuate myocardial oxygen supply-demand 
balance in the metabolic syndrome (MetS). Experiments were conducted in conscious, 
chronically instrumented Ossabaw swine fed either a normal maintenance diet or an 
excess calorie atherogenic diet that produces the clinical phenotype of early MetS. Data 
were obtained under resting conditions and during graded treadmill exercise before and 
after inhibition of KV channels with 4-aminopyridine (4-AP, 0.3 mg/kg, i.v.). In lean-
control swine, 4-AP reduced coronary blood flow ~15% at rest and ~20% during 
exercise. Inhibition of KV channels also increased aortic pressure (P < 0.01) while 
reducing coronary venous PO2 (P < 0.01) at a given level of myocardial oxygen 
consumption (MVO2). Administration of 4-AP had no effect on coronary blood flow, aortic 
pressure, or coronary venous PO2 in swine with MetS. The lack of response to 4-AP in 
MetS swine was associated with a ~20% reduction in coronary KV current (P < 0.01) and 
decreased expression of KV1.5 channels in coronary arteries (P < 0.01). Together, these 
data demonstrate that KV channels play an important role in balancing myocardial 
oxygen delivery with metabolism at rest and during exercise-induced increases in MVO2. 
Our findings also indicate that decreases in KV channel current and expression 
contribute to impaired control of coronary blood flow in the MetS. 
 
 
 
 
Keywords: Coronary, exercise, KV channels, metabolic syndrome, swine 
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Introduction 
 The myocardium is highly dependent on a continuous supply of oxygen and 
nutrients from the coronary circulation to meet its metabolic requirements and to 
maintain contractile performance (82; 294). Despite extensive investigation over the past 
half century, the primary mechanisms responsible for balancing myocardial oxygen 
delivery with myocardial energy demand have remained elusive. Metabolic control of 
coronary blood flow is hypothesized to occur via local production of vasoactive 
substances which regulate microvascular resistance via activation of downstream K+ 
channels on vascular smooth muscle (74). Although multiple types of K+ channels are 
expressed in coronary smooth muscle, recent data from our investigative team indicate 
that voltage-dependent K+ (KV) channels represent a critical end effector mechanism that 
modulates coronary blood flow at rest (73; 264), during cardiac pacing or catecholamine-
induced increases in myocardial oxygen consumption (MVO2) (264), following brief 
periods of cardiac ischemia (73), and endothelial-dependent and independent 
vasodilation (25; 32; 73). However, the functional contribution of KV channels to 
metabolic control of coronary blood flow during physiologic increases in MVO2, as occur 
during exercise, has not been examined.   
 Earlier studies have demonstrated that disease states such as obesity and the 
metabolic syndrome (MetS) markedly impair the ability of the heart to adequately 
balance coronary blood flow with myocardial metabolism (31; 39; 175). Coronary 
microvascular dysfunction in the MetS is evidenced by reductions in coronary venous 
PO2 (39; 269; 329), diminished vasodilatory responses to pharmacologic agonists (i.e. 
coronary flow reserve) (201; 218; 246; 265), and alterations in functional and reactive 
coronary hyperemia (37; 290). Decreases in K+ channel function contribute to this 
impairment as MetS depresses outward K+ current in coronary artery smooth muscle 
cells (38; 48; 202; 218) and diminishes the role of specific K+ channels in coronary 
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vasodilatory responses (25; 37). In particular, decreases in KV channel activity have 
been associated with key components of the MetS, including hypercholesterolemia (132; 
133), hypertension (45), and hyperglycemia (195; 199; 200). We hypothesize that such 
reductions in the functional expression of KV channels contribute to the impaired control 
of coronary blood flow in the setting of the MetS. 
 Accordingly, the primary goals of the present study were to: 1) examine the 
contribution of coronary KV channels to regulation of coronary blood flow at rest and 
during exercise-induced increases in MVO2; and 2) determine the effects of the MetS on 
coronary KV channel activity and expression. Experiments were designed to test the 
hypothesis that decreases in KV channel function and/or expression significantly 
attenuate myocardial oxygen supply-demand balance in MetS. This hypothesis was 
examined in chronically instrumented Ossabaw swine fed either a normal maintenance 
diet or an excess calorie, atherogenic diet that produces the common clinical phenotype 
of early MetS; i.e. obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, 
hypertension, and atherosclerosis (90; 281). Hemodynamic data and arterial/coronary 
venous blood samples were obtained before and during inhibition of KV channels with 4-
aminopyridine (4-AP, 0.3 mg/kg, iv) at rest and during graded treadmill exercise. In 
addition, whole cell K+ currents were measured in freshly isolated coronary artery 
smooth muscle cells from lean and MetS swine and expression of coronary KV1.5 and 
KV3.1 channels determined by Western blot. 
 
Methods 
 Ossabaw swine model of metabolic syndrome. All experimental procedures and 
protocols used in this investigation were approved by the Institutional Animal Care and 
Use Committee in accordance with the Guide for the Care and Use of Laboratory 
Animals.  Lean control swine were fed ~2200 kcal/day of standard chow (5L80, Purina 
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Test Diet, Richmond, IN) containing 18% kcal from protein, 71% kcal from complex 
carbohydrates, and 11% kcal from fat.  MetS swine were fed an excess ~8000 kcal/day 
high fat/fructose, atherogenic diet containing 16% kcal from protein, 41% kcal from 
complex carbohydrates, 19% kcal from fructose, and 43% kcal from fat (mixture of lard, 
hydrogenated soybean oil, and hydrogenated coconut oil), and supplemented with 2.0% 
cholesterol and 0.7% sodium cholate by weight (KT324, Purina Test Diet, Richmond, 
IN).  Both lean (n = 7) and MetS (n = 5) castrated male swine were fed their respective 
diets for 16 weeks prior to surgical instrumentation. 
 Surgical instrumentation. Following an overnight fast, Ossabaw swine were 
sedated with telazol (5 mg/kg, sc) and xylazine (2.2 mg/kg, sc). After endotracheal 
intubation, a surgical plane of anesthesia was maintained by mechanical ventilation with 
1-3% isoflurane gas, supplemented with oxygen.  Utilizing sterile technique, a left lateral 
thoracotomy was performed in the fifth intercostal space.  A 17 Ga pressure monitoring 
catheter (Edwards LifeSciences) was implanted in the descending thoracic aorta for 
blood pressure measurements and arterial blood sampling. A second catheter was 
placed in the coronary interventricular vein for coronary venous blood sampling and 
intravenous drug infusions. The left anterior descending coronary artery (LAD) was 
dissected free and a perivascular flow transducer (Transonic Systems Inc.) was placed 
around the artery. The pneumothorax was evacuated and the chest was closed in 
layers. Catheters and the flow transducer wire were tunneled subcutaneously and 
exteriorized between the scapulae.  Antibiotics (excede, 5 mg/kg, im), rimadyl (4mg/kg, 
im) and buprenorphine (0.015mg/kg, im) were administered to prevent infection and 
manage post-operative pain. Externalized wires/catheters were protected by a jacket 
and an elastomeric balloon pump (MILA International) was connected to the coronary 
venous catheter for continuous infusion of heparinized saline (5U/ml at 5ml/hr). The 
aortic catheter was flushed daily and filled with heparinized saline (5,000 U/ml). 
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 Experimental protocol and blood sampling. Following recovery from surgery, 
experiments were conducted in lean (n = 7) and MetS (n = 5) Ossabaw swine under 
resting conditions and during graded treadmill exercise before and during inhibition of KV 
channels with 4-AP (0.3 mg/kg, iv). Hemodynamics were continuously recorded at 
baseline and during two levels of treadmill exercise at ~ 2 mph and ~5 mph. Arterial and 
coronary venous blood samples were collected simultaneously in heparinized syringes 
when hemodynamic variables were stable at rest and at each level of exercise.  Each 
exercise period was ~2 min in duration, and the animals were allowed to rest sufficiently 
between each level for hemodynamic variables to return to baseline. 
 Arterial and coronary venous blood samples were collected, immediately sealed 
and placed on ice.  The samples were analyzed in duplicate for pH, PCO2, PO2, glucose, 
hematocrit, and oxygen content with an Instrumentation Laboratories automatic blood 
gas analyzer (GEM Premier 3000) and CO-oximeter (682) system. LAD perfusion 
territory was estimated to be 30% of total heart weight, as previously described by Feigl 
(103). MVO2 (µl O2/min/g) was calculated by multiplying coronary blood flow by the 
arterial coronary venous difference in oxygen content.   
 Patch-clamp electrophysiology. Coronary smooth muscle cells were freshly 
isolated from proximal segments of the LAD as previously described (38). Briefly, patch-
clamp recordings were performed within 8 h of cell dispersion. Whole-cell K+ currents 
were measured at room temperature with the conventional dialyzed configuration of the 
patch-clamp technique. Bath solution contained (in mM) 138 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 glucose, 10 HEPES, and 5 Tris (pH 7.4). Pipettes had tip resistances of 2-4 
MΩ when filled with solution containing (in mM) 140 KCl, 3 Mg-ATP, 0.1 Na-GTP, 0.1 
EGTA, 10 HEPES, and 5 Tris (pH 7.1). After whole-cell access was established, series 
resistance and membrane capacitance were compensated. Current voltage relationships 
 75 
were assessed by 400-ms step pulses from -60 to +20 mV in 10-mV increments from a 
holding potential of -80 mV.  
 Western blot analysis. Following excision of hearts, coronary arteries from lean 
(n = 5) and MetS (n = 5) swine were quickly isolated, cleaned of adventitia, placed in 
liquid N2 and stored at -80C. Arteries were homogenized with lysis buffer and total 
protein collected and quantified by DC Protein Assay. Equivalent amounts of protein (40 
µg) were loaded onto 7.5% acrylamide gels and transferred overnight. Membranes were 
blocked for 1 h at ambient temperature prior to 24 h incubation at 4C with rabbit 
polyclonal antibodies (Alomone Labs) directed against KV 1.5 (1:100) and KV 3.1 (1:500) 
in blocking buffer with 0.1% Tween 20 and mouse anti-actin antibody (MP Biomedicals, 
1:15,000). Blots were washed and incubated for 1 h with IRDye 800 donkey anti-rabbit 
(1:10,000) and IRDye 700 donkey anti-mouse (1:20,000) secondary antibodies. 
Immunoreactivity for KV channel subtypes was determined by the Li-Cor Odyssey 
system (Li-Cor Biosciences) and expressed relative to actin (loading control). 
 Statistical Analyses. Data are presented as mean ± SE.  Statistical comparisons 
were made by unpaired t-test (phenotype data in Table 4-1) or by two-way analysis of 
variance (ANOVA) for within group analysis (Factor A: drug treatment; Factor B: 
exercise level) and between group analysis (Factor A: diet with drug treatment; Factor B: 
exercise level) as appropriate. For all statistical comparisons, P < 0.05 was considered 
statistically significant. When significance was found with ANOVA, a Student-Newman-
Keuls multiple comparison test was performed to identify differences between groups 
and treatment levels. Multiple linear regression analysis was used to compare slopes of 
response variables (aortic pressure, coronary venous PO2) plotted vs. MVO2. If the 
slopes of the regression lines were not significantly different, an analysis of covariance 
(ANCOVA) was used to adjust response variables for linear dependence on MVO2. 
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Results 
Table 4-1 Phenotypic characteristics of lean and metabolic syndrome Ossabaw swine. 
 Lean MetS 
Body Weight (kg) 46 ± 3 72 ± 4* 
Heart wt. / Body wt. (x 100) 0.36 ± 0.03 0.41 ± 0.03 
Glucose (mg/dl) 74 ± 4 85 ± 5 
Insulin (U/ml) 16 ± 6 30 ± 9 
HOMA index 2.9 ± 1.1 6.0 ± 1.5 
Total cholesterol (mg/dl) 87 ± 5 486 ± 70* 
LDL/HDL ratio 1.6 ± 0.1 5.9 ± 1.4* 
Triglycerides (mg/dl) 43 ± 5 67 ± 18 
Values are mean ± SE for lean (n = 7) and MetS (n = 5) swine. * P<0.05 vs lean. 
 
 Phenotype of Ossabaw swine. Phenotypic characteristics of lean and MetS 
swine are given in Table 4-1.  Consistent with our recent studies (37-39; 44), we found 
that the excess calorie, atherogenic diet induced classic features of early MetS in 
Ossabaw swine. In particular, relative to their lean counterparts MetS swine exhibited a 
significant 1.6-fold increase in body weight, a 5.6-fold increase in total cholesterol, a 3.7-
fold increase in LDL/HDL ratio and a 1.5-fold increase in triglyceride levels. Blood 
samples obtained from swine at the time of exercise experiment (non-fasted) revealed 
modest increases in plasma glucose and insulin concentration (P = 0.10). Homeostatic 
model assessment (HOMA) index values were also ~2-fold higher in MetS swine (P = 
0.13). 
 
Table 4-2   Hemodynamic and blood gas variables at rest and during graded treadmill 
exercise in lean and metabolic syndrome Ossabaw swine with and without 4AP (0.3mg/kg). 
  Exercise  
 Rest  Level 1 Level 2 
Systolic Blood Pressure (mmHg)    
Lean 113  5 112  4 121  5 
Lean + 4AP 119  6 119  4 125  5 
MetS 119  6   131  9† 138  9 
MetS + 4AP 126  7 125  6 134  4 
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Diastolic Blood Pressure  (mmHg)    
Lean 73  4 70  4 75  4 
Lean + 4AP 79  6 76  4  86  6* 
MetS 86  3   89  8†   92  6† 
MetS + 4AP 89  5 81  7 90  5 
    
Mean Aortic Pressure (mmHg)    
Lean  93  4  92  3  98  4 
Lean + 4AP    99  6*    99  4*  105  4* 
MetS 103  5   108  8†   115  8† 
MetS + 4AP 100  6 104  7 114  5 
    
Heart Rate (beats/min)    
Lean 120  8    162  11   212  13 
Lean + 4AP   129  10  172  9    201  10 
MetS   134  19    168  20    183  14 
MetS + 4AP 125  6  170  7  184  6 
    
Coronary Blood Flow (ml/min/g)    
Lean 1.11  0.09 1.46  0.12 1.92  0.12 
Lean + 4AP 0.94  0.13  1.24  0.16*  1.54  0.17* 
MetS 0.80  0.08   1.07  0.14†   1.21  0.15† 
MetS + 4AP 0.95  0.16 1.07  0.16 1.25  0.17 
    
Coronary Conductance (l/min/g/mmHg)   
Lean  11.9  0.8 15.8  0.8 19.5  0.6 
Lean + 4AP     9.3  1.0*   12.4  1.3*   14.6  1.4* 
MetS      8.0  1.1†    10.2  1.8†   10.6  1.3† 
MetS + 4AP    9.7  1.9  10.3  1.5 11.0  1.4 
    
Myocardial O2 Consumption (l O2/min/g)   
Lean  117  14 178  23 244  21 
Lean + 4AP  102  18 131  19   166  14* 
MetS        102  7 143  19    158  22† 
MetS + 4AP  117  23 132  21  151  21 
    
Arterial pH    
Lean 7.55  0.01  7.55  0.01 7.54  0.01 
Lean + 4AP 7.60  0.03  7.60  0.03 7.56  0.03 
MetS 7.53  0.02    7.52  0.01†   7.50  0.02† 
MetS + 4AP  7.58  0.02*  7.56  0.01 7.54  0.01 
 
 
   
Coronary Venous pH    
Lean 7.47  0.01 7.48  0.01  7.47  0.01 
Lean + 4AP 7.50  0.02  7.50  0.02  7.49  0.02 
MetS 7.45  0.02  7.45  0.01  7.45  0.01 
MetS + 4AP  7.50  0.02*   7.49  0.01*   7.48  0.01* 
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Arterial PCO2 (mmHg)    
Lean 32  1 31  2 31  1 
Lean + 4AP  26  2*   25  2*           27  2 
MetS 33  2  31  2 30  1 
MetS + 4AP 29  2  27  1 29  1 
    
Coronary Venous PCO2 (mmHg)    
Lean 49  1 43  3 45  1 
Lean + 4AP  41  2*  42  3   40  3 
MetS 49  3  46  2 44  3 
MetS + 4AP  42  3*   42  3* 44  3 
    
Arterial PO2 (mmHg)    
Lean 94  3   98  3    95  4 
Lean + 4AP 107  3* 108  3  100  8 
MetS 89  4   89  3    94  4 
MetS + 4AP 98  4   97  2    96  3 
    
Coronary Venous PO2 (mmHg)    
Lean  18  0.6  18  0.8  17  0.7 
Lean + 4AP    15  0.6*    16  0.9*   16  0.8 
MetS     14  1.4†     12  1.2†     12  1.0† 
MetS + 4AP   13  1.4   13  1.5   13  1.7 
    
Coronary Venous O2 Saturation (%)   
Lean  16  2 13  3 14  2 
Lean + 4AP  13  3 13  3 13  2 
MetS  14  2 11  1 10  1 
MetS + 4AP  13  2 12  2 12  3 
    
Arterial Hematocrit (%)    
Lean  34  1 37  1 37  1 
Lean + 4AP  30  2  30  1* 33  2 
MetS  36  3 37  2 37  1 
MetS + 4AP  32  2  31  2* 33  2 
Values are mean  SE for lean (n = 7) and MetS (n = 5) swine.  * P < 0.05 vs. untreated control, same 
diet/condition; † P < 0.05 vs. lean, same treatment. 
 
 Coronary and cardiovascular response to exercise: lean vs. MetS swine. 
Hemodynamic and blood gas data for lean and MetS Ossabaw swine at rest and during 
exercise are summarized in Table 4-2. Although no changes in systolic blood pressure 
were observed in untreated MetS vs. lean swine under baseline-resting conditions, MetS 
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swine tended to have higher diastolic blood pressure (Table 4-2; P = 0.08). Exercise-
induced increases in mean aortic pressure were significantly augmented in MetS swine 
while no differences in heart rate were noted between groups at rest or during exercise. 
Given these changes in blood pressure, coronary blood flow was reduced ~30-35% at 
rest and during exercise (Table 4-2). Normalizing coronary blood flow to aortic pressure 
revealed significant reductions in coronary conductance in MetS vs. lean swine at all 
levels (Table 4-2). MVO2 was modestly reduced ~15% in MetS swine under baseline 
conditions (P = 0.57), but was significantly depressed ~35% at the highest level of 
exercise (Table 4-2). These changes in coronary blood flow and MVO2 were associated 
with a significant decrease in coronary venous PO2 (index of tissue PO2) at rest and 
during exercise. Importantly, the slope of the relationship between coronary venous PO2 
and MVO2 (Fig. 4-1A vs. Fig. 4-1B) was significantly increased (lower PO2 at given level 
of MVO2) in untreated MetS vs. lean swine (P < 0.02).  
 Role of KV channels in coronary and cardiovascular response to exercise. Effects 
of KV channel inhibition with 4-AP (0.3 mg/kg, iv) on hemodynamic and blood gas 
variables at rest and during exercise are also summarized in Table 4-2. Administration 
of 4-AP significantly increased mean aortic pressure at rest and during exercise in lean, 
but not MetS swine. Blockade of KV channels also increased aortic pressure in lean 
animals to a level closer to that observed in MetS swine (Table 4-2). Heart rate was 
unaffected by 4-AP in either group. Despite increases in blood pressure in lean swine, 4-
AP reduced coronary blood flow ~15% at rest (P = 0.17) and ~20% at the highest level 
of exercise (P < 0.05) (Table 4-2). Coronary blood flow was not significantly altered by 
the administration of 4-AP in MetS swine at rest or during exercise. Coronary 
conductance was significantly decreased by 4-AP at rest and during exercise in lean, but 
not MetS swine (Table 4-2). Increases in MVO2 to exercise were also diminished ~30% 
by inhibition of KV channels in lean swine. Regression analysis demonstrated that 4-AP 
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produced a significant, parallel downward shift in the relationship between coronary 
venous PO2 vs. MVO2 in lean, but not MetS swine (Fig. 4-1).  
 
 
 
 Functional expression of coronary KV channels in lean vs. MetS swine. Whole 
cell patch clamp recordings (Fig. 4-2A) demonstrate a ~20% reduction in coronary K+ 
current at potentials greater than 0 mV, i.e. currents biophysically consistent with KV 
channels (Fig. 4-2B, P < 0.01). Pharmacological characterization of KV current, including 
separation from BKCa current can be found in the supplement. KV channels produce 
characteristic tail currents upon repolarization of the membrane (inset Fig. 4-2A), the 
magnitude of which was reduced in cells from MetS pigs (1.4 ± 0.3 vs. 2.0 ± 0.2 pA/pF; 
P < 0.05). This observation supports the idea that the difference in outward current in 
Figure 4-2B is a reduction in KV current. Importantly, however, other characteristics of 
the tail currents were not different (voltage of half activation and slope factor of -6 ± 1 
mV and 8 ± 1 vs. -8 ± mV and 8 ± 1), suggesting the same types of KV channels are 
expressed in cells from lean and MetS swine (Fig. 4-2C). 
 
Figure 4-1 Effect of KV channel inhibition on the relationship between coronary venous PO2 and myocardial 
oxygen consumption in lean (A) and MetS (B) swine. Inhibition of KV channels with 4-aminopyridine (4-AP) 
significantly reduced coronary venous PO2 at a given level of metabolism in lean (P < 0.01) but not MetS 
swine (P = 0.84). The slope of this relationship was also significantly decreased in untreated lean vs. MetS 
swine (P < 0.02). 
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 Several KV channel proteins have been proposed to underlie the native current in 
smooth muscle, including KV1.5 (291) and KV3.1 (132). Protein expression data of KV1.5 
and KV3.1 channels in coronary arteries from lean and MetS swine are shown in Figure 
4-3. Bands for KV1.5 and KV3.1 were 68 and 98 kDa, respectively. Western analysis 
revealed a significant ~49% reduction in coronary KV1.5 channel expression in arteries 
from MetS swine (Fig. 4-3A; P < 0.05). No significant difference in coronary KV 3.1 
channel expression was noted in lean vs. MetS swine  (Fig. 4-3B; P = 0.36).  
 
Figure 4-2. Whole-cell voltage-dependent K
+
 current in coronary smooth muscle of lean and MetS swine. 
(A) Families of current traces from representative cells of lean and MetS pigs. Voltage template is 400 
ms long. KV channels produce characteristic tail currents upon repolarization of the membrane (inset), 
the magnitude of which was reduced in cells from MetS pigs. (B) Group I-V data demonstrate a 
significant reduction in outward K
+
 current at potentials greater than 0 mV, i.e. currents biophysically 
consistent with KV channels. (C) Group G-V curves derived from tail currents at -40 mV. The voltage-
sensitivity of the currents were not different (voltage of half activation and slope factor of -6 ± 1 mV and 8 
± 1 vs. -8 ± mV and 8 ± 1 in control and MetS pigs, respectively. * P < 0.01 vs. lean, same voltage. 
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Discussion 
 The primary goal of this investigation was to examine the hypothesis that 
coronary KV channels contribute to local metabolic control of coronary blood flow and 
that reduced functional expression of these channels plays a role in microvascular 
dysfunction in the setting of the MetS. This hypothesis is supported by earlier studies 
indicating that KV channels modulate coronary blood flow in vivo (37; 73; 257; 264) and 
that specific components of the MetS decrease smooth muscle KV current and their 
contribution to arteriolar vasodilatory responses (26; 45; 62; 132; 133; 177; 200; 324). 
The novel findings of this study are: 1) inhibition of KV channels increases blood 
pressure at rest and during exercise in lean, but not MetS swine; 2) KV channels 
contribute to the regulation of coronary blood flow at rest and during increases in MVO2 
in lean, but not MetS swine; 3) induction of MetS significantly decreases KV channel 
current in coronary artery smooth muscle cells; 4) expression of KV 1.5 channels is 
diminished in the coronary circulation of MetS swine. Taken together, these data 
demonstrate that KV channels play a crucial role in balancing myocardial oxygen delivery 
Figure 4-3. Expression of KV1.5 and KV3.1 channels in coronary arteries of lean and MetS swine. (A) 
Western blot analysis demonstrated a significant reduction in KV1.5 channel protein expression in 
coronary arteries from MetS swine. (B) Expression of coronary KV3.1 channel protein was not 
significantly affected by induction of MetS (P = 0.36). * P < 0.05 vs. lean. 
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with myocardial oxygen demand at rest and during exercise-induced increases in MVO2 
in normal lean swine. Our findings also indicate that decreases in KV channel activity and 
expression contribute to impaired control of coronary blood flow in the MetS.  
 Role of KV channels in control of blood pressure and coronary blood flow. KV 
channels are widely expressed in both the systemic and coronary circulation (74). Earlier 
investigations have established an active role for KV channels in modulating smooth 
muscle membrane potential in isolated smooth muscle cells, arteries, and arterioles as 
well as vascular tone in anaesthetized preparations (74). In particular, data from the 
present study demonstrate that inhibition of KV channels with 4-AP significantly elevates 
mean aortic pressure at rest and during exercise in normal lean animals (Table 4-2). 
These data are consistent with previous findings from our laboratory (37) as well as 
others (1; 26; 326) and implicate a critical role for KV channels in the control of systemic 
vascular resistance. We propose that the effects of 4-AP on blood pressure are 
mediated by effects on vascular smooth muscle and not by direct cardiac effects as 
intracoronary administration of 4-AP at concentrations  0.3 mM does not significantly 
alter arterial pressure (73). In addition, 4-AP has also been shown to augment arterial 
pressure in the presence of adrenoceptor antagonists in anesthetized cats, arguing 
against direct sympathetic pressor effects (326).  
 Consistent with other recent studies (73; 256; 257; 264), the present findings 
support a prominent role for KV channels in regulating coronary blood flow. This effect is 
primarily evidenced by the ~15-20% reduction in coronary blood flow at rest and during 
exercise (Table 4-2) following 4-AP administration in lean swine. It is important to 
recognize that this decrease in coronary flow occurred in the presence of significant 
increases in blood pressure, i.e. 4-AP markedly reduced coronary conductance (Table 
4-2). However, the parallel downward shift in the relationship between coronary venous 
PO2 and MVO2 supports more of a “tonic” role for KV channels in the control of coronary 
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blood flow; i.e. similar contribution to coronary vascular resistance at rest and during 
increases in MVO2 (Fig. 4-1A). Together, these results indicate that vasodilator 
substances that converge on KV channels are required for adequate myocardial oxygen 
supply-demand balance over a wide range of MVO2. Although we did not examine the 
identity of specific factor(s) that mediate coronary vasodilation via KV channels in this 
study, previous studies from our investigative team implicate H2O2 as a feedforward 
dilator that couples coronary blood flow with myocardial metabolism, predominantly 
through 4-AP sensitive K+ channels (256; 257; 264). Other factors that have been shown 
to induce coronary vasodilation, at least in part, through KV channels include adenosine, 
nitric oxide, prostacyclin, and EDHF (74). However, a prominent role for these factors in 
local metabolic control is unlikely as inhibition of these pathways has little, if any effect 
on coronary blood flow at rest or during increases in MVO2 (294).   
 Effects of MetS on function and expression of coronary KV channels. Although KV 
channels regulate membrane potential, arteriolar diameter (74; 132), and coronary blood 
flow (73; 264) in normal lean animals, data from this study importantly demonstrate that 
the MetS markedly impairs the functional expression of KV channels in vascular smooth 
muscle. In particular, while inhibition of KV channels influenced blood pressure, coronary 
blood flow and the balance between coronary blood flow and MVO2 in lean swine, 4-AP 
had no effect on any of these key variables in obese, MetS swine (Table 4-2). 
Interestingly, MVO2 was significantly decreased in MetS vs. lean swine during exercise, 
despite a larger rate-pressure product in MetS swine (Table 4-2). The reason for this 
difference is not apparent but is not clearly associated with alterations in KV channel 
function and suggests that the MetS independently abrogates the relationship between 
coronary blood flow and myocardial metabolism. The absence of any cardiovascular 
effect of 4-AP in MetS swine, along with the augmented pressor response (Table 4-2) 
and substantial imbalance between coronary blood flow and myocardial metabolism 
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(Fig. 4-1B), indicates that microvascular dysfunction typically observed in the setting of 
the MetS (31) is directly related to the diminished contribution of KV channels to overall 
vascular resistance. It is possible that the lack of an effect of 4-AP on the balance 
between coronary blood flow and MVO2 is related to a generalized vasoconstriction of 
the coronary vasculature in MetS hearts.  However, the absence of coronary effects of 4-
AP in combination with the reduction in outward KV current and expression of coronary 
KV channels indicates that diminished functional expression of KV channels contributes 
to the impairment in the control of coronary blood flow in the MetS. The overall degree to 
which decreased KV channel function influences coronary microvascular dysfunction in 
MetS is unclear, but could be related to alterations in the release of specific 
vasoregulatory factors that converge on KV channels, changes in KV channel activity, 
specific channel subunit expression and/or a combination of these mechanisms.  
 To examine potential mechanisms by which MetS impairs the contribution of KV 
channels to the control of coronary blood flow, we performed patch-clamp 
electrophysiology and Western blot studies in order to address functional and molecular 
expression of the channel proteins. Functional expression of KV current was reduced in 
smooth muscle cells from MetS pigs (Fig. 4-2B). Importantly, our supplemental data 
show that the currents we recorded in porcine coronary smooth muscle cells possessed 
pharmacological properties consistent with those mediated by KV channels (i.e. largely 
sensitive to inhibition by 4-AP) and were not contaminated by large conductance, Ca2+-
sensitive K+ (BKCa) current (i.e. insensitive to penitrem A). This raises the possibility that 
MetS: a) reduces the expression of KV channels and/or b) induces a phenotypic switch 
to other KV channel types. The latter mechanism, however, seems unlikely, as intrinsic 
KV current characteristics including the voltage-dependence of activation were not 
changed (V½ and slope factor k; Fig. 4-2C). Thus, we further investigated the possibility 
that MetS decreases KV channel protein expression. It is unclear what KV channel 
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subtypes underlie the native KV current in coronary smooth muscle, but candidates 
include KV1.5 (291) and KV3.1 (132). In particular, KV1.5 has been implicated as 
redox/oxygen sensing channels (291) while KV3.1 has been interrogated in impaired 
adenosine-induced dilation in hypercholesterolemic swine (132). Importantly, KV3.1b 
channels are also sensitive to oxygen (237) and auxiliary β subunits can confer oxygen 
sensitivity to subtypes not typically considered to be redox-sensitive (241). We found 
that expression of KV1.5 protein was reduced in coronary arteries from MetS pigs (Fig. 
4-3A), while expression of KV3.1 protein was not statistical affected (P = 0.36). These 
data indicate that KV1.5 channels are a component of the native KV current and that the 
MetS-induced reduction in KV current in coronary smooth muscle could be related to 
reduced molecular expression of KV1.5 channels. Our interpretation is consistent with 
recent preliminary data indicating that metabolic coronary vasodilatation is reduced in 
KV1.5 knockout mice (231). The potential contribution of alternative KV channels 
subtypes (e.g. KV 1.2, 1.3, 1.5, and/or 2.1) merits further investigation. 
It remains unclear what component(s) of the MetS milieu alters KV channel 
function and expression in coronary smooth muscle; however, several of the individual 
constituents have been investigated previously. These include hyperglycemia, 
hypercholesterolemia, and increased levels of circulating neurohumoral factors 
(endothelin, angiotensin II, and catecholamines). In particular, elevated glucose and an 
associated increase in reactive oxygen species production impaired KV channel function 
in smooth muscle cells from rat coronary arteries (195; 200). Whether a similar 
mechanism is at play in MetS pigs with modestly elevated glucose, insulin, and HOMA 
scores remains to be determined. Hypercholesterolemia also impairs coronary arteriolar 
relaxation mediated by KV channels and reduces KV current in coronary vascular smooth 
muscle (132; 133). Our swine MetS model produces profound hypercholesterolemia; 
therefore, it is possible that this factor contributes to decreased molecular and functional 
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expression of KV channels. In addition, MetS is associated with an increase in circulating 
levels of endothelin (5; 107; 132; 145) and sensitization of endothelin-mediated coronary 
vasoconstriction in dogs (176) and humans (207). Endothelin also inhibits vascular 
smooth muscle KV channels by a pathway involving protein kinase C (252), the activity of 
which we have recently reported to be increased in our MetS swine (240). Thus, it is 
possible that elevated endothelin levels alter the functional and molecular expression of 
KV channels in MetS swine. Similarly, related signal mechanisms activated by 
catecholamines (76) and angiotensin II (329) may contribute to impaired KV channel 
function and expression in MetS pigs. 
Limitations of the study. It is important to point out that systemic administration of 
4-AP may confound interpretation of the present findings as increases in arterial 
pressure (~6 mmHg) influence both coronary blood flow and MVO2 (82; 294). However, 
any effect of 4-AP on MVO2, the primary determinant of coronary blood flow, is 
accounted for by plotting key coronary response variables (coronary venous PO2) 
relative to MVO2 (Fig. 4-1). Intravenous administration of 4-AP also tended to decrease 
hematocrit in both lean and MetS swine (Table 4-2). The mechanism underlying this 
effect is unclear but it would likely act to increase (not decrease) coronary blood flow 
secondary to a reduction in myocardial oxygen delivery. Given these effects, we 
speculate that the overall contribution of KV channels to the control of coronary blood 
flow may be underestimated in this study. This hypothesis is supported by earlier data 
from our laboratory which showed a much greater reduction in coronary blood flow (~40-
50% decrease) in response to intracoronary 4-AP in normal-lean canines (73). Thus, 
future studies to examine the effects of intracoronary 4-AP on metabolic control of 
coronary blood flow are warranted. 
We also acknowledge the use of conduit coronary arteries for patch-clamp 
studies and measurement of KV channel expression as a limitation as changes in conduit 
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K+ channel current and protein expression may not directly reflect alterations at the 
microvascular level. Whether differences in macro vs. microcirculation account for the 
disparate ~20% reduction in KV current (Fig. 4-2) relative to the complete loss of an 
effect of 4-AP on coronary blood flow (Table 4-2) is unclear. However, data obtained 
from the idealized conditions that allow for examination of K+ current in isolated coronary 
vascular smooth muscle cells may not directly associate with overall K+ channel function 
in vivo, where other compensatory mechanisms could also be at play (82). Unfortunately 
we were unable to acquire sufficient measures of whole cell K+ current in the presence 
of 4-AP in smooth muscle cells from lean and MetS swine. Characterization of the 
currents is provided in the supplement.   
 
Conclusions 
 In summary, data from this investigation support that vasodilatory factors that 
converge on KV channels play a critical role in the control of systemic vascular 
resistance and the balance between coronary blood flow with myocardial metabolism at 
rest and during exercise in conscious, lean swine. In addition, our findings also 
demonstrate that diminished functional expression of KV channels significantly 
contributes to coronary microvascular dysfunction and the imbalance between 
myocardial oxygen supply-demand observed in the setting of the MetS (31). We 
hypothesize that therapeutic targeting of MetS components (e.g. hypercholesterolemia, 
angiotensin II) and/or signaling pathways (e.g. PKC) that are known to alter KV channel 
activity and expression could improve cardiovascular outcomes in patients with the 
MetS. 
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Supplemental data 
 Smooth muscle cells from the coronary artery possess a number of K+ channels 
(74); therefore, it is important to demonstrate isolation of voltage-dependent K+ (KV) 
current in our recordings. Specifically, we show that the currents we recorded in porcine 
coronary smooth muscle cells: 1) possessed pharmacological properties consistent with 
those mediated by KV channels and 2) were not contaminated by large conductance, 
Ca2+-sensitive K+ (BKCa) current. Currents between -60 and +20 mV were largely 
sensitive to 4-aminopyridine (4-AP; 3 mM; Supplemental figure, panel A), indicating they 
were mediated by KV channels (299). In contrast, currents were largely insensitive to 
penitrem A (1 M; Supplemental figure, panel B), indicating very little contribution of 
BKCa channels (173).  
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Abstract 
 Previous investigations by our group indicate that diminished functional 
expression of KV channels impairs control of coronary blood flow in obesity/metabolic 
syndrome (MetS). The goal of this investigation was to test the hypothesis that KV 
channels are electromechanically coupled to CaV1.2 channels and that coronary 
microvascular dysfunction in MetS is related to subsequent increases in CaV1.2 channel 
activity. Initial studies revealed that inhibition of KV channels with 4-aminopyridine (4AP, 
0.3 mM) increased intracellular [Ca2+], contracted isolated coronary arterioles, and 
decreased coronary reactive hyperemia, and that these effects were reversed by 
blockade of CaV1.2 channels. Further studies in chronically instrumented Ossabaw 
swine showed that inhibition of CaV1.2 channels with nifedipine (10 µg/kg, iv) had no 
effect on coronary blood flow at rest or during exercise in lean swine. However, blockade 
of CaV1.2 channels significantly elevated coronary blood flow, conductance, and the 
balance between flow and metabolism in swine with the MetS (P < 0.05). These changes 
were associated with a ~50% increase in inward CaV1.2 current and elevations in α1c 
membrane expression in coronary smooth muscle cells from MetS swine. Taken 
together, the results from this investigation indicate that increased functional expression 
of coronary CaV1.2 channels contributes to coronary microvascular dysfunction in the 
MetS.  
 
 
 
 
Keywords: Coronary, exercise, CaV1.2 channels, metabolic syndrome, swine 
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Introduction 
 Coronary ion channels play a critical role in the regulation of microvascular 
resistance and consequently coronary blood flow. Multiple channels function in dynamic 
equilibrium to effect changes in coronary smooth muscle membrane potential (EM) and 
vascular tone in response to metabolic needs of the surrounding myocardium. Thus, 
modulation of key coronary ion channels facilitates the preservation of the delicate 
balance between myocardial oxygen delivery and consumption (MVO2). Although the 
mechanisms by which this balance is regulated are not fully understood, previous 
investigations implicate voltage-gated CaV1.2 channels as a predominant mediator of 
extracellular Ca2+ influx and coronary vascular resistance (175; 225). Activation of 
CaV1.2 channels occurs in response to various stimuli, including changes in smooth 
muscle EM elicited by voltage-dependent K
+ (KV) channels, which have been shown to 
contribute to the regulation of coronary blood flow at rest (73), during increases in MVO2 
(30), and following myocardial ischemia (32). However, the extent to which this 
“electromechical coupling” between KV and CaV1.2 channels modulates coronary 
microvascular tone and reactivity has not been specifically examined.  
Recent studies indicate that obesity and the metabolic syndrome (MetS) 
markedly attenuate coronary vascular function and the ability of the coronary circulation 
to adequately balance coronary blood flow with myocardial metabolism (31). We recently 
documented that this impairment is related, at least in part, to diminished expression and 
activity of coronary KV channels (30). These findings are intriguing in relation to earlier 
studies which documented that inhibition of KV channels depolarizes smooth muscle to 
within the activation threshold for CaV1.2 channels and elevates cytosolic [Ca
2+](239), an 
effect abolished by removal of extracellular Ca2+ (205). Accordingly, we hypothesize that 
diminished KV channel function in MetS impairs coronary microvascular function, at least 
in part, via increases in CaV1.2 activity. Recent data from our laboratory support this 
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hypothesis as we have demonstrated that the MetS increases intracellular [Ca2+] in 
coronary smooth muscle, augments coronary vasoconstriction to the CaV1.2 channel 
agonist Bay K 8644 and increases coronary vasodilation in response to the CaV1.2 
channel antagonist nicardipine (38; 175). However, the extent to which alterations in 
CaV1.2 channels contributes to the deleterious effects of the MetS on coronary blood 
flow regulation in vivo has not been investigated.   
The purpose of the present investigation was to: 1) determine the functional 
significance of electromechical coupling between KV and CaV1.2 channels in the 
coronary circulation; 2) evaluate the contribution of CaV1.2 channels to the regulation of 
coronary blood flow at rest and during physiologic-induced increases in myocardial 
metabolism; 3) assess the influence of the MetS on the interaction between coronary KV 
and CaV1.2 channels, the role of CaV1.2 channels in metabolic control of coronary blood 
flow as well as CaV1.2 channel current and subunit expression. In particular, vertically 
integrative experiments utilizing a wide variety of molecular/cellular and whole-systems 
approaches were performed to test the hypothesis that diminished KV channel function 
and impaired physiologic regulation of coronary blood flow in the setting of the MetS is 
related to increased activity and/or expression of CaV1.2 channels. 
 
Methods 
 Ossabaw swine model of metabolic syndrome. All experimental procedures and 
protocols used in this investigation were approved by the Institutional Animal Care and 
Use Committee in accordance with the Guide for the Care and Use of Laboratory 
Animals.  Lean control swine were fed ~2200 kcal/day of standard chow (5L80, Purina 
Test Diet, Richmond, IN) containing 18% kcal from protein, 71% kcal from complex 
carbohydrates, and 11% kcal from fat.  MetS swine were fed an excess ~8000 kcal/day 
high fat/fructose, atherogenic diet containing 16% kcal from protein, 41% kcal from 
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complex carbohydrates, 19% kcal from fructose, and 43% kcal from fat (mixture of lard, 
hydrogenated soybean oil, and hydrogenated coconut oil), and supplemented with 2.0% 
cholesterol and 0.7% sodium cholate by weight (KT324, Purina Test Diet, Richmond, 
IN). Both lean and MetS castrated male swine were fed their respective diets for 16 
weeks prior to surgical instrumentation. Additional lean animals were also utilized for 
acute open-chest procedures. Coronary arteries, microvessels and myocardium were 
isolated immediately following heart excision for subsequent functional/molecular 
experiments. 
 Isolated Vessels. Epicardial coronary arteries were isolated, cleaned of 
adventitia, cut into 3mm rings, and mounted in organ baths containing Krebs buffer 
(37°C) for isometric tension studies as previously described (240). Coronary segments 
were adjusted to optimal length (~3.5 g tension) as determined by <10% change in 
active tension in response to 60 mM KCl before administration of either BayK 8644 (10 
µM, n = 6 lean) or KCl (20 mM, n = 4 lean/MetS) directly to the organ bath. Following a 
wash, administration of respective drugs was then repeated in the presence of the 
selective KV channel antagonist 4-aminopyridine (4AP, 0.3 mM). Active tension 
development was measured using Emka software (Falls Church, VA). Remaining 
coronary arteries not used for tension studies were enzymatically digested to disperse 
smooth muscle cells or frozen for subsequent molecular experiments.  
Subepicardial coronary arterioles (n = 3; 50- to 150-μm diameter) were also 
isolated from the left ventricular apex of lean swine, cannulated, and pressurized to 60 
cmH2O, as described previously (25). Intraluminal diameter was measured continuously 
with  videomicrometers and recorded on a MacLab workstation. Arterioles free from 
leaks were allowed to equilibrate for ∼1 h at 37°C with the bath solution changed every 
15 min. Arterioles that did not develop at least 20% spontaneous tone were excluded. 
Following development of tone, arterioles were treated with 4AP (0.3mM). Once a stable 
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diameter was achieved with 4AP, the CaV1.2 Ca
2+ channel antagonist nifedipine (10µM) 
was added to the vessel bath.  Diameter responses were normalized to maximal 
arteriolar diameter determined at the end of each experiment by changing the bath 
solution to Ca2+-free physiological salt solution. 
 Cell Dispersions and Molecular Expression. Coronary myocytes were isolated as 
described previously (38; 310) for microfluorimetry, patch-clamp, and flow cytometry. 
Coronary arteries from lean animals were loaded with Fura-2 (0.1 mM, n = 59 cells from 
3 animals), placed in a superfusion chamber and observed with a monochromator-based 
imaging system (TILL-Photonics, Martinsreid, Germany) equipped with a DU885 charge-
coupled device camera (Andor Technology plc, South Windsor, CT) used to monitor 
Fura-2 wavelengths. Fura-2 fluorescence was excited at 345 and 380 nM. Emitted light 
was collected with a 510-nam long-pass filter. Data were analyzed using TILLvisION 
software and reported as the change in baseline F345/380 in response to KCl (120 mM) 
or KCl + 4AP (0.3mM).  
Coronary smooth muscle cells from lean and MetS swine were isolated from 
proximal segments of the LAD and patch-clamp recordings were performed within 8 h of 
cell dispersion. Whole-cell CaV1.2 currents were measured at room temperature with the 
conventional dialyzed configuration of the patch-clamp technique. Bath solution 
contained (in mM) 138 NaCl, 5 KCl, 2 BaCl2, 1 MgCl2, 10 glucose, 10 HEPES, and 5 Tris 
(pH 7.4). Pipettes had tip resistances of 2-4 MΩ when filled with solution containing (in 
mM) 140 CsCl, 3 Mg-ATP, 0.1 Na-GTP, 0.1 EGTA, 10 HEPES, and 5 Tris (pH 7.1). After 
whole-cell access was established, series resistance and membrane capacitance were 
compensated. Current voltage relationships were assessed by 400-ms step pulses from 
-60 to +60 mV in 10-mV increments from a holding potential of -80 mV.  
Dispersed coronary myocytes from lean (n = 3) and MetS (n = 3) swine were 
fixed and permeabilized using the cytofix/cytoperm kit (BD). Cells were blocked in 
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permwash containing 10mg/ml BSA and stained for smooth muscle actin (R&D) and 
CaV1.2
 α1c (Santa Cruz Biotech) or concentration matched isotype controls (R&D, 
Calbiochem respectively). Samples were run using Cellquest Pro software on a 
FACSCalibur (BD) and analyzed with flow cytometry software. Membrane expression 
was determined by gating against isotype control with cells that were positive for smooth 
muscle actin and α1c positive staining.  
Coronary arteries from lean (n = 5) and MetS (n = 5) swine were homogenized 
with lysis buffer and total protein collected and quantified by DC Protein Assay. 
Equivalent amounts of protein (40 µg) were loaded onto 7.5% acrylamide gels and 
transferred. Membranes were blocked for 1 h at ambient temperature prior to 24 h 
incubation at 4C with rabbit polyclonal antibodies (Santa Cruz Biotech) directed against 
CaV1.2 α1c (1:150), β (1:200) and α2δ1 (1:200) subunits. Primary antibodies were added 
to blocking buffer with 0.1% Tween 20 and mouse anti-actin antibody (MP Biomedicals, 
1:20,000). Blots were washed and incubated for 1 h with IRDye 800 donkey anti-
rabbit/goat (1:10,000) and IRDye 700 donkey anti-mouse (1:20,000) secondary 
antibodies. Immunoreactivity for CaV1.2 channel subunits was determined by the Li-Cor 
Odyssey system (Li-Cor Biosciences) and expressed relative to actin (loading control).  
 In vivo coronary blood flow studies. Lean Ossabaw swine (n = 5) utilized for 
reactive hyperemia experiments were sedated as described previously (37). Blood 
pressure was monitored via catheters in the right femoral artery. Arterial blood samples 
were analyzed to maintain blood gas parameters within physiologic limits via ventilatory 
adjustments and/or intravenous sodium bicarbonate adminstration. Following a 
thoracotomy, the LAD was isolated to measure coronary blood flow using a perivascular 
flow transducer (Transonic Systems Inc.) and snare was used to occlude the LAD. Once 
hemodynamics were stabilized (15-30 min) and baseline measurements acquired, 
reactive hyperemia was assessed via 15 second coronary occlusions in the 
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presence/absence of diltiazem (0.3 mg/kg, iv) to inhibit CaV1.2 channels and/or 4-
aminopyridine (0.3 mg/kg iv) to block KV channels.  
Lean and MetS Ossabaw swine were instrumented as previously reported for 
exercise experiments (30). Briefly, utilizing a sterile technique, a left lateral thoracotomy 
was performed in the fifth intercostal space. Pressure monitoring catheters (Edwards 
LifeSciences) were implanted in the descending thoracic aorta for blood pressure 
measurements and arterial blood sampling. Another catheter was placed in the coronary 
interventricular vein for coronary venous blood sampling and intravenous drug infusions. 
A perivascular flow transducer (Transonic Systems Inc.) was placed around the left 
anterior descending (LAD) coronary artery to measure coronary blood flow. 
Catheters/wires were externalized, the chest closed in layers, and appropriate post-
operative pain/antibiotics administered. Following recovery from surgery, experiments 
were conducted in lean (n = 7) and MetS (n = 6) Ossabaw swine under resting 
conditions and during graded treadmill exercise (~ 2 mph and ~5 mph) before and during 
inhibition of CaV1.2 channels with nifedipine (10 µg/kg, iv). Arterial and coronary venous 
blood samples were collected simultaneously in heparinized syringes when 
hemodynamic variables were stable and analyzed in duplicate with an automatic blood 
gas analyzer (IL GEM Premier 3000) and CO-oximeter (682) system. Each exercise 
period was ~2 min in duration, and the animals were allowed to rest sufficiently between 
each level for hemodynamic variables to return to baseline. LAD perfusion territory was 
estimated as previously described by Feigl (x).  
  Statistical Analyses. Data are presented as mean ± SE.  Statistical comparisons 
were made by unpaired t-test (phenotype data) or by two-way analysis of variance 
(ANOVA) for within group analysis (Factor A: drug treatment; Factor B: exercise level) 
and between group analysis (Factor A: diet with drug treatment; Factor B: exercise level) 
as appropriate. When significance was found with ANOVA, a Student-Newman-Keuls 
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multiple comparison test was performed to identify differences between groups and 
treatment levels. Multiple linear regression analysis was used to compare slopes of 
coronary blood flow plotted vs. MVO2. If the slopes of the regression lines were not 
significantly different, an analysis of covariance (ANCOVA) was used to adjust response 
variables for linear dependence on MVO2. Hyperemic volume was determined by 
calculating the area under the curve using Prism software (GraphPad). For all statistical 
comparisons, P < 0.05 was considered statistically significant. 
 
Results 
Table 5-1 Phenotypic characteristics of lean and metabolic syndrome Ossabaw swine. 
 Lean MetS 
Body Weight (kg) 47 ± 2 72 ± 3* 
Heart wt. / Body wt. (x 100) 0.37 ± 0.02 0.40 ± 0.03 
Glucose (mg/dl) 75 ± 3 87 ± 5* 
Insulin (U/ml) 21 ± 4 30 ± 8 
HOMA index 3.9 ± 0.8 6.2 ± 1.2 
Total cholesterol (mg/dl) 85 ± 6 439 ± 74* 
LDL/HDL ratio 1.6 ± 0.1 4.5 ± 0.4* 
Triglycerides (mg/dl) 41 ± 5 70 ± 15 
Values are mean ± SE for lean (n = 7) and MetS (n = 5) swine. * P<0.05 vs lean. 
 
 Phenotype of Ossabaw swine. Phenotypic characteristics of lean and MetS 
swine are given in Table 5-1.  Consistent with our recent studies (37-39; 44), we found 
that the excess calorie, atherogenic diet induced classic features of early MetS in 
Ossabaw swine. In particular, relative to their lean counterparts MetS swine exhibited 
significant increases in body weight, glucose, total cholesterol, and LDL/HDL ratio. Blood 
samples obtained from swine at the time of exercise experiment (non-fasted) revealed 
modest increases in triglyceride levels and insulin concentrations. Homeostatic model 
assessment (HOMA) index values were also 1.6-fold higher in MetS swine (P = 0.13).  
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Figure 5-1 KV channel inhibition increases intracellular Ca
2+
 and coronary active tension. (A) Time 
course tracing of Fura-2 experiments in isolated coronary myocytes showing effect of 4AP on F345/F380 
in response to KCl (scale bar = 30 sec). (B) 4AP (0.3mM) significantly increased KCl-mediated 
elevations in intracellular Ca
2+
 (P < 0.05). (C) Active tension development in isolated coronary artery 
segments in response to the CaV1.2 channel agonist BayK 8644 (10 µM) was significantly increased by 
4AP (P < 0.01). 
 
KV-dependent modulation of coronary CaV1.2 channels 
 Activation of CaV1.2 channels by KCl (120 mM) increased baseline F345/380 
~15% in coronary smooth muscle myocytes from lean animals (P < 0.05). This response 
was elevated ~2-fold by subsequent addition of 4AP (Fig. 5-1A, P < 0.01). Isometric 
tension experiments in epicardial coronary artery segments support that inhibition of KV 
channels increases CaV1.2-mediated constriction as active tension development in 
response to the selective CaV1.2 channel agonist BayK 8644 (10 µM) was also 
increased ~2-fold following the administration of 4AP (Fig. 5-1B, P < 0.01). The 
contribution of functional coupling between coronary KV and CaV1.2 channels to the 
control of coronary microvascular resistance is demonstrated in Figure 5-2. Inhibition of 
KV channels in isolated coronary microvessels (pressurized diameter = 102 ± 8 µM) 
reduced arteriolar diameter (Fig 5-2A) as evidenced by a significant ~2-fold increase in 
arteriolar tone (Fig. 5-2B, P < 0.01). Subsequent administration of the CaV1.2 channel 
antagonist nifedipine (10 µM) reversed arteriolar constriction to 4AP, i.e. inhibition of 
CaV1.2 channels abolished reductions in coronary arteriolar diameter in response to 4AP 
(Fig. 5-2B, P < 0.01).  
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 To examine the potential for electromechanical coupling between KV and CaV1.2 
channels in vivo, coronary reactive hyperemia experiments were performed before and 
after the inhibition of KV channels with 4AP and/or CaV1.2 channels with diltiazem. A 
representative tracing demonstrating the marked reduction in coronary reactive 
hyperemia following 4AP administration is shown in Figure 5-2C. We found that 
diltiazem alone did not significantly alter the reactive hyperemic response relative to 
untreated-control hearts (tracing not shown; P value for repayment to debt ratio = 0.24). 
In agreement with data from isolated coronary microvessels (Fig. 5-2B), we importantly 
found that adminstration of diltiazem prior to the inhibition KV channels completely 
prevented 4AP-mediated reductions in coronary reactive hyperemia (Fig. 5-2C). More 
specifically, diltiazem abolished 4AP-induced reductions in both the peak hyperemic 
response and the overall repayment of coronary flow debt (Fig. 5-2D).  
 
 
Figure 5-2. Functional coupling between coronary KV and CaV1.2 channels. (A) Protocol tracing of 
isolated supepicardial coronary microvessels during 4AP and nifedipine treatments (scale bar = 2 
min). (B) Elevations in microvascular tone by 4AP were abolished by inhibition of Inhibition of CaV1.2 
channels with nifedipine (P < 0.01). (C) Representative tracing from past and present reactive 
hyperemia experiments in open-chest aneasthetized swine showing effects of additive CaV1.2 and KV 
channel blockade with diltiazem and 4AP on ischemic vasodilation (scale bar = 20 sec). (D) Addition 
of 4AP to diltiazem did not alter the hyperemia peak or repayment to debt responses relative to 
diltiazem alone or untreated controls.  
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 Alterations in KV and CaV1.2 channels in Metabolic Syndrome. Additional 
isometric tension studies were performed on isolated coronary arteries from lean and 
MetS swine. Active tension development in response to KCl (20 mM) was elevated ~2-
fold in arteries from MetS relative to lean swine under untreated-control conditions (P = 
0.02). The response to 20 mM KCl in lean swine was augmented ~40% by the 
administration of 4AP (Fig. 5-3A, P < 0.05). Importantly, inhibition of KV channels had no 
effect on active tension development to KCl in arteries from MetS swine (Fig. 5-3A, P = 
0.83). In agreement with these results, we found that 4AP significantly decreased 
baseline coronary blood flow in conscious, instrumented lean but not MetS swine (Fig. 
5-3B, P = 0.05). Furthermore, inhibition of CaV1.2 channels with nifedipine (10 µg/kg, iv) 
had no effect on baseline coronary flow in lean animals, but significantly increased 
coronary flow in MetS swine (Fig. 5-3B, P < 0.02).  
. 
 
 
 Coronary and cardiovascular response to exercise. Hemodynamic and blood gas 
data for lean and MetS Ossabaw swine at rest and during exercise are summarized in 
Table 5-2. Systolic, diastolic and mean aortic pressure were not significantly different in 
Figure 5-3 KV and CaV1.2 coupling in lean and MetS swine. (A) Active tension development in response 
to KCl (20mM) is significantly arteries from MetS relative to lean swine (P = 0.02). 4AP increased this 
response in arteries from lean (P < 0.05) but not MetS swine (P = 0.83). (B) Baseline coronary blood 
flow is reduced by 4AP lean swine (P = 0.05) while the change in coronary blood flow in response to 
nifedipine is markedly elevated in swine with the MetS (P < 0.02).  
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MetS vs. lean swine under baseline/resting conditions in either treated or untreated 
groups. However, the systemic pressure response to exercise was elevated in MetS 
swine as both systolic and mean aortic pressure were significantly increased during 
exercise relative to their lean counterparts; a finding that occurred in the absence of 
differences in heart rate. Despite this increase in arterial pressure, coronary blood flow 
was modestly reduced ~5-15% in MetS swine and was associated with significant 
decreases in coronary venous PO2 (index of myocardial tissue PO2) at rest and during 
exercise (Table 5-2). MetS also reduced coronary conductance (flow/pressure) ~25% at 
the highest level of exercise. Evaluation of coronary blood flow in lean and MetS swine 
at a given level of MVO2 revealed a modest reduction in the slope of the relationship 
between coronary blood flow and MVO2 under untreated-control conditions (Fig. 5-4A 
vs. 5-4B). However, taking into account the effects of blood pressure revealed a 
significant reduction in the slope of the relationship between coronary conductance and 
MVO2 in MetS relative to lean swine (P < 0.02, Fig. 5-4C vs. 5-4D); indicating a marked 
impairment of exercise-induced coronary vasodilation in MetS swine.  
Table 5-2 Hemodynamic and blood gas variables at rest and during graded treadmill exercise 
in lean and metabolic syndrome Ossabaw swine with and without Nifedipine. 
  Exercise  
 Rest  Level 1 Level 2 
Systolic Blood Pressure (mmHg)    
Lean 116  7 114  3 126  4 
Lean + Nifedipine 109  4 113  4 119  4 
MetS 126  6   136  7†   151  1† 
MetS + Nifedipine 116  4   125  4†    133  4*† 
    
Diastolic Blood Pressure  (mmHg)    
Lean 76  5 76  2 84  4 
Lean + Nifedipine 73  4 74  3 78  3 
MetS   88  11 82  4 92  5 
MetS + Nifedipine 76  3 76  3 80  6 
    
Mean Aortic Pressure (mmHg)    
Lean  98  6  97  3 106  3 
Lean + Nifedipine  91  3  95  3 100  3 
MetS        102  3        109  5     125  10† 
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MetS + Nifedipine  97  4 101  3  107  5* 
    
Heart Rate (beats/min)    
Lean   148  11 187  8   201  18 
Lean + Nifedipine   145  11 183  8 205  7 
MetS 149  6   201  19 194  9 
MetS + Nifedipine 145  5 186  8 203  8 
    
Coronary Blood Flow (ml/min/g)    
Lean 1.01  0.11 1.35  0.11 1.64  0.13 
Lean + Nifedipine 1.01  0.12 1.39  0.14 1.60  0.15 
MetS 0.96  0.07 1.25  0.10 1.41  0.10 
MetS + Nifedipine 1.11  0.11 1.39  0.11  1.62  0.15* 
    
Coronary Conductance (l/min/g/mmHg)   
Lean 10.3  1.0 13.9  0.9 15.7  1.5 
Lean + Nifedipine 11.3  1.4 14.7  1.4 16.1  1.5 
MetS   9.5  0.9 11.6  0.9   11.5  1.0† 
MetS + Nifedipine 11.5  1.1   13.8  1.1*  15.3  1.4* 
    
Myocardial O2 Consumption (l O2/min/g)   
Lean 116  14 176  24 231  24 
Lean + Nifedipine 111  13 163  17  201  26* 
MetS 126  14 165  14 182  21 
MetS + Nifedipine 111  13 178  12 185  11 
    
Arterial pH    
Lean 7.57  0.01 7.55  0.01 7.56  0.02 
Lean + Nifedipine  7.59  0.02*  7.60  0.01* 7.57  0.02 
MetS 7.54  0.02 7.52  0.01   7.51  0.01† 
MetS + Nifedipine   7.52  0.01†   7.52  0.02†   7.50  0.02† 
    
Coronary Venous pH    
Lean 7.47  0.01 7.49  0.01 7.48  0.01 
Lean + Nifedipine 7.49  0.01 7.51  0.01 7.50  0.01 
MetS 7.44  0.02   7.45  0.01† 7.45  0.01 
MetS + Nifedipine 7.47  0.01 7.48  0.02 7.47  0.01 
    
Arterial PCO2 (mmHg)    
Lean 31  1 31  2 29  2 
Lean + Nifedipine 29  3 28  2 30  2 
MetS 31  2 30  2 29  2 
MetS + Nifedipine 33  2 31  2 30  2 
Coronary Venous PCO2 (mmHg)    
Lean 51  1 43  3 45  2 
Lean + Nifedipine  44  2* 42  2  44  2 
MetS 46  3 44  2 41  3 
MetS + Nifedipine  41  2* 41  3 40  2 
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Arterial PO2 (mmHg)    
Lean  97  3 100  3         101  5 
Lean + Nifedipine        102  4 105  4  99  5 
MetS  92  4   91  3  93  3 
MetS + Nifedipine    88  2†     90  3†  94  2 
    
Coronary Venous PO2 (mmHg)    
Lean 17  0.8   17  1.1 16  1.0 
Lean + Nifedipine 18  1.4  16  1.1 16  1.1 
MetS   14  1.4†    12  1.3†   12  1.1† 
MetS + Nifedipine 15  1.9    14  1.3*   14  1.2* 
    
Coronary Venous O2 Saturation (%)   
Lean 14  2 11  3 12  2 
Lean + Nifedipine 16  2 13  2 12  2 
MetS 14  2 11  1 10  1 
MetS + Nifedipine 15  2 11  2 11  2 
    
Arterial Hematocrit (%)    
Lean 34  1 38  1 39  1 
Lean + Nifedipine 33  2  33  2* 37  1 
MetS 36  2 38  2 37  1 
MetS + Nifedipine 32  2 35  2 33  1 
Values are mean  SE for lean (n = 7) and MetS (n = 6) swine.  * P < 0.05 vs. untreated control, same 
diet/condition; † P < 0.05 vs. lean, same treatment. 
 
 Role of CaV1.2 channels in coronary and cardiovascular response to exercise. 
Effects of CaV1.2 channel inhibition with nifedipine (10 µg/kg, iv) on hemodynamic and 
blood gas variables at rest and during exercise are also summarized in Table 5-2. 
Administration of nifedipine significantly reduced systolic and mean aortic pressure 
during exercise in MetS, but not lean swine. Augmented blood pressure responses to 
exercise in MetS swine were also abolished by nifedipine (Table 5-2). Similar to 
untreated conditions, heart rate was unaffected by nifedipine in either group. Coronary 
blood flow and conductance were not significantly altered by nifedipine administration in 
lean swine at rest or during exercise (Table 5-2, Fig. 5-4A and 5-4C). In contrast, 
nifedipine markedly increased coronary blood flow and conductance during exercise in 
MetS swine (Table 5-2, Fig. 5-4B and 5-4D). Regression analysis demonstrated that 
nifedipine significantly increased the slope of the relationship between coronary blood 
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flow (P = 0.03) and conductance (P < 0.01) vs. MVO2 in MetS, but not lean swine (Fig. 
5-4). Importantly, no differences in slope were noted between MetS nifedipine treated vs. 
lean untreated swine, indicating that inhibition of CaV1.2 channels in MetS restored the 
coronary response to exercise to a similar level as that which is observed in lean swine.  
 
 
 
 Functional and molecular expression of coronary CaV1.2 channels in MetS. 
Whole cell patch clamp recordings (Fig. 5-5A) demonstrated a significant ~35-60% 
increase in native coronary CaV1.2 currents at 0-30 mV potentials (Fig. 5-5B, P < 0.05) 
over a voltage range consistent with CaV1.2 channel activity. Electrophysiologic 
Figure 5-4 Effects of CaV1.2 channel inhibition on exercise-mediated coronary vasodilation. (A) 
Inhibition of CaV1.2 channels did not alter the relationship between coronary blood flow and MVO2 in 
lean swine. (B) Nifedipine produced a significant upward shift in the relationship between coronary 
blood flow and MVO2 in swine with MetS (P = 0.03). (C) No affect of nifedipine on conductance vs. 
MVO2 were observed in lean swine. (D) Similar to coronary blood flow, the slope relationship between 
coronary conductance and MVO2 was markedly exacerbated in MetS swine (P < 0.02). 
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recordings did not indicate any alterations in properties of channel activation/inactivation, 
i.e. changes in current may be related to an increase in the number of CaV1.2 channels.  
 
 
Accordingly, protein expression of regulatory subunits implicated in membrane targeting 
of the pore-forming α1c subunit was determined. CaV1.2 α1c channel pore protein 
expression was increased ~70% in MetS coronary arteries (Fig. 5-6B, P < 0.05). In 
contrast, β1 subunit was decreased ~70% (P < 0.01) while α2δ1 subunit expression was 
unchanged (P = 0.49). Determination of CaV1.2 membrane expression with flow 
cytometry revealed a ~2-fold increase in α1c membrane expression in MetS relative to 
lean swine (Fig. 7B, P < 0.05). 
 
 
 
 
Discussion 
Figure 5-6. Expression of coronary CaV1.2 channel subunits. (A) Representative westerns blots of 
whole cell CaV1.2 subunit expression. (B) Analysis of western blots demonstrated significant increases 
in α1c and reductions in β1 subunit expression in coronary arteries from MetS vs. lean swine. Expression 
ofα2δ1 was not affected by MetS. * P < 0.05 vs. lean. 
Figure 5-5 Whole-cell voltage-dependent CaV1.2 current in coronary smooth muscle of lean and MetS 
swine. (A) Representative current tracings from lean and MetS coronary myocytes. Voltage template is 
400 ms long. (B) Group I-V data demonstrate a significant increase in inward CaV1.2 channel current at 
potentials greater than -10 mV. * P < 0.01 vs. lean, same voltage. 
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Discussion 
The goal of this investigation was to determine the functional significance of 
electromechical coupling between coronary KV and CaV1.2 channels and the contribution 
of CaV1.2 channels to the regulation of coronary blood flow at rest and during 
physiologic-induced increases in myocardial metabolism. In addition, we assessed the 
influence of the MetS on the interaction between coronary KV and CaV1.2 channels, the 
role of CaV1.2 channels in metabolic control of coronary blood flow as well as CaV1.2 
channel current and subunit expression. Specifically, we hypothesized that diminished 
KV channel functional expression contributes to increased CaV1.2 channel activity and 
coronary dysfunction in MetS. This hypothesis is supported by previous investigations by 
our laboratory demonstrating that the contribution of KV channels to local metabolic 
control of coronary blood flow and ischemic coronary vasodilation is impaired by MetS 
(30; 32). We have also documented that MetS results in an increase in intracellular 
[Ca2+], BayK activated channel current and coronary vasoconstriction (38; 175). 
However, whether increases in CaV1.2 channel activity in MetS is attributable to 
reductions in KV channel function or the result of alterations in the CaV1.2 regulatory 
subunits and channel expression is unclear. Accordingly, the major findings of this study 
are: 1) increases in coronary smooth muscle [Ca2+]i and vascular tone in response to KV 
channel inhibition are attributable to activation of CaV1.2 channels; 2) attenuated KV 
channel function in MetS is associated with elevated CaV1.2 channel activity; 3) 
enhanced CaV1.2 activity and molecular expression contributes to diminished exercise-
induced coronary vasodilation in MetS. Taken together, these data demonstrate 
electromechanical coupling between KV and CaV1.2 channels is critical to the regulation 
of coronary vasomotor tone and that increases in CaV1.2 channel activity contributes to 
coronary microvascular dysfunction in the setting of MetS.  
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 Functional coupling of coronary KV and CaV1.2 channels. Evidence to date 
supports a prominent role for KV channels in the control of smooth muscle EM and 
coronary blood flow (74). In addition, CaV1.2 channels represent a significant source of 
extracellular Ca2+ influx and coronary smooth muscle contraction (225; 292). Since 
CaV1.2 channels are activated within the range for smooth muscle EM, we hypothesized 
that alterations in EM elicited by KV channels modulate CaV1.2 channel activity and 
control coronary blood flow. The potential for functional interactions between these 
channels is important given the ability for modest alterations in smooth muscle EM to 
have large affects on CaV1.2-mediated Ca
2+ conductance and vascular tone. Opening of 
only a few CaV1.2 channels during depolarization in the presence of large 
transmembrane Ca2+ gradients can cause significant (~10-fold) increases in [Ca2+]i (161). 
Thus, even modest fluctuations in EM (~3 mV) are capable of producing ~2-fold changes 
in [Ca2+]i (225; 227). Accordingly, potential voltage-dependent interactions between KV 
and CaV1.2 channels may have profound consequences on the control of coronary 
vascular resistance and blood flow.  
In agreement with the premise of coupling between KV and CaV1.2 channels, 
administration of 4AP has been shown to markedly increase [Ca2+]i in various cell types 
(72; 125; 262). Although we now demonstrate this in coronary smooth muscle (Fig. 5-
1A), discrepancies exist as to whether increases in [Ca2+]i from 4AP are the result of 
voltage-dependent activation of CaV1.2 channels or IP3-mediated mobilization of SR 
stores and subsequent opening of store operated calcium channels (19; 108; 205; 314). 
Specifically, previous studies have shown that 4AP can increase [Ca2+]i in the absence of 
extracellular Ca2+ in isolated neurons, astrocytes, and skeletal muscle (125). While a 
parallel role for 4AP-induced SR Ca2+ release in smooth muscle cannot be disregarded 
(96), it is unlikely that this mechanism contributes to coronary vasoconstriction given that 
SR Ca2+ release mainly functions as a negative feedback mechanism to contraction; i.e. 
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spark-induced activation of calcium-sensitive K+ channels (156; 306). Importantly, our 
data demonstrate that the increase in [Ca2+]i during KV channel inhibition potentiates 
CaV1.2-mediated coronary vasoconstriction in response to BayK 8644 (Fig. 5-1B). In 
addition, administration of 4AP alone is sufficient to induce marked CaV1.2-sensitive 
vasoconstriction in isolated microvessels (Fig. 5-2A) thus supporting that increases in 
[Ca2+]i and arteriolar tone are the direct result of KV-dependent modulation of 
extracellular Ca2+ influx via CaV1.2 channels, i.e. electromechanical coupling.  
Our data are the first to demonstrate that the influence of KV and CaV1.2 channel 
interactions on the regulation of [Ca2+]i and vascular tone shown in vitro also plays an 
important role in the control of coronary blood flow. Our laboratory has previously 
demonstrated that inhibition of KV channels significantly impairs coronary reactive 
hyperemia as the repayment to debt ratio is reduced ~30% by 4AP (representative 
tracing Fig. 5-3C). Experiments performed in the present study in lean swine show that 
these reductions in the hyperemic response during KV channel inhibition are abolished 
by subsequent blockade of CaV1.2 channels with diltiazem (Fig. 5-3D). These data 
indicate that reductions in coronary blood flow during KV channel inhibition are 
attributable to the direct activation of CaV1.2 channels and support the functional 
importance of KV-CaV1.2 electromechanical coupling in vivo.  
Implications of electromechanical coupling between KV and CaV1.2 channels 
shown during ischemic coronary vasodilation is particularly important given the growing 
body of evidence indicating that K+ channel function is altered in various disease states 
(30; 37; 74). Specifically, findings from our laboratory demonstrate that the MetS 
reduces KV channel current, molecular expression, and exercise-mediated coronary 
vasodilation (30). Based on these previous studies and current findings regarding 
coupling between KV and CaV1.2 channels, we hypothesized that decreases in KV 
channel function in MetS may impair the control of coronary blood flow via increases in 
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CaV1.2 channel activity. This hypothesis is supported by significant increases in 
coronary active tension and diminished effects of 4AP in MetS vs. lean coronary artery 
segments (Fig. 5-3A). Likewise, coronary blood flow was not reduced by 4AP and was 
significantly increased by nifedipine in swine with MetS; results which are opposite to 
lean counterparts and indicative of impaired KV and elevated CaV1.2 channel function 
(Fig. 5-3B).  
 Effects of MetS on function and expression of coronary CaV1.2 channels. 
Findings from the present investigation demonstrate that MetS impairs the regulation of 
coronary blood flow via a CaV1.2-dependent mechanism. These results are consistent 
with previous studies on individual components of MetS (i.e. diabetes, hypertension, 
hypercholesteremia) showing that elevations in vascular tone are associated with 
increases in intracellular [Ca2+] and calcium channel current (181; 209; 242; 249). 
However, the extent to which potential alterations in CaV1.2 channel function contributes 
to impaired coronary vasomotor responses to physiologic stimuli in MetS has not 
previously studied. In agreement with findings from Bache et al. (16), nifedipine did not 
alter coronary blood flow or conductance in lean animals at rest or during exercise, nor 
were these variables different from untreated controls at a given level of MVO2 (Fig. 5-
4A, 5-4C). Relative to coronary and cardiovascular responses to exercise in lean swine, 
MetS significantly increased microvascular resistance (i.e. impaired coronary dilation 
and elevated pressure) as evidenced by decreases in the slope relationship between 
coronary conductance and MVO2 under untreated control conditions. Importantly, the 
dysfunction observed in swine with the MetS was ameliorated by subsequent inhibition 
of CaV1.2 channels with nifedipine as the relationship between both coronary blood flow 
and conductance vs. MVO2 were restored to lean untreated levels (Fig. 5-4B, 5-4C). 
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Figure 5-7 Membrane expression of coronary CaV1.2 channels. (A) Representative scatter showing 
double positive stained cells for α1c and coronary smooth muscle actin. (B) Membrane expression of 
CaV1.2 α1c subunit is significantly elevated in coronary smooth muscle from swine with MetS.  * P < 0.05 
vs. lean. 
 
 In order to determine whether increases in CaV1.2 channel function is the result 
of alterations in CaV1.2 regulatory pathways (i.e. KV channels) or intrinsic to changes 
within the channels themselves, we evaluated the effects of MetS on CaV1.2 channel 
current and subunit expression. MetS significantly increased inward CaV1.2 channel 
current ~35-60% without significantly affecting thresholds for activation/inactivation (Fig. 
5-5). Accordingly, we speculated that such marked increases in CaV1.2 channel current 
may be the result of elevated membrane expression. Indeed, whole cell expression of 
the α1c pore-forming subunit was increased ~70% in coronary arteries from swine with 
MetS (Fig. 5-6B). Interestingly, flow cytometry revealed that membrane expression of 
α1c is further elevated ~2-fold in MetS coronary myocytes suggesting possible 
alterations in β1 or α2δ1-dependent membrane targeting of the channel pore (Fig. 7B). 
Although both of these subunits have been implicated in membrane targeting of the α1c 
channel pore (18; 40; 97), our data do not demonstrate the expected increase in either 
subunit as α2δ1 expression was unchanged while β1 expression was significantly 
depressed in MetS. While our findings for reductions in β1 subunit are paradoxical, this 
may be attributable to conformational changes/splice variants in α1c subunits. 
Specifically, previous studies have demonstrated that an ER retention signal exists in the 
I-II loop of α1c subunits that is masked upon binding with β1 subunits (40; 97). In 
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addition, β subunits have also been implicated in proteasomal degradation of CaV1.2 
channels (8). However, whether our findings are the result of structural changes in the 
α1c interaction domain or impaired signaling for degradation is unknown. Additional 
studies at the transcriptional level are likely needed to clarify this discrepancy.  
 Implications. Results obtained from this investigation demonstrate that 
electromechanical coupling between KV and CaV1.2 channels is a critical mechanism by 
which coronary blood flow is regulated in health and disease. Given the prominent role 
for KV channels and the marked effect diminished coronary KV channel function has on 
coronary blood flow regulation, establishing the functional consequences of coupling 
between these channels is vital to our understanding of coronary (patho)physiology. 
However, our findings also demonstrate that in addition to the contribution of impaired KV 
channel function to elevated CaV1.2 activity, MetS is also associated with an increase in 
CaV1.2 activity which likely occurs independent of differential modulation by KV channels. 
In particular, our data indicate that MetS increases CaV1.2 channel current and 
membrane expression of the pore-forming α1c subunit. However, the mechanism 
underlying this increase in CaV1.2 molecular expression is unknown and merits further 
investigation.  
 Currently, thiazide-like diuretics are the first-line therapy in most subjects with 
hypertension (93). However, in MetS patients, the use of thiazides has been shown to 
increase insulin insensitivity, triglyceride levels (327), the incidence of new-onset 
diabetes (153; 251) and produce overall less favorable metabolic profiles (34). In 
contrast to thiazides, studies have found that metabolically neutral calcium channel 
blockers can improve insulin sensitivity and reduce total plasma cholesterol and lipid 
levels in hypertensive subjects with obesity and glucose intolerance (6; 11; 94; 153). 
Moreover, findings from several trials indicate that these agents are equally effective at 
managing blood pressure (47; 130) and are superior in reducing cardiovascular 
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morbidity and mortality compared to HCTZ (251). This cardioprotective effect is further 
supported by a recent meta-analysis of ~27 trials which found that long-acting calcium 
channel blockers reduce the risk of all-cause mortality (61).  
 Taken together, these trials along with data from the present investigation 
suggest that administration of calcium channel blockers to MetS subjects without overt 
hypertension may not only attenuate coronary microvascular dysfunction via CaV1.2 
inhibition, but could possibly improve metabolic profiles and cardiovascular outcomes. In 
individuals with MetS and hypertension, adjunctive therapy with ACE inhibitors may 
confer an additional and more favorable combined therapeutic option for managing 
blood pressure compared to thiazide-like diuretics (327). However, to more clearly define 
the contribution of increased CaV1.2 channel activity in MetS to adverse cardiovascular 
outcomes, a multi-center randomized control trial comparing the efficacy of calcium 
channel blockers (and possibly ACE inhibitors/ARBs) in MetS vs. MetS hypertensive 
subjects is required and will likely provide improve our ability to treat this growing patient 
population.  
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Chapter 6: Discussion 
Major Findings of Investigation 
Extensive research into coronary physiology has greatly improved our 
understanding of how coronary blood flow is regulated. However, despite our best 
efforts, many key questions remain unanswered. The focus of this investigation was 
centered on these critical components of coronary physiology that continue to elude us. 
In particular, no study to date has been able to delineate the primary mechanisms 
responsible for pressure-flow autoregualtion or ischemic and exercise-mediated 
coronary vasodilation. Given that coronary microvascular dysfunction is a significant 
contributor to cardiovascular disease, our ability to provide targeted therapies for 
individual patient populations is absolutely contingent on level of understanding we have 
for these central components of coronary physiology.  
The prevalence of obesity and MetS in western society is growing at an alarming 
rate and the management of cardiovascular disease in these patients continues to be a 
challenge for clinicians and healthcare systems. Evidence to date indicates that MetS 
has profound deleterious effects on coronary microvascular function that precedes the 
development of overt cardiovascular disease and contributes to the increased incidence 
of morbidity and mortality in patients with the MetS. Findings from our laboratory and 
others have identified that coronary dysfunction in MetS is associated with alterations in 
important vasoregulatory pathways. Critical to note is that these pathways elicit their 
effect via modulation of end-effector ion channels, namely K+ and Ca2+ channels. 
However, despite growing evidence that cardiovascular disease alters ion channel 
function, the physiologic role for more prominent coronary ion channels such as voltage-
dependent K+ and Ca2+ has not been characterized.  
Accordingly, the overall goal of this investigation was to: 1) delineate the 
functional role for coronary KV and CaV1.2 channels in the coronary response to 
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upstream converging metabolites (i.e. adenosine, peroxide), cardiac ischemia, exercise, 
and pressure-flow autoregulation; 2) determine potential electromechanical coupling 
between these channels; and 3) examine the contribution of KV and CaV1.2 channels to 
coronary microvascular dysfunction in MetS. In order to address these key questions in 
coronary physiology, the following specific aims were investigated:  
 Aim 1 was designed to elucidate the contribution of adenosine A2A and A2B 
receptors to coronary reactive hyperemia and downstream K+ channels involved. 
The major findings of this study are: 1) A2A receptors contribute to coronary vasodilation 
in response to exogenous adenosine administration and cardiac ischemia; 2) A2A 
receptor-induced coronary vasodilation is mediated via signaling pathways that converge 
on KV and KATP channels; 3) A2A and A2B receptors do not contribute to the regulation of 
coronary blood flow under baseline-resting conditions; and 4) A2B receptors contribute to 
coronary vasodilation in response to exogenous adenosine, but are not required for 
dilation in response to cardiac ischemia.  
 
 
 
 
 
 
 
  
 
 The role of adenosine in the coronary circulation has been extensively 
scrutinized with most reports failing to support a vasoactive function for endogenous 
adenosine (27; 73; 297). However, few studies have examined the contribution of 
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Figure 6-1 Role of adenosine receptors in ischemic coronary vasodialtion and K
+
 channel activation. (A) 
Inhibition of A2A receptors significantly attenuates coronary reactive hyperemia while A2B blockade has 
no effect. (B) Selective A2A activation causes significant KV and KATP-dependent coronary vasodilation. * 
P < 0.05 
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individual adenosine receptor subtypes to the regulation of coronary blood flow, 
particularly during cardiac ischemia. Thus, findings from investigating aim 1 are novel 
and demonstrate that in contrast to earlier studies, adenosine A2A receptors significantly 
contribute to coronary vasodilation in response to exogenous adenosine administration 
and cardiac ischemia. This conclusion is supported by the ~30% reduction in hyperemia 
repayment to debt during inhibition of A2A receptors. Subsequent additive blockade of 
A2B receptors did not further reduce the hyperemic response or dilation to exogenous 
adenosine indicating that A2A is the predominant adenosine receptor involved in 
adenosine-mediated coronary vasodilation and reactive hyperemia (Fig. 6-1A). We have 
also identified that A2A-induced coronary vasodilation in vivo is mediated via activation of 
KV and KATP channels (Fig. 6-1B). Moreover, combined blockade of KV and KATP 
channels abolished coronary reactive hyperemia; a result that has not been previously 
achieved and greatly extends the critical nature of these ion channels in coronary 
physiology.  
 
 
 
Figure 6-2 Mechanism of A2A-induced coronary vasodilation. Stimuluation of A2A receptors by 
adenosine leads to coronary vasodilation via subsequent cAMP-dependent activation of KV and KATP 
channels. 
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Aim 2 was designed to examine the contribution of KV and CaV1.2 channels 
to coronary pressure-flow autoregulation in vivo. The major findings from 
investigating aim 2 are: 1) KV channels exert a tonic contribution to the control of 
coronary microvascular resistance over wide range of CPPs (60-140 mmHg); 2) KV 
channels and vasodilatory pathways known to converge on them (i.e. adenosine, NO, 
H2O2) are not required for coronary responses to changes in perfusion pressure; and 3) 
progressive activation of coronary CaV1.2 channels is essential for maintaining blood 
flow constant with alterations in perfusion pressure. 
 
 
The importance of coronary pressure-flow autoregulation has resulted in decades 
of investigations attempting to delineate the underlying mechanisms responsible for this 
phenomenon. However, the possible contribution of KV and CaV1.2 channels has not 
been determined. Consistent with earlier investigations by our laboratory (73; 74), results 
from investigating aim 2 supports that KV channels significantly contribute to the control 
of coronary vascular resistance. In general, we found that inhibition of KV channels 
causes a tonic reduction in coronary blood flow over a wide range of pressures (Fig. 6-
3A). Such marked flow reductions diminished cardiac contractile function while 
preserving the balance between flow and metabolism, i.e. resulted in myocardial 
Figure 6-3 Role of KV and CaV1.2 channels in coronary pressure-flow autoregulation. (A) Inhibtion of KV 
and CaV1.2 channels results in tonic reductions and progressive increases in coronary blood flow in 
response to increases in perfusion pressure. (B) Coronary pressure-flow autoregulation is abolished by 
CaV1.2 channel inhibition while blockade of KV channels has no effect.  
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hibernation. However, despite significant reductions in coronary blood flow at pressures 
> 50 mmHg, the sensitivity of the coronary circulation to changes in perfusion pressure 
(autoregulatory gain) was unaffected (Fig. 6-3B). Thus, although our data extend the 
importance of KV channels in regulating coronary microvascular resistance, we failed to 
find a prominent role for KV channels in pressure-flow autoregulation.  
To date, no study has been able to identify a primary mechanism responsible for 
pressure-flow autoregulation. However, data from this study are the first to demonstrate 
that inhibition of a particular target, CaV1.2 channels, essentially abolishes the ability of 
the coronary circulation to maintain blood flow constant with alterations in perfusion 
pressure. In particular, progressive increases in coronary blood flow with elevations in 
perfusion pressure in the presence of diltiazem was independent of significant 
alterations in cardiac metabolism or function, i.e. reflected pressure-dependent changes 
in coronary blood flow. Most importantly, however, is that Gc was reduced to -0.21 ± 
0.08 over the classic autoregulatory range of 60-120 mmHg (Fig. 6-3B). These hallmark 
findings are the first to isolate a single factor responsible for coronary pressure-flow 
autoregulation in vivo. 
 
 
 
 
 
 
 
 
Figure 6-4 Effects of 
alterations in coronary 
perfusion pressure on KV 
and CaV1.2 channel 
activation. Elevations in 
pressure progressively 
activate CaV1.2 channels 
to increase coronary 
resistance and maintain 
blood flow constant. Tonic 
activation of KV channels 
may serve to limit CaV.2-
dependent constriction in 
response to increases in 
perfusion pressure.  
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Aim 3 was designed to determine the role for KV channels in metabolic 
control of coronary blood flow and to test the hypothesis that decreases in KV 
channel function and/or expression significantly attenuate myocardial oxygen 
supply-demand balance in the MetS. The novel findings of this study are: 1) inhibition 
of KV channels increases blood pressure at rest and during exercise in lean, but not 
MetS swine; 2) KV channels contribute to the regulation of coronary blood flow at rest 
and during increases in MVO2 in lean, but not MetS swine; 3) induction of MetS 
significantly decreases KV channel current in coronary artery smooth muscle cells; and 
4) expression of KV 1.5 channels is diminished in the coronary circulation of MetS swine.  
 
Findings from this investigation support that vasodilatory factors convering on KV 
channels play a critical role in the control of systemic vascular resistance and coronary 
blood flow at rest and during exercise in conscious lean swine (Fig. 6-5A). In addition, 
our data demonstrate that diminished functional expression of KV channels significantly 
contributes to coronary microvascular dysfunction (Fig. 6-5B) and the imbalance 
between myocardial oxygen supply-demand observed in the setting of the MetS (31). 
Our findings also attribute this impairment to decreases in KV channel current and 
expression. Thus, results obtained from investigating aim 3 greatly improve our 
Figure 6-5 Diminished KV channel function impairs exercise-induced coronary vasodilation in MetS. 
4AP significantly reduces coronary conductance in lean (A) but not MetS swine (B).  
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understanding of exercise-mediated coronary vasodilation and microvascular 
dysfunction in MetS.  
  Aim 4 was designed to delineate the relationship between coronary KV and 
CaV1.2 channels and to evaluate the contribution of CaV1.2 channels to coronary 
microvascular dysfunction in MetS. The major findings of this study are: 1) increases 
in coronary smooth muscle [Ca2+]i and vascular tone in response to KV channel inhibition 
are attributable to activation of CaV1.2 channels; 2) attenuated KV channel function in 
MetS is associated with elevated CaV1.2 channel activity; and 3) enhanced CaV1.2 
functional and molecular expression in MetS impairs exercise-induced coronary 
vasodilation.  
 
 
 Results obtained from this investigation demonstrate that KV-CaV1.2 
electromechanical coupling is a critical mechanism by which coronary blood flow is 
regulated. Our data indicate that inhibition of KV channels increases [Ca
2+]i via voltage-
dependent activation of CaV1.2 channels leading to subsequent reductions in arteriolar 
diameter and coronary blood flow. Given the prominent role for KV channels and the 
marked effect diminished coronary KV channel function has on coronary blood flow 
regulation, establishing the functional consequence of coupling between these channels 
Figure 6-6 Elevated CaV1.2 channel function impairs exercise-induced coronary vasodilation in MetS. 
Inhibition of CaV1.2 channels significantly increases coronary conductance in MetS (B) but not lean 
swine (A).  
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Figure 6-7 Schematic diagram illustrating primary investigative findings.  
 
is vital to our understanding of coronary dysfunction in MetS. Notwithstanding impaired 
KV channel function, our data indicate that MetS also increases CaV1.2 channel current 
and α1c membrane expression. Taken together, these data demonstrate that KV-CaV1.2 
electromechanical coupling plays a significant role in the regulation of coronary 
vasomotor tone and that increases in CaV1.2 channel activity contributes to coronary 
microvascular dysfunction in the setting of MetS (Fig. 6-6). 
 
 
Implications 
In addition to extending our physiologic understanding of coronary physiology, 
overall findings from this investigation also have significant clinical implications. For 
example, determining the mechanism for A2A-induced coronary vasodilation is of 
particular importance given previously documented alterations in A2 receptor expression 
(25) along with present findings for impaired KV channel function in MetS (Fig. 6-7). 
Based on these data and the clinical applications for adenosine (i.e. supraventricular 
tachycardia, stress testing), we propose that the normal clinical indications may prove to 
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be ineffective in MetS patients or other populations with altered A2 receptor and/or KV 
channel function. 
Although our findings do not support an active role for KV channels in coronary 
pressure-flow autoregulation, these findings are of interest given the emphasis on a 
metabolic component of autoregulation. Specifically, our data indicate that these 
channels, and the vasodilatory pathways known to converge on them (adenosine, NO, 
H2O2), are not required for coronary responses to changes in perfusion pressure within 
the autoregulatory range. Additionally, our findings do support that KV channels serve as 
a negative-feedback mechanism that limits myogenic constriction, particularly at higher 
perfusion pressures. Even though a negative finding for KV channels in coronary 
autoregulation lacks clinical implications, our results shift the focus from previously 
emphasized metabolic to myogenic components of pressure-flow autoregulation, 
particularly when taking into account the role for CaV1.2 channels.  
In contrast to KV, CaV1.2 channels do play a prominent role in coronary pressure-
flow autoregulation (Fig. 6-7). Although the exact mechanisms by which these channels 
are modulated during alterations in perfusion pressure are unknown, the preponderance 
of evidence suggests that these channels are end-effectors to mygoenic constriction 
thus further supporting this component of pressure-flow autoregulation. In addition, 
CaV1.2 channel blockers are often used clinically in the management of blood pressure. 
Although our findings indicate that administration of calcium channel blockers would 
abolish coronary autoregulatory capacity, they would still provide a significant benefit to 
hypertensive patients given that they function to increase coronary blood flow, reduce 
left ventricular afterload, and improve the balance between myocardial oxygen delivery 
and metabolism. 
 Perhaps the greatest implication of our investigation surrounds the findings for KV 
and CaV1.2 electromechanical coupling and their associated alterations in MetS (Fig. 6-
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7). Several components of MetS have been shown to impair KV channel function, namely 
hypercholesterolemia, hyperglycemia, and elevations in endothelin and reactive oxygen 
species (5; 107; 132; 133; 145). Thus, we propose that targeting these pathways may 
attenuate coronary dysfunction through direct effects on KV channels and indirect 
reductions in CaV1.2 channel activity via electromechanical coupling. However, based on 
our findings, a more targeted approach may be obtained through inhibition of CaV1.2 
channels. 
 Several concerns have been expressed regarding the indication for calcium 
channel blockers in blood pressure management (194; 250). Currently, thiazide-like 
diuretics are the first-line therapy in most subjects with hypertension (93). However, in 
MetS patients, the use of thiazides and/or β-blockers has been shown to increase insulin 
insensitivity, triglyceride levels (327), the incidence of new-onset diabetes (153; 251) and 
produce overall less favorable metabolic profiles (34). Despite these findings, many 
clinicians still use low-dose thiazides in combination with β-blockers or ACE inhibitors to 
control blood pressure in obese diabetic patients.  
 Less frequently administered in MetS patients are calcium channel blockers 
which have been shown to be as equally effective at managing blood pressure (47; 130). 
In contrast to thiazide-like diuretics, calcium channel blockers are metabolically neutral 
and have been shown to reduce insulin insensitivity (as do ACE inhibitors), total plasma 
cholesterol and lipids in hypertensive subjects with obesity and glucose intolerance (6; 
11; 94; 153). Moreover, a recent meta-analysis of ~27 trials suggests that these agents 
reduce the risk of all-cause mortality (61) to various conditions which supports 
cardioprotective effects demonstrated by the hypertension optimal treatment trial in 
diabetic hypertensive patients (327). Further, the combination of ACE inhibitors (which 
confer additional renal and vascular protection (327)) with calcium channel blockers has 
been shown to be more advantageous than β-blockers/diuretics in obese hypertensive 
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patients (266) and is superior in reducing cardiovascular morbidity and mortality 
compared to hydrochlorothiazide (251).  
 Based on these adverse findings for thiazide-like diuretics and results from our 
current investigation, we advocate that calcium channel blockers be indicated as a first-
line therapy for patients with MetS as CaV1.2 inhibition in these patients may not only 
attenuate coronary microvascular dysfunction, but will likely improve metabolic profiles 
and cardiovascular outcomes. In individuals with MetS and overt hypertension, 
adjunctive therapy with angiotensin-converting enzyme inhibitors may provide an 
additional and more favorable therapeutic option for blood pressure management.  
 
Future Directions 
Several issues remain unresolved by this investigation. While data from this 
study support a critical role for CaV1.2 channels in pressure-flow autoregulation, the 
mechanism by which CaV1.2 channels are activated (i.e. myogenic vs. metabolic) 
requires further investigation. Although CaV1.2 channel activation likely represents a 
myogenic element of pressure-flow autoregulation given that these channels can be 
directly activated by pressure/stretch-induced membrane deformation, there still remains 
a diltiazem and nifedipine insensitive component to myogenic constriction (68; 69). Data 
suggests that such residual myogenic activity may be the result of mechanosensitive 
nonselective cation channels (67). Thus, other pathways have been implicated. 
Narayanan et al. showed that IP3 and DAG are produced in increasing proportions to 
elevations in intraluminal pressure. Such factors are capable of modulating CaV1.2 
channels via subsequent activation of PKC (214) in addition to mobilization of 
intracellular stores through IP3 receptors (68; 142). Therefore, future studies should 
address the role of non-selective cation channels and metabolically activated 
intracellular messengers in coronary pressure-flow autoregulation. More importantly, 
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however, is that no study to date has determined the effects of disease states such as 
MetS on coronary autoregulation. In addition, the patho-physiologic contribution of 
increases in CaV1.2 channel functional expression to coronary pressure-flow responses 
remains to be determined.  
 Additional findings from studies in MetS swine demonstrate a paradoxical 
decrease in CaV1.2 β1 expression with elevations in pore-forming α1c membrane 
expression. The preponderance of evidence suggests that CaV1.2 β1 subunits are 
responsible for trafficking of α1c from the ER to the membrane (97). Thus, we would 
predict that β1 subunit expression would be increased. Interestingly, the degree of 
change between α1c and β1 subunit expression is proportional (~70%). Based on these 
observations, it is interesting to speculate that such reductions in β1 expression may be 
the result of a feedback mechanism. Specifically, it has been shown that an ER retention 
signal exists in the I-II loop of α1c subunits that is masked upon binding with β1 subunits 
(40; 97). We hypothesize that a potential splice variant in this region may alter the 
retention signal thus resulting in constitutive α1c membrane targeting. Accordingly, 
reflexive decreases in β1 expression may occur to compensate for uninhibited α1c 
membrane expression. Alternatively, β1 subunits have also been implicated in 
proteasomal degradation of CaV1.2 channels (8). However, in order to determine the role 
for these potential mechanisms during increased α1c membrane expression, further 
analysis of splice variants in α1c and β1 subunits is required. 
 Notwithstanding the contribution of altered KV and CaV1.2 channel function to 
coronary microvascular dysfunction in MetS, the upstream mechanisms by which these 
changes in channel expression occur has not been determined. Recent findings indicate 
that MetS is associated with an upregulation of RAAS signaling pathways (31; 308; 329). 
In addition, increases in circulating levels of angiotensin II and AT1 receptor expression 
have been shown to modulate ion channel function (26). Thus, these findings provide a 
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strong rationale for studies in patients and instrumented MetS swine involving chronic 
administration of AT1 and/or mineralocorticoid receptor antagonists. Further, to more 
clearly define the contribution of increased CaV1.2 channel activity in MetS to adverse 
cardiovascular outcomes, a multi-center randomized control trial comparing the efficacy 
of calcium channel blockers (and possibly ACE inhibitors/ARBs) in MetS vs. MetS 
hypertensive subjects is needed.  
 
Concluding Remarks 
In summary, investigating the aims of this study has concluded in several key 
findings that greatly advance our understanding of how coronary blood flow is regulated 
and the mechanisms which contribute to coronary microvascular dysfunction in MetS. 
Specifically, we have established that adenosine A2A receptors play a significant role in 
ischemic coronary vasodilation via subsequent activation of coronary KV and KATP 
channels. Moreover, inhibition of these critical end-effectors essentially abolishes the 
hyperemic response. Although a similar critical finding for KV channels in pressure-flow 
autoregulation was not obtained, our findings do indentify that CaV1.2 channel activation 
may be the single most important contributor to coronary autoregulation. In addition, we 
have established that electromechanical coupling between KV and CaV1.2 channels is a 
vital mechanism by which coronary blood flow is regulated. The interaction between 
these channels is of particular importance in MetS whereby reductions in KV channel 
activity and expression is associated with elevated CaV1.2 functional and molecular 
expression. Importantly, evidence obtained from this investigation demonstrates that KV 
and CaV1.2 channel dysfunction significantly impairs the balance between coronary 
blood flow and myocardial metabolism in MetS. 
The epidemic of MetS in western society is a crisis with fatal and extensive 
financial consequences. Despite coronary dysfunction being a central contributor to 
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increased mortality in these patients, many of the mechanisms underlying impaired 
regulation of coronary blood flow remain poorly understood. Although the focus on MetS 
is growing, much of what we know today and our therapeutic approach stems from 
investigations on the individual components which comprise MetS. Thus, given the 
complexity of the multifaceted MetS, our ability to integrate proposed pathological 
components into an effective and targeted therapy has been limited. Hence, much work 
remains to fully understand the etiology of MetS in hopes of abrogating adverse 
cardiovascular outcomes in this patient population.  
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